CN1368511A - Human protein with cancer inhibiting function and its coding sequence - Google Patents

Abstract

The invention discloses a novel human protein with tumor suppressor function, a polynucleotide encoding the polypeptide and a method for producing the polypeptide through recombinant technology. The invention also discloses a method for using the polypeptide to treat various diseases such as cancer and the like. The invention also discloses an antagonist against the polypeptide and its therapeutic effect. The invention also discloses the application of the polynucleotide encoding this novel human protein with tumor suppressor function.

Description

Novel human protein with tumor suppressor function and its coding sequence

The invention belongs to the field of biotechnology, in particular, the invention relates to a new polynucleotide encoding a human protein with tumor suppressor function and a polypeptide encoded by the polynucleotide. The present invention also relates to the use and preparation of such polynucleotides and polypeptides.

Human genomics research is currently a hot spot in the world. In addition to large-scale sequencing of human chromosomal DNA and expressed sequence sequencing (EST), there is still a lack of high-throughput methods for screening functional genes starting from function.

Cancer is one of the major diseases that endanger human health. In order to effectively treat and prevent tumors, people have paid more and more attention to gene therapy of tumors. Therefore, there is an urgent need in this field to develop and study human proteins with tumor suppressor functions and their agonists/inhibitors.

The object of the present invention is to provide a new class of human protein polypeptides with tumor suppressor function and fragments, analogs and derivatives thereof.

Another object of the present invention is to provide polynucleotides encoding these polypeptides.

Another object of the present invention is to provide methods for producing these polypeptides and uses of the polypeptides and coding sequences.

In the first aspect of the present invention, a novel isolated protein polypeptide with tumor suppressor function is provided, which comprises a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, 5, 8, 11, 14, 17 , 20, 23, 26, 29, 32, 35; or its conservative variant polypeptide, or its active fragment, or its active derivative.

Preferably, the polypeptide is a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35.

In a second aspect of the present invention there is provided an isolated polynucleotide comprising a nucleotide sequence having at least 85% identity to a nucleotide sequence selected from the group consisting of: (a) a polynucleotide encoding the above-mentioned protein polypeptide with a tumor suppressor function; (b) a polynucleotide complementary to the polynucleotide (a). Preferably, the polypeptide encoded by the polynucleotide has an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35. More preferably, the sequence of the polynucleotide is selected from the following group: SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 coding region sequence or full-length sequence .

In the third aspect of the present invention, there are provided vectors containing the above-mentioned polynucleotides, and host cells transformed or transduced by the vectors or host cells directly transformed or transduced by the above-mentioned polynucleotides.

In the fourth aspect of the present invention, there is provided a method for preparing a polypeptide having a protein activity of a tumor suppressor function, the method comprising: (a) cultivating the above-mentioned transformed or transformed protein under conditions suitable for expressing a protein with a tumor suppressor function (b) isolating the polypeptide with protein activity of tumor suppressor function from the culture.

In the fifth aspect of the present invention, an antibody specifically binding to the above-mentioned protein polypeptide with tumor suppressor function is provided. Also provided is a nucleic acid molecule that can be used for detection, which contains 10 consecutive nucleotides to the full-length nucleotides of the above-mentioned polynucleotide, preferably it contains continuous about 10-800 nucleotides.

In the sixth aspect of the present invention, a pharmaceutical composition is provided, which contains a safe and effective amount of the protein polypeptide with tumor suppressor function of the present invention and a pharmaceutically acceptable carrier. These pharmaceutical compositions can treat diseases such as cancer and abnormal proliferation of cells.

Other aspects of the invention will be apparent to those skilled in the art from the disclosure herein.

3T3 cells are a type of mouse fibroblasts (J. Cell. Biol., 17:299, 1963). In the field of cancer research, exogenous genes (especially human genes) are often introduced into 3T3 cells, and their effects on the growth of 3T3 cells are observed. It is generally believed that the genes that affect the growth of 3T3 cells are cancer-related genes, and the genes that inhibit the growth of 3T3 cells are mostly tumor suppressor genes, while the genes that promote the growth of 3T3 cells are mostly (proto)oncogenes.

The invention adopts large-scale cDNA clones to transfect mouse embryonic fibroblasts, obtains a tumor-suppressing effect, and further obtains full-length cDNA clones after being sequenced and proved to be new genes. The DNA transfection test proves that the protein with tumor suppressor function of the present invention has the effect of inhibiting the formation of clones on 3T3 cells, and the inhibition rate is ≥ 50%.

As used herein, "isolated" means that the material is separated from its original environment (if the material is native, the original environment is the natural environment). For example, polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotides or polypeptides are isolated and purified if they are separated from other substances that exist together in the natural state .

As used herein, "isolated protein or polypeptide with tumor suppressor function" means that the protein or polypeptide with tumor suppressor function does not substantially contain other proteins, lipids, carbohydrates or other substances associated with it in nature. Those skilled in the art can use standard protein purification techniques to purify proteins with tumor suppressor function. Substantially pure polypeptides yield a single major band on non-reducing polyacrylamide gels.

The polypeptide of the present invention can be a recombinant polypeptide, a natural polypeptide, a synthetic polypeptide, preferably a recombinant polypeptide. Polypeptides of the present invention may be naturally purified, or chemically synthesized, or produced using recombinant techniques from prokaryotic or eukaryotic hosts (eg, bacteria, yeast, higher plants, insect and mammalian cells). Depending on the host used in the recombinant production protocol, the polypeptides of the invention may be glycosylated, or may be non-glycosylated. Polypeptides of the invention may or may not include an initial methionine residue.

The present invention also includes fragments, derivatives and analogs of human proteins with tumor suppressor function. As used herein, the terms "fragment", "derivative" and "analogue" refer to a polypeptide that substantially maintains the same biological function or activity of the natural human protein with tumor suppressor function of the present invention. The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues It may or may not be encoded by the genetic code, or (ii) a polypeptide having a substituent group in one or more amino acid residues, or (iii) a mature polypeptide in combination with another compound (such as a compound that extends the half-life of the polypeptide, e.g. polyethylene glycol), or (iv) an additional amino acid sequence fused to the polypeptide sequence (such as a leader sequence or secretory sequence or a sequence used to purify the polypeptide or a proprotein sequence). Such fragments, derivatives and analogs are within the purview of those skilled in the art in light of the teachings herein.

A polynucleotide of the invention may be in the form of DNA or RNA. Forms of DNA include cDNA, genomic DNA or synthetic DNA. DNA can be single-stranded or double-stranded. DNA can be either the coding strand or the non-coding strand. Taking the PP239 protein (in this application, the protein is named by its clone number) as an example, the coding region sequence encoding the mature polypeptide can be the same as the coding region sequence shown in SEQ ID NO: 3 or a degenerate variant. As used herein, "degenerate variant" in the present invention refers to a nucleic acid sequence that encodes a protein with SEQ ID NO: 2, but differs from the sequence of the coding region shown in SEQ ID NO: 3. Taking the PP446 protein as an example again, the coding region sequence encoding the mature polypeptide can be the same as the coding region sequence shown in SEQ ID NO: 6 or a degenerate variant. For other proteins with tumor suppressor function, it can be deduced by analogy.

A polynucleotide encoding a mature polypeptide includes: a coding sequence that encodes only the mature polypeptide; a coding sequence for the mature polypeptide and various additional coding sequences; a coding sequence for the mature polypeptide (and optionally additional coding sequences) and non-coding sequences.

The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may also include additional coding and/or non-coding sequences.

The present invention also relates to variants of the above-mentioned polynucleotides, which encode polypeptides or polypeptide fragments, analogs and derivatives having the same amino acid sequence as the present invention. Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants and insertion variants. As known in the art, an allelic variant is an alternative form of a polynucleotide which may be a substitution, deletion or insertion of one or more nucleotides without substantially altering the function of the polypeptide it encodes .

The present invention also relates to polynucleotides that hybridize to the above-mentioned sequences and have at least 50%, preferably at least 70%, more preferably at least 80% identity between the two sequences. The invention particularly relates to polynucleotides which are hybridizable under stringent conditions to the polynucleotides of the invention. In the present invention, "stringent conditions" refers to: (1) hybridization and elution at lower ionic strength and higher temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) hybridization with There are denaturing agents, such as 50% (v/v) formamide, 0.1% calf serum/0.1% Ficoll, etc.; or (3) only the identity between the two sequences is at least 95%, more Preferably hybridization occurs above 97%. Moreover, the polypeptide encoded by the hybridizable polynucleotide has the same biological function (taking PP239 protein as an example) and activity as the mature polypeptide shown in SEQ ID NO: 2.

The present invention also relates to nucleic acid fragments that hybridize to the above-mentioned sequences. As used herein, a "nucleic acid fragment" is at least 15 nucleotides in length, preferably at least 30 nucleotides in length, more preferably at least 50 nucleotides in length, most preferably at least 100 nucleotides in length. Nucleic acid fragments can be used in nucleic acid amplification techniques (such as PCR) to identify and/or isolate polynucleotides encoding proteins with tumor suppressor function.

The polypeptides and polynucleotides of the invention are preferably provided in isolated form, more preferably purified to homogeneity.

The DNA sequences of the present invention can be obtained in several ways. For example, DNA is isolated using hybridization techniques well known in the art. These techniques include, but are not limited to: 1) hybridization of probes to genomic or cDNA libraries to detect homologous nucleotide sequences, and 2) antibody screening of expression libraries to detect cloned DNA fragments with common structural features .

The production of specific DNA fragment sequences encoding proteins with tumor suppressor function can also be obtained by the following methods: 1) isolation of double-stranded DNA sequences from genomic DNA; 2) chemical synthesis of DNA sequences to obtain double-stranded DNA of desired polypeptides.

Direct chemical synthesis of DNA sequences is often the method of choice when the entire amino acid sequence of the desired polypeptide product is known. If the entire sequence of the desired amino acids is not known, direct chemical synthesis of the DNA sequence is not possible and the method of choice is isolation of the cDNA sequence. The standard method for isolating cDNA of interest is to isolate mRNA from donor cells that highly express the gene and perform reverse transcription to form a plasmid or phage cDNA library. There are many mature technologies for the method of extracting mRNA, and the kit is also available from commercial sources (Qiagene). And constructing a cDNA library is also a common method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory. New York, 1989). Commercially available cDNA libraries are also available, such as various cDNA libraries from the company Clontech. When combined with polymerase reaction technology, even minimal expression products can be cloned.

These cDNA libraries can be screened for the gene of the present invention by a conventional method. These methods include (but are not limited to): (1) DNA-DNA or DNA-RNA hybridization; (2) function appearance or loss of marker genes; (3) measuring the level of transcripts of proteins with tumor suppressor function; (4) ) Detection of protein products expressed by genes by immunological techniques or assays of biological activity. The above methods can be used alone or in combination with multiple methods.

In the (1) method, the probe used for hybridization is homologous to any part of the polynucleotide of the present invention, and its length is at least 15 nucleotides, preferably at least 30 nucleotides, more preferably At least 50 nucleotides, preferably at least 100 nucleotides. In addition, the length of the probe is usually within 2kb, preferably within 1kb. The probes used here are usually DNA sequences chemically synthesized based on the gene DNA sequence information of the present invention. The genes themselves or fragments of the present invention can of course be used as probes. DNA probes can be labeled with radioactive isotopes, luciferin or enzymes (such as alkaline phosphatase) and the like.

In the (4) method, immunological techniques such as Western blotting, radioimmunoprecipitation, and enzyme-linked immunosorbent assay (ELISA) can be used to detect the protein product expressed by the protein gene with tumor suppressor function.

A method of amplifying DNA/RNA using the PCR technique (Saiki, et al. Science 1985; 230: 1350-1354) is preferably used to obtain the gene of the present invention. Especially when it is difficult to obtain full-length cDNA from the library, the RACE method (RACE-cDNA terminal rapid amplification method) can be preferably used, and the primers used for PCR can be appropriately selected according to the sequence information of the present invention disclosed herein, And can be synthesized by conventional methods. Amplified DNA/RNA fragments can be separated and purified by conventional methods such as by gel electrophoresis.

The nucleotide sequence of the gene of the present invention obtained as described above, or various DNA fragments, etc., can be determined by conventional methods such as the dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such nucleotide sequence determination can also use commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, sequencing needs to be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones before splicing into a full-length cDNA sequence.

The present invention also relates to the vector containing the polynucleotide of the present invention, the host cell produced by genetic engineering using the vector of the present invention or the protein coding sequence with tumor suppressor function, and the method for producing the polypeptide of the present invention by recombinant technology.

Through conventional recombinant DNA technology (Science, 1984; 224: 1431), the polynucleotide sequence of the present invention can be used to express or produce recombinant protein polypeptides with tumor suppressor function. Generally speaking, there are the following steps:

(1). Transform or transduce a suitable host cell with the polynucleotide (or variant) encoding a human protein with tumor suppressor function of the present invention, or with a recombinant expression vector containing the polynucleotide;

(2). Host cells cultured in a suitable medium;

(3). Isolate and purify protein from culture medium or cells.

In the present invention, the human protein polynucleotide sequence with tumor suppressor function can be inserted into the recombinant expression vector. The term "recombinant expression vector" refers to bacterial plasmid, phage, yeast plasmid, plant cell virus, mammalian cell virus such as adenovirus, retrovirus or other vectors well known in the art. Vectors applicable in the present invention include, but are not limited to: T7-based expression vectors (Rosenberg, et al. Gene, 1987, 56: 125) expressed in bacteria; pMSXND expression vectors expressed in mammalian cells (Lee and Nathans, J Bio Chem.263:3521, 1988) and vectors derived from baculovirus expressed in insect cells. In short, any plasmid and vector can be used as long as it can be replicated and stabilized in the host. An important feature of expression vectors is that they usually contain an origin of replication, a promoter, marker genes, and translational control elements.

Methods well known to those skilled in the art can be used to construct expression vectors containing human protein-coding DNA sequences with tumor suppressor function and appropriate transcription/translation control signals. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, etc. (Sambroook, et al.). Said DNA sequence can be operably linked to an appropriate promoter in the expression vector to direct mRNA synthesis. Representative examples of these promoters are: E. coli lac or trp promoter; lambda phage _PL promoter; eukaryotic promoters including CMV immediate early promoter, early and late SV40 promoter, retrovirus LTRs and Other known promoters that control gene expression in prokaryotic or eukaryotic cells or their viruses. The expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.

In addition, the expression vector preferably contains one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase for eukaryotic cell culture, neomycin resistance, and green Fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.

Vectors containing the above-mentioned appropriate DNA sequences and appropriate promoters or control sequences can be used to transform appropriate host cells so that they can express proteins.

The host cell may be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples are: Escherichia coli, Streptomyces spp; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; plant cells; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS or Bowes melanoma cells, etc.

When the polynucleotide of the present invention is expressed in higher eukaryotic cells, if an enhancer sequence is inserted into the vector, the transcription will be enhanced. Enhancers are cis-acting elements of DNA, usually about 10 to 300 base pairs in length, that act on promoters to enhance gene transcription. Examples include the SV40 enhancer of 100 to 270 base pairs on the late side of the replication origin, the polyoma enhancer on the late side of the replication origin, and the adenovirus enhancer.

Those of ordinary skill in the art will know how to select appropriate vectors, promoters, enhancers and host cells.

Transformation of host cells with recombinant DNA can be performed using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as E. coli, competent cells capable of taking up DNA can be harvested after the exponential growth phase and treated with the _CaCl2 method using procedures well known in the art. An alternative is to use _MgCl2 . Transformation can also be performed by electroporation, if desired. When the host is eukaryotic, the following DNA transfection methods can be used: calcium phosphate co-precipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.

The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. The medium used in the culture can be selected from various conventional media according to the host cells used. The culture is carried out under conditions suitable for the growth of the host cells. After the host cells have grown to an appropriate cell density, the selected promoter is induced by an appropriate method (such as temperature shift or chemical induction), and the cells are cultured for an additional period of time.

The recombinant polypeptide in the above method can be encapsulated inside the cell, outside the cell or expressed on the cell membrane or secreted outside the cell. The recombinant protein can be isolated and purified by various separation methods by taking advantage of its physical, chemical and other properties, if desired. These methods are well known to those skilled in the art. Examples of these methods include, but are not limited to: conventional refolding treatment, treatment with protein precipitating agents (salting out method), centrifugation, osmotic disruption, supertreatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.

The recombinant human protein or polypeptide with tumor suppressor function has many uses. These uses include (but are not limited to): direct use as a drug to treat diseases caused by the hypofunction or loss of proteins with tumor suppressor functions, and screening for antibodies, polypeptides or other ligands that promote or resist the functions of proteins with tumor suppressor functions. body. For example, antibodies can be used to activate or inhibit the function of human proteins that function as tumor suppressors. Screening the polypeptide library with the expressed recombinant human protein with tumor suppressor function can be used to find therapeutically valuable polypeptide molecules that can inhibit or stimulate the function of the human protein with tumor suppressor function.

The invention also provides methods of screening drugs to identify agents that enhance (agonists) or repress (antagonists) human proteins with tumor suppressor function. Agonists enhance biological functions of human proteins with tumor suppressor functions such as stimulating cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers. For example, mammalian cells or membrane preparations expressing a human protein with tumor suppressor function can be cultured with the labeled human protein with tumor suppressor function in the presence of a drug. The ability of the drug to enhance or repress this interaction is then determined.

Antagonists of human proteins with tumor suppressor function include screened antibodies, compounds, receptor deletions and analogs. The antagonist of the human protein with tumor suppressor function can combine with the human protein with tumor suppressor function and eliminate its function, or inhibit the production of the human protein with tumor suppressor function, or combine with the active site of the polypeptide so that the polypeptide cannot perform biological functions. Antagonists of human proteins that function as tumor suppressors are useful for therapeutic use.

When screening a compound as an antagonist, the protein of the present invention can be added to a bioanalytical assay, and whether the compound is an antagonist can be determined by measuring the effect of the compound on the interaction between the protein with tumor suppressor function and its receptor. Receptor deletions and analogs that function as antagonists can be screened in the same manner as described above for screening compounds.

The polypeptide of the present invention can be directly used in the treatment of diseases, for example, various malignant tumors, abnormal cell proliferation and the like.

The polypeptides of the present invention, and fragments, derivatives, analogs thereof or their cells can be used as antigens to produce antibodies. These antibodies can be polyclonal or monoclonal. Polyclonal antibodies can be obtained by injecting the polypeptide directly into animals. Techniques for preparing monoclonal antibodies include hybridoma technology, trioma technology, human B-cell hybridoma technology, EBV-hybridoma technology, and the like.

The polypeptides and antagonists of the present invention can be used in combination with suitable pharmaceutical carriers. These carriers can be water, dextrose, ethanol, salts, buffers, glycerol and combinations thereof. The composition contains safe and effective doses of polypeptides or antagonists as well as carriers and excipients that do not affect the drug effect. These compositions can be used as medicine for disease treatment.

The invention also provides kits or kits comprising one or more containers containing one or more ingredients of the pharmaceutical compositions of the invention. Along with these containers, there may be an indicative notice given by the governmental regulatory agency that manufactures, uses or sells the drug or biological product reflecting its approval for human administration by the governmental regulatory agency that manufactures, uses or sells the drug or biological product. In addition, the polypeptides of the invention can be used in combination with other therapeutic compounds.

The pharmaceutical compositions may be administered in a convenient manner, such as by topical, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes of administration. Proteins with tumor suppressor function are administered in amounts effective to treat and/or prevent the particular indication. The amount and dosage range of the protein with tumor suppressor function administered to a patient will depend on many factors, such as the mode of administration, the health condition of the person to be treated, and the judgment of the diagnosing physician.

Polynucleotides of human proteins with tumor suppressor function can also be used for various therapeutic purposes. Gene therapy technology can be used to treat abnormalities in cell proliferation, development or metabolism due to non-expression or abnormal/inactive expression of proteins with tumor suppressor functions. The recombinant gene therapy vector can be used to treat diseases caused by abnormal expression or activity of protein with tumor suppressor function. Expression vectors derived from viruses such as retroviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, and parvoviruses can be used to transfer protein genes with tumor suppressor functions into cells. The method for constructing a recombinant virus vector carrying a protein gene with tumor suppressor function can be found in the existing literature (Sambrook, et al.). In addition, the recombinant human protein gene with tumor suppressor function can be packaged into liposomes and transferred into cells.

Oligonucleotides (including antisense RNA and DNA) and ribozymes that inhibit human protein mRNA with tumor suppressor function are also within the scope of the invention. A ribozyme is an enzyme-like RNA molecule that can specifically decompose a specific RNA. Its mechanism of action is that the ribozyme molecule specifically hybridizes with a complementary target RNA to perform an endonucleic cut. Antisense RNA, DNA and ribozyme can be obtained by any existing RNA or DNA synthesis technology, such as solid-phase phosphoamide chemical synthesis of oligonucleotides, which has been widely used. Antisense RNA molecules can be obtained by in vitro or in vivo transcription of the DNA sequence encoding the RNA. This DNA sequence has been integrated into the vector downstream of the RNA polymerase promoter. In order to increase the stability of nucleic acid molecules, it can be modified in a variety of ways, such as increasing the sequence length on both sides, and the connection between ribonucleosides should use phosphothioester bonds or peptide bonds instead of phosphodiester bonds.

The methods for introducing polynucleotides into tissues or cells include: directly injecting polynucleotides into tissues in the body; or first introducing polynucleotides into cells in vitro through vectors (such as viruses, phages, or plasmids, etc.) , and then transplant the cells into the body, etc.

The polypeptide of the present invention can also be used for peptide spectrum analysis, for example, the polypeptide can be specifically cleaved physically, chemically or enzymatically, and subjected to one-dimensional, two-dimensional or three-dimensional gel electrophoresis analysis.

The invention also provides an antibody against the human protein antigenic determinant with tumor suppressor function. These antibodies include, but are not limited to: polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies, Fab fragments and fragments produced by a Fab expression library. These antibodies can be prepared by conventional methods. Antibodies against human tumor suppressor proteins can be used in immunohistochemical techniques to detect human tumor suppressor proteins in biopsy specimens.

Monoclonal antibodies that bind to human proteins with tumor suppressor functions can also be labeled with radioactive isotopes, and injected into the body to track their location and distribution. The antibody of the present invention can be used to treat or prevent diseases related to the human protein with tumor suppressor function. Administration of appropriate doses of antibodies can stimulate or block the production or activity of human proteins with tumor suppressor functions.

Antibodies can also be used to design immunotoxins that target a particular site in the body. For example, high-affinity monoclonal antibodies to human proteins with tumor suppressor functions can be covalently combined with bacterial or plant toxins (such as diphtheria toxin, ricin, rhododine, etc.).

The production of polyclonal antibodies can be used to immunize animals, such as rabbits, mice, rats, etc., with human proteins or polypeptides with tumor suppressor functions. Various adjuvants can be used to enhance the immune response, including but not limited to Freund's adjuvant and the like.

Human protein monoclonal antibodies with tumor suppressor function can be produced by hybridoma technology (Kohler and Milstein. Nature, 1975, 256: 495-497). Chimeric antibodies combining human constant regions and non-human variable regions can be produced using existing techniques (Morrison et al, PNAS, 1985, 81:6851). The existing technology for producing single-chain antibodies (U.S. Pat No. 4946778) can also be used to produce single-chain antibodies against human proteins with tumor suppressor functions.

The polypeptide molecule capable of binding to the protein of the present invention can be obtained by screening a random polypeptide library composed of various possible combinations of amino acids bound to solid phases. During screening, human protein molecules with tumor suppressor function must be labeled.

The invention also relates to a diagnostic test method for quantitative and localized detection of the human protein level with tumor suppressor function. These assays are well known in the art and include FISH assays and radioimmunoassays. The level of human protein with tumor suppressor function detected in the test can be used to explain the importance of human protein with tumor suppressor function in various diseases and to diagnose diseases in which the protein with tumor suppressor function plays a role.

The polynucleotide of the protein with tumor suppressor function can be used for the diagnosis and treatment of diseases related to the protein with tumor suppressor function. In terms of diagnosis, the polynucleotide of the protein with tumor suppressor function can be used to detect the expression of the protein with tumor suppressor function or the abnormal expression of the protein with tumor suppressor function in a disease state. For example, DNA sequences of proteins with tumor suppressor function can be used for hybridization of biopsy specimens to determine abnormal expression of proteins with tumor suppressor function. Hybridization techniques include Southern blotting, Northern blotting, in situ hybridization, and the like. These technical methods are all open and mature technologies, and relevant kits are available from commercial sources. Part or all of the polynucleotides of the present invention can be used as probes to be immobilized on microarrays (Microarray) or DNA chips (also known as "gene chips") for analysis of differential expression of genes in tissues and gene diagnosis. RNA-polymerase chain reaction (RT-PCR) in vitro amplification with specific primers of the protein with tumor suppressor function can also detect the transcription product of the protein with tumor suppressor function.

The detection of the mutation of the protein gene with tumor suppressor function can also be used to diagnose the diseases related to the protein with tumor suppressor function. The form of protein mutation with tumor suppressor function includes point mutation, translocation, deletion, recombination and any other abnormality compared with the normal wild type protein DNA sequence with tumor suppressor function. Mutations can be detected using established techniques such as Southern blotting, DNA sequence analysis, PCR and in situ hybridization. In addition, mutations may affect protein expression, so Northern blotting and Western blotting can be used to indirectly determine whether a gene has a mutation.

The sequences of the invention are also valuable for chromosome identification. These sequences are specific for a specific location on a human chromosome and can hybridize thereto. Currently, there is a need to identify the specific site of each gene on the chromosome. However, only a few chromosomal markers based on actual sequence data (repeated polymorphisms) are currently available to mark chromosomal positions. In order to correlate these sequences with disease-associated genes. The first step is to locate the DNA sequence of the present invention on the chromosome.

In short, PCR primers (preferably 15-35bp) are prepared according to the cDNA, and the sequence can be positioned on the chromosome. These primers were then used for PCR screening of somatic heterozygous cells containing individual human chromosomes. Only those cells heterozygous for the human gene corresponding to the primer will produce an amplified fragment.

The PCR mapping method of somatic heterozygous cells is a quick method to locate DNA to specific chromosomes. Using the oligonucleotide primers of the present invention, sublocalization can be achieved using a set of fragments from a specific chromosome or a large number of genomic clones by a similar method. Other similar strategies that can be used for chromosome mapping include in situ hybridization, chromosome prescreening by flow sorting with markers, and hybridization preselection to construct chromosome-specific cDNA libraries.

Fluorescence in situ hybridization (FISH) of cDNA clones to metaphase chromosomes allows precise chromosomal mapping in a single step. For a review of this technique, see Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988).

Once a sequence has been mapped to an exact chromosomal location, the physical location of the sequence on the chromosome can be correlated with gene map data. These data can be found, for example, in V. Mckusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library). Linkage analysis can then be used to determine the relationship between the gene and the disease that has been mapped to the chromosomal region.

Next, the cDNA or genome sequence differences between affected and non-affected individuals need to be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individual, the mutation may be the cause of the disease. Comparing affected and unaffected individuals usually involves first looking for structural changes in chromosomes, such as deletions or translocations that are visible at the chromosomal level or detectable with cDNA sequence-based PCR.

The protein nucleotide full-length sequence or its fragments with tumor suppressor function of the present invention can usually be obtained by PCR amplification method, recombination method or artificial synthesis method. For the PCR amplification method, primers can be designed according to the relevant nucleotide sequences disclosed in the present invention, especially the open reading frame sequence, and the cDNA prepared by a commercially available cDNA library or a conventional method known to those skilled in the art can be used. The library is used as a template to amplify related sequences. When the sequence is long, it is often necessary to carry out two or more PCR amplifications, and then splice together the amplified fragments in the correct order.

Once the relevant sequences are obtained, recombinant methods can be used to obtain the relevant sequences in large quantities. Usually, it is cloned into a vector, then transformed into a cell, and then the relevant sequence is isolated from the proliferated host cell by conventional methods.

In addition, related sequences can also be synthesized by artificial synthesis, especially when the fragment length is relatively short. Often, fragments with very long sequences are obtained by synthesizing multiple small fragments and then ligating them.

At present, the DNA sequence encoding the protein of the present invention (or its fragments, or its derivatives) can be completely chemically synthesized. This DNA sequence can then be introduced into various DNA molecules (such as vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequences of the invention by chemical synthesis.

In addition, since the protein with tumor suppressor function of the present invention has a natural amino acid sequence derived from humans, it is expected to have higher activity and/or lower Low side effects (eg, less or no immunogenicity in humans).

Below in conjunction with specific embodiment, further illustrate the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental method that does not indicate specific conditions in the following examples, usually according to conventional conditions such as Sambrook et al., molecular cloning: the conditions described in the laboratory manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's instructions suggested conditions.

Example 1: Obtaining of cDNA gene and its inhibitory effect on 3T3 cell clone formation

PP239, PP446, PP5715, PP6977, PP8482, PP8607, PP8857, PP8875, PP8997, PP9012, PP9286 and PP9363 were obtained by constructing human placenta cDNA library by conventional methods. Placental tissues at 3, 6, and 10 months old were taken, and total RNA was extracted with Trizol reagent (GIBCO BRL Company) according to the manufacturer's instructions, and mRNA was extracted with an mRNA purification kit (Pharmacia Company). The cDNA library of the above mRNA was constructed with the pCMV-script TMXR cDNA library construction kit (Stratagene). The reverse transcriptase was changed to MMLV-RT-Superscript II (GIBCO BRL), and the reverse transcription reaction was carried out at 42°C. XL10-Gold competent cells were transformed, and a cDNA library with a titer of 1×10 ⁶ cfu/μg was obtained. In the first round, cDNA clones were randomly selected, and then high-abundance cDNA clones and cDNA clones that had been proven to inhibit the growth of cancer cells were used as probes to hybridize and screen the cDNA library to pick weakly positive and negative clones. Plasmid DNA was extracted using Qiagen 96-well plate plasmid extraction kit according to the manufacturer's instructions. Plasmid DNA and empty vector were transfected into the cell line 3T3 at the same time. After 100ng DNA was precipitated and dried by alcohol, 6μl H ₂ O was added to dissolve it and wait for transfection. Add 0.74 μl liposome and 9.3 μl serum-free culture solution to each DNA sample, mix well, and place at room temperature for 10 minutes. Add 150 μl of serum-free culture medium to each tube, add evenly to 7721 cells grown in 96-well plates in 3 wells, place at 37°C for 2 hours, add 50 μl of serum-free culture medium to each well, and incubate at 37°C for 24 hours. Change 100 μl of whole culture solution in each well, 37°C for 24 hours, change 100 μl of whole culture solution containing G418, and keep at 37°C for 24-48 hours, while observing, change the culture solution with different concentrations of G418. After about 2-3 times, until the microscopic examination of the cells has colony formation, count. It was found that the above 12 clones have the effect of inhibiting cell clone formation, and the results are shown in the table below.

Cloning formation of cDNA clone transfected cells (3T3) cDNA clone name Number of cDNA clones (three replicates) Number of empty vector clones (three replicates) PP239PP446PP5715PP6977PP8482PP8607PP8857PP8875PP8997PP9012PP9286PP9363 6 5 38 6 310 12 1414 15 1913 14 1811 15 1710 12 1411 15 1710 21 1413 15 197 6 33 2 4 50 36 2550 36 2527 29 3027 29 3027 29 3027 29 3027 29 3027 29 3027 29 3027 29 3027 29 3027 29 30

The dideoxy termination method was used for the cDNA clone, and the nucleotide sequence of nearly 500 bp at one end was determined on an ABI377 DNA automatic sequencer. After analysis, it was determined to be a new gene clone, and the other end was sequenced, but the full-length cDNA sequence was still not obtained, primers were designed, and sequencing was performed again until the full-length sequence (SEQ ID NO: 1, 4, 7, 10, 13, 16 , 19, 22, 25, 28, 31, 34).

Embodiment 2: PCR obtains full-length gene from placenta cDNA:

Placenta tissues at 3, 6, and 10 months old were taken, and total RNA was extracted with Trizol reagent (GIBCO BRL Company) according to the manufacturer's instructions, and mRNA was extracted with an mRNA purification kit (Pharmacia Company). Using MMLV-RT-SuperscriptII (GIBCO BRL) and reverse transcriptase at 42°C for reverse transcription reaction to obtain placental cDNA. Use the transmutation primers of each gene (as shown in the table below), according to 97°C 3′1 cycle; 94°C 30″→60°C 30″→72°C 1′, a total of 35 cycles; 72°C 10′, 1 cycle PCR amplification is carried out in cycles to obtain the amplification products of each protein gene containing the complete open reading frame sequence. The amplified product was verified by sequencing and was consistent with the sequence measured in Example 1, and then the amplified product was transferred to a host cell using conventional techniques to obtain recombinant proteins (SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35).

gene specific primers clone name Specific primer 1 (5'→3') Specific primer 2 (5'→3') PP239PP446PP5715PP6977PP8482PP8607PP8857PP8875PP8997PP9012PP9286PP9363 TAGTGATTGAGGCCATGCTGTTTGCCATCACATACCTGGACTTTGGACTGAGGTCCCTGTAGGACCTGTGTGAGCTGCATGGGGGTATGATAAGCTGGGACCTCCCGCTGAGTGTATTTCAGATGAATGTGGCCTTCGAGAGGGGTTAACGTTAGCATGGCTCGTCCCTCGCAGTCTGAGACGCAGCTGTGTGAAATCCGTCCTGAATGTCTTGAGAGCTCTC AGAGGCACAAGGAGGCAGTAGCTGCAGTCTTGGATGGTCTCAGCATTTGTGCTTCTGAGCCAGGTAGCCCCGTAGCAGTTCGTCACTCTCCATGTCCAGGCTCTGGGATGAACTTGGAGGGATCCAGCAGTGAGAAGGACAAACCTGAGTCCTCCTCCAGGAAGGGGTTCATGTCATTGTTTGGAGAAAGCTGCAAAAGCAGGCTCGTCTTCAATAGTGTGGTCAGGT

Embodiment 3: cDNA clone sequence analysis 1. PP239A：核苷酸序列(SEQ ID NO：1)长度：24531  GGCCATTTTG CGGGAAGAGG AGGCGCTGTA CCTGCAGTGC TGCTTTTCTT GCCTAGACTC61  TAGGAACTAT CCGAGCTCCA CTCCCCACAA CATACTCAAA GGAACGGAGA GAACCGGGAC121  CCCCCTGCGG GGACCCGGAA CTGATCTGAC AGGATGGCAT CTGATGACTT TGACATAGTG181  ATTGAGGCCA TGCTGGAAGC TCCCTATAAA AAAGAAGAGG ATGAGCAACA AAGGAAAGAA241  GTTAAAAAGG ATTATCCTAG CAATACCACC AGCAGCACCA GCAACAGTGG CAATGAGACC301  AGTGGAAGCA GCACCATCGG GGAGACAAGC AAGAAGAAGA GGAGTCGGAG CCATAATAAA361  AGCAGGGATA GAAAGCGCAG TCGTAGTCGA GATCGGGATC GGTATAGACG GAGAAATAGT421  CGGAGCCGAA GTCCAGGTCG GCAGTGTCGT CACCCGTAGC CGTAGCTGGG ATCGTCGACA481  TGGTAGTGAG TCGCGAAGTC GGGACCATCG TCGTGAGGAT CGTGTGCATT ACAGGAGTCC541  TCCACTTACC ACTGGTTATA GATATGGACA CAGTAAGAGT CCTCATTTCA GAGAGAAGAG601  CCCAGTCAGG GAGCCAGTTG ATAATCTGAG TCCTGAGGAG CGTGATGCCC GCACAGTTTT661  CTGTATGCAG TTAGCTGCCC GAATTCGGCC TCGAGATCTG GAGGACTTTT TCTCTGCTGT721  AGGCAAGGTT CGCGATGTAC GTATCATTTC AGATCGGAAC TCACGTCGTT CTAAGGGCAT781  TGCCTACGTG GAATTCTGTG AAATCCAGTC TGTGCCACTG GCCATTGGGC TGACTGGGCA841 GCGGTTGCTG GGAGTGCCTA TCATTGTACA GGCTTCACAG GCAGAGAAAA ACCGACTGGC901  AGCCATGGCC AACAACCTGC AAAAGGGCAA TGGTGGACCA ATGCGCCTCT ATGTGGGTTC961  CCTGCACTTC AATATCACTG AAGACATGCT CCGGGGCATC TTTGAGCCCT TTGGTAAAAT1021  TGATAATATT GTCCTGATGA AGGACTCAGA TACAGGCCGC TCTAAAGGTT ATGGTTTCAT1081  CACGTTCTCT GATTCTGAGT GTGCCCGGCG GGCCCTGGAA CAGTTGAATG GGTTTGAGCT1141  TGCTGGTCGA CCTATGAGGG TTGGCCATGT GACTGAGCGA CTGGATGGTG GCACAGACAT1201  CACTTTTCCT GATGGGGACC AGGAGCTGGA TCTGGGATCA GCAGGTGGAC GTTTTCAGCT1261  CATGGCAAAA CTGGCAGAAG GCGCTGGAAT CCAACTGCCA AGCACTGCTG CTGCTGCTGC1321  TGCCGCCGCC GCCGCCCAGG CTGCTGCCTT GCAACTGAAT GGAGCAGTTC CCTTGGGGGC1381  CCTGAATCCA GCAGCTCTGA CTGCTCTGAG TCCAGCCCTG AACCTTGCCT CCCAGTGTTT1441  CCAGCTCTCC AGCCTCTTTA CCCCCCAGAC CATGTAAATC AGTGGCACAG TATACTGCCT1501  CCTTGTGCCT CTGGATCCTG CCACTTCACA TCTACTCTTC CATGGCCCCA TTTCTCCATT1561  TTGTGGACCA AGCCATCCTG AGGGCATGGA CATTGTCTCT GAGGAAATTG GGGCCACCCT1621  TAAGATACCA AGAAAAGCTC CTGCCCATGG TCCCACTGGA AATGGACTCT GCTGAGCAAA1681  GCCACCAGTT GAAGAGAACA GAATCCACAC CTGCATTGAA TACCTGTTTC TCCATGTGTA1741  TCGTCTCTGA GATTACCTTC TTGCCCTTTC CAACACCTTA GTGATTCCTC AATTTCTCCC1801  CCATTGGGAA GGCCATAGGG CATTAACTGA AGGAACTGAC CTCTCTCCTT TTCCTGTACC1861  TTTAACCTTT AGTCTGTCAA GGAAAACCCT TAGGACCTCT GAATCAAGAG GACTGAGTTT1921  GTGGGTGAAC CTTGAAGGTG CTCTTTCTGC TACAAGGGCC CTGGGAGATA GCATGGACGT1981  GCATTGAGAA GCCAGCCTCA GACCTTAGCT TGAAGCAGCT TGAGGCCAGA CCTACTGTAG2041  CCTCAGCATC TTGCTAGGAG GCATGGAAGT GATCTATCCT GCCAGGAGGC CTCAGAGTGA2101  TCTGTCCTGC CAGGAGGTGT GAGAGTGATC TGTCCTGTGA GGCATTTAGG GGCTTTCAGG2161  AATTTAGTAA AAGGTGGAGT ATGCCTTTCC AGTATCTTCC ATCTTCCTTT GTATACTTGT2221  CCTTCCTCCC ATTTCCTCCC TTTGGCCCGA GGTAGGAGGA TGGAGGGAGG CTGCTACTCT2281  ACCACTTCCT GTGTGCCTCT ACTGTGGCCT CAACCCTGGC AATTATAGCT ACTCCCATCC2341 CTTACCTGGG CATGTGTGAG CCCTTCTCAC TGGATTTTAT ACCCTTGTGT CTGTGTACAT2401  AAATATATAT ACATATATAT ATCCATAAAA AAAAAAAAAA AAAAAAAAAA AAAB：核苷酸序列(SEQ ID NO：2)长度：4181   MSNKGKKLKR IILAIPPAAP ATVAMRPVEA APSGRQARRR GVGAIIKAGI ESAVVVEIGI61   GIDGEIVGAE VQVGSVVTRS RSWDRRHGSE SRSRDHRRED RVHYRSPPLT TGYRYGHSKS121   PHFREKSPVR EPVDNLSPEE RDARTVFCMQ LAARIRPRDL EDFFSAVGKV RDVRIISDRN181   SRRSKGIAYV EFCEIQSVPL AIGLTGQRLL GVPIIVQASQ AEKNRLAAMA NNLQKGNGGP241   MRLYVGSLHF NITEDMLRGI FEPFGKIDNI VLMKDSDTGR SKGYGFITFS DSECARRALE301   QLNGFELAGR PMRVGHVTER LDGGTDITFP DGDQELDLGS AGGRFQLMAK LAEGAGIQLP361   STAAAAAAAA AAQAAALQLN GAVPLGALNP AALTALSPAL NLASQCFQLS SLFTPQTMC. Nucleotide and amino acid combination sequence (SEQ ID NO: 3) Clone number: PP239 Start code: 221 ATG Stop code: 1475 TAA Protein molecular weight: 45028. 93 (Note: (1) The position of the first nucleotide of the start and end codes is given, (2) The molecular weight unit is Dalton.) 1 G GCC ATT TTG CGG GAA GAG GAG GCG CTG TAC CTG CAG TGC TGC TTT      4647  TCT TGC CTA GAC TCT AGG AAC TAT CCG AGC TCC ACT CCC CAC AAC ATA      9495  CTC AAA GGA ACG GAG AGA ACC GGG ACC CCC CTG CGG GGA CCC GGA ACT     142143  GAT CTG ACA GGA TGG CAT CTG ATG ACT TTG ACA TAG TGA TTG AGG CCA     190191  TGC TGG AAG CTC CCT ATA AAA AAG AAG AGG ATG AGC AAC AAA GGA AAG     2381                                          Met Ser Asn Lys Gly Lys       6239  AAG TTA AAA AGG ATT ATC CTA GCA ATA CCA CCA GCA GCA CCA GCA ACA     2867  Lys Leu Lys Arg Ile Ile Leu Ala Ile Pro Pro Ala Ala Pro Ala Thr      22287  GTG GCA ATG AGA CCA GTG GAA GCA GCA CCA TCG GGG AGA CAA GCA AGA     33423  Val Ala Met Arg Pro Val Glu Ala Ala Pro Ser Gly Arg Gln Ala Arg      38335  AGA AGA GGA GTC GGA GCC ATA ATA AAA GCA GGG ATA GAA AGC GCA GTC     38239  Arg Arg Gly Val Gly Ala Ile Ile Lys Ala Gly Ile Glu Ser Ala Val      54383  GTA GTC GAG ATC GGG ATC GGT ATA GAC GGA GAA ATA GTC GGA GCC GAA     43055  Val Val Glu Ile Gly ILE GLY GLY GLY GLU ILE Val Gly Ala Glu 70431 GTC CAG GGC GGC GTC GTC ACC CGT AGC CGT CGT CGT CGT CGT CGT CGT CGT 87871 Val Val Val Val THR ARG ARG ARG ARG ARG SERG SERG SERG SERG Serg Ser THRGRGRGRGR ARG ARGRGRGRGRGRG's's's's CAT GGT AGT GAG TCG CGA AGT CGG GAC CAT CGT CGT GAG GAT CGT GTG     52687  His Gly Ser Glu Ser Arg Ser Arg Asp His Arg Arg Glu Asp Arg Val     102527  CAT TAC AGG AGT CCT CCA CTT ACC ACT GGT TAT AGA TAT GGA CAC AGT 574103  His Tyr Arg Ser Pro Pro Leu Thr Thr Gly Tyr Arg Tyr Gly His Ser     118575  AAG AGT CCT CAT TTC AGA GAG AAG AGC CCA GTC AGG GAG CCA GTT GAT     622119  Lys Ser Pro His Phe Arg Glu Lys Ser Pro Val Arg Glu Pro Val Asp     134623  AAT CTG AGT CCT GAG GAG CGT GAT GCC CGC ACA GTT TTC TGT ATG CAG     670135  Asn Leu Ser Pro Glu Glu Arg Asp Ala Arg Thr Val Phe Cys Met Gln     150671  TTA GCT GCC CGA ATT CGG CCT CGA GAT CTG GAG GAC TTT TTC TCT GCT     718151  Leu Ala Ala Arg Ile Arg Pro Arg Asp Leu Glu Asp Phe Phe Ser Ala     166719  GTA GGC AAG GTT CGC GAT GTA CGT ATC ATT TCA GAT CGG AAC TCA CGT     766157  Val Gly Lys Val Arg Asp Val Arg Ile Ile Ser Asp Arg Asn Ser Arg     182767  CGT TCT AAG GGC ATT GCC TAC GTG GAA TTC TGT GAA ATC CAG TCT GTG     814183  Arg Ser Lys Gly Ile Ala Tyr Val Glu Phe Cys Glu Ile Gln Ser Val     198815  CCA CTG GCC ATT GGG CTG ACT GGG CAG CGG TTG CTG GGA GTG CCT ATC     862199  Pro Leu Ala Ile Gly Leu Thr Gly Gln Arg Leu Leu Gly Val Pro Ile     214863  ATT GTA CAG GCT TCA CAG GCA GAG AAA AAC CGA CTG GCA GCC ATG GCC     910215  Ile Val Gln Ala Ser Gln Ala Glu Lys Asn Arg Leu Ala Ala Met Ala     230911  AAC AAC CTG CAA AAG GGC AAT GGT GGA CCA ATG CGC CCC TAT GTG GGT     958231  Asn Asn Leu Gln Lys Gly Asn Gly Gly Pro Met Arg Leu Tyr Val Gly     246959  TCC CTG CAC TTC AAT ATC ACT GAA GAC ATG CTC CGG GGC ATC TTT GAG    1006247  Ser Leu His Phe Asn Ile Thr Glu Asp Met Leu Arg Gly Ile Phe Glu     2621007  CCC TTT GGT AAA ATT GAT AAT ATT GTC CTG ATG AAG GAC TCA GAT ACA    1054263  Pro Phe Gly Lys Ile Asp Asn Ile Val Leu Met Lys Asp Ser Asp Thr     2781055  GGC CGC TCT AAA GGT TAT GGT TTC ATC ACG TTC TCT GAT TCT GAG TGT    1102279  Gly Arg Ser Lys Gly Tyr Gly Phe Ile Thr Phe Ser Asp Ser Glu Cys     2941103  GCC CGG CGG GCC CTG GAA CAG TTG AAT GGG TTT GAG CTT GCT GGT CGA    1150295  Ala Arg Arg Ala Leu Glu Gln Leu Asn Gly Phe Glu Leu Ala Gly Arg     3101151  CCT ATG AGG GTT GGC CAT GTG ACT GAG CGA CTG GAT GGT GGC ACA GAC    1198311  Pro Met Arg Val Gly His Val Thr Glu Arg Leu Asp Gly Gly Thr Asp     3261199  ATC ACT TTT CCT GAT GGG GAC CAG GAG CTG GAT CTG GGA TCA GCA GGT    1246327  Tle Thr Phe Pro Asp Gly Asp Gln Glu Leu Asp Leu Gly Ser Ala Gly     3421247  GGA CGT TTT CAG CTC ATG GCA AAA CTG GCA GAA GGC GCT GGA ATC CAA    1294 343  Gly Arg Phe Gln Leu Met Ala Lys Leu Ala Glu Gly Ala Gly Ile Gln     3581295  CTG CCA AGC ACT GCT GCT GCT GCT GCT GCC GCC GCC GCC GCC CAG GCT    1342359  Leu Pro Ser Thr Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala Gln Ala     3741343  GCT GCC TTG CAA CTG AAT GGA GCA GTT CCC TTG GGG GCC CTG AAT CCA    1390375  Ala Ala Leu Gln Leu Asn Gly Ala Val Pro Leu Gly Ala Leu Asn Pro     3901391  GCA GCT CTG ACT GCT CTG AGT CCA GCC CTG AAC CTT GCC TCC CAG TGT    1438391  Ala Ala Leu Thr Ala Leu Ser Pro Ala Leu Asn Leu Ala Ser Gln Cys     4061439  TTC CAG CTC TCC AGC CTC TTT ACC CCC CAG ACC ATG TAA ATC AGT GCC    1486407  Phe Gln Leu Ser Ser Leu Phe Thr Pro Gln Thr Met ***                 4191487  ACA GTA TAC TGC CTC CTT GTG CCT CTG GAT CCT GCC ACT TCA CAT CTA    15341535  CTC TTC CAT GGC CCC ATT TCT CCA TTT TGT GGA CCA AGC CAT CCT GAG    15821583  GGC ATG GAC ATT GTC TCT GAG GAA ATT GGG GCC ACC CTT AAG ATA CCA    16301631  AGA AAA GCT CCT GCC CAT GGT CCC ACT GGA AAT GGA CTC TGC TGA GCA    16781679  AAG CCA CCA GTT GAA GAG AAC AGA ATC CAC ACC TGC ATT GAA TAC CTG    17261727  TTT CTC CAT GTG TAT CGT CTC TGA GAT TAC CTT CTT GCC CTT TCC AAC    17741775  ACC TTA GTG ATT CCT CAA TTT CTC CCC CAT TGG GAA GGC CAT AGG GCA    18221823  TTA ACT GAA GGA ACT GAC CTC TCT CCT TTT CCT GTA CCT TTA ACC TTT    18701871 AGT CTG TCA AGG AAA ACC CTT AGG ACC TCT GAA TCA AGA GGA CTG AGT    19181919  TTG TGG GTG AAC CTT GAA GGT GCT CTT TCT GCT ACA AGG GCC CTG GGA    19661967  GAT AGC ATG GAC GTG CAT TGA GAA GCC AGC CTC AGA CCT TAG CTT GAA 20142015  GCA GCT TGA GGC CAG ACC TAC TGT AGC CTC AGC ATC TTG CTA GGA GGC    20622063  ATG GAA GTG ATC TAT CCT GCC AGG AGG CCT CAG AGT GAT CTG TCC TGC    21102111  CAG GAG GTG TGA GAG TGA TCT GTC CTG TGA GGC ATT TAG GGG CTT TCA    21582159  GGA ATT TAG TAA AAG GTG GAG TAT GCC TTT CCA GTA TCT TCC ATC TTC    22062207  CTT TGT ATA CTT GTC CTT CCT CCC ATT TCC TCC CTT TGG CCC GAG GTA    22542255  GGA GGA TGG AGG GAG GCT GCT ACT CTA CCA CTT CCT GTG TGC CTC TAC    23022303  TGT GGC CTC AAC CCT GGC AAT TAT AGC TAC TCC CAT CCC TTA CCT GGG    23502351  CAT GTG TGA GCC CTT CTC ACT GGA TTT TAT ACC CTT GTG TCT GTG TAC    23982399  ATA AAT ATA TAT ACA TAT ATA TAT CCA TAA AAA AAA AAA AAA AAA AAA 24462447 AAA AAA A 24532. PP446A：核苷酸序列(SEQ ID NO：4)长度：20861  GGGCATCAAG TCTCTGTCTC CCTTTGCCAT CACATACCTG GATCGGCTGC TCCTGATGCA61  TCCCAACCTT ACCAAGGGCT TCGGCATGAT TGGCCCCAAG GACTTCTTCC CACTTCTGGA121  CTTTGCCTAT ATGCCGAACA ACTCCCTGAC ACCCAGCCTG CAGGAGCAGC TGTGTCAGCT181  CTACCCCCGA CTGAAAGTGC TGGCATTTGG AGCAAAGCCG GATTCCACCC TGCATACCTA241  CTTCCCTTCT TTCCTGTCCA GAGCCACCCC TAGCTGTCCC CCTGAGATGA AGAAAGAGCT301  CCTGAGCAGC CTGACTGAGT GCCTGACGGT GGACCCCCTC AGTGCCAGCG TCTGGAGGCA361  GTTGTACCCT AAGCACCTGT CACAGTCCAG CCTTCTGCTG GAGCACTTGC TCAGCTCCTG421  GGAGCAGATT CCCAAGAAGG TACAGAAGTC TTTGCAAGAA ACCATTCAGT CCCTCAAGCT481  TACCAACCAG GAGCTGCTGA GGAAGGGTAG CAGTAACAAC CAGGATGTCG TCACCTGTGA541  CATGGCCTGC AAGGGCCTGT TGCAGCAGGT TCAGGGTCCT CGGCTGCCCT GGACGCGGCT601  CCTCCTGTTG CTGCTGGTCT TCGCTGTAGG CTTCCTGTGC CATGACCTCT GGTCACACAG661  CTCCTTCCAG GCCTCCCTTA CTGGCCGGTT GCTTCGATCA TCTGGCTTCT TACCTGCTAG721  CCAACAAGCG TGTGCCAAGC TCTACTCCTA CAGTCTGCAA GGCTACAGCT GGCTGGGGGA781  GACACTGCCG CTCTGGGGCT CCCACCTGCT CACCGTGGTG CGGCCCAGCT TGCAGCTGGC841 CTGGGCTCAC ACCAATGCCA CAGTCAGCTT CCTTTCTGCC CACTGTGCCT CTCACCTTGC901  GTGGTTTGGT GACAGTCTCA CCAGTCTCTC TCAGAGGCTG CAGATCCAGC TCCCCGATTC961  CGTGAATCAG CTACTCCGCT ATCTGAGAGA GCTGCCCCTG CTTTTCCACC AGAATGTGCT1021  GCTGCCACTG TGGCACCTCT TGCTTGAGGC CCTGGCCTGG GCCCAGGAGC ACTGCCATGA1081  GGCATGCAGA GGTGAGGTGA CCTGGGACTG CATGAAGACA CAGCTCAGTG AGGCTGTCCA1141  CTGGACCTGG CTTTGCCTAC AGGACATTAC AGTGGCTTTC TTGGACTGGG CACTTGCCCT1201  GATATCCCAG CAGTAGGCCC TGCCTTCCTG GCCACTGATT TCTGCATGGG TAGACCATCC1261  AAGACTGCAG CGGGTAGAAG GTGGCAGTTC TTCATGGGAG TCTTTTTAAC TTGGTGCCTG1321  AGTTCTCTCC TAGGCAAGTG GCCAGTTGCC TCCACCTCAG TTCTTCCATC TTTGGTGGGG1381  ACAGGGCCCA GCAGCATCTC AGCCTCCTAC CCACAATTCC ACTGAACACT TTTCTGGCCC1441  TACTGCACAT GGCCCCCAGC CTCCATCCTT GTGCTGGTAG CCTCTCACAA CTCCGCCCTT1501  GCCCTCTGCC TTCCACTTCC TTCCATCTCA TTTCTAAACC CCAAACAGCT CATCTCTAAA1561  AAGATAGAAC TCCCAGCAGG TGGCTTCTGT GTTCTTCTGA CAAATGATTC CTGCTTCTCC1621  AGACTTTAGC AGCCTCCTGT TCCCATTCTT GGTCACAGCT CTAGCCACAG CAGAAGGAAA1681  GGGGCTTCCA GAAGAATATA GCACGGCATT GGGAAACAGC AGCCTCACCT CCACCTGAAG1741  CCTGGGTGTG GCTGTCAGTG GACATGGGGA GCTGGATGGA AATGCCTCTC ACTTCAAAAT1801  GCCCAGCCTG CCCCAAATGC CTCTAAGCCC CTCCCTGTCC CCTCCCTTGT AGTCCTACTT1861  CTTCCAACTT TCCATTCCCC ATCATGCTGG GGGTCTTGGT CACAAGGCTC AGCTTCTCTC1921  CACTGTCCAT CCCTCCTATC ATCTGTAGAG CAGAGCACAG GCAGTTGTGT GCCTTGGGCC1981  CAGGGAACCC TCCATCAACC TGAGACAGGA CTCAGTATAT GGTTCTTGGG TATGCCCTAC2041  CAGGTGGAAT AAAGGACACA GATTTGAAAA AAAAAAAAAA AAAAAAB：核苷酸序列(SEQ ID NO：5)长度：3861  MHPNLTKGFG MIGPKDFFPL LDFAYMPNNS LTPSLQEQLC QLYPRLKVLA FGAKPDSTLH61  TYFPSFLSRA TPSCPPEMKK ELLSSLTECL TVDPLSASVW RQLYPKHLSQ SSLLLEHLLS121  SWEQIPKKVQ KSLQETIQSL KLTNQELLRK GSSNNQDVVT CDMACKGLLQ QVQGPRLPWT181  RLLLLLLVFA VGFLCHDLWS HSSFQASLTG RLLRSSGFLP ASQQACAKLY SYSLQGYSWL241  GETLPLWGSH LLTVVRPSLQ LAWAHTNATV SFLSAHCASH LAWFGDSLTS LSQRLQIQLP301  DSVNQLLRYL RELPLLFHQN VLLPLWHLLL EALAWAQEHC HEACRGEVTW DCMKTQLSEA361  VHWTWLCLQD ITVAFLDWAL ALISQQC. Nucleotide and amino acid combination sequence (SEQ ID NO: 6) Clone number: PP446 Start code: 56 ATG Stop code: 1214 TAG Protein molecular weight: 43684. 301 GGC ATC AAG TCT CTG TCT CCC TTT GCC ACA TAC CTG Gat CGG 4647 CTG CTC CTG CAC ACC ACC AAG GGC GGC ATT GGC 941 MET HIS PHLL LYS GLY MEU GLY MEU GLY MEU GLY AAG GAC TTC TTC CCA CTT CTG GAC TTT GCC TAT ATG CCG AAC AAC     14214  Pro Lys Asp Phe Phe Pro Leu Leu Asp Phe Ala Tyr Met Pro Asn Asn      29143  TCC CTG ACA CCC AGC CTG CAG GAG CAG CTG TGT CAG CTC TAC CCC CGA     19030 Ar is Leu, Leu, GLN Leu's GGG, 45191 CTG, 45191 CTG, CTG, CTG, CCTG, has av, Leu, has Player, has PHHS Player, has Prop, has Player, has Prop, has Prop, has Prop, has av, Leu. 61239  TAC TTC CCT TCT TTC CTG TCC AGA GCC ACC CCT AGC TGT CCC CCT GAG     28662  Tyr Phe Pro Ser Phe Leu Ser Arg Ala Thr Pro Ser Cys Pro Pro Glu      77287  ATG AAG AAA GAG CTC CTG AGC AGC CTG ACT GAG TGC CTG ACG GTG GAC     33478  Met Lys Lys Glu Leu Leu Ser Ser Leu Thr Glu Cys Leu Thr Val Asp      93335  CCC CTC AGT GCC AGC GTC TGG AGG CAG TTG TAC CCT AAG CAC CTG TCA     38294  Pro Leu Ser Ala Ser Val Trp Arg Gln Leu Tyr Pro Lys His Leu Ser     109383  CAG TCC AGC CTT CTG CTG GAG CAC TTG CTC AGC TCC TGG GAG CAG ATT     430110  Gln Ser Ser Leu Leu Leu Glu His Leu Leu Ser Ser Trp Glu Gln Ile     125431  CCC AAG AAG GTA CAG AAG TCT TTG CAA GAA ACC ATT CAG TCC CTC AAG     478126  Pro Lys Lys Val Gln Lys Ser Leu Gln Glu Thr Ile Gln Ser Leu Lys     141479  CTT ACC AAC CAG GAG CTG CTG AGG AAG GGT AGC AGT AAC AAC CAG GAT     526142  Leu Thr Asn Gln Glu Leu Leu Arg Lys Gly Ser Ser Asn Asn Gln Asp     157527  GTC GTC ACC TGT GAC ATG GCC TGC AAG GGC CTG TTG CAG CAG GTT CAG     574158  Val Val Thr Cys Asp Met Ala Cys Lys Gly Leu Leu Gln Gln Val Gln     173575  GGT CCT CGG CTG CCC TGG ACG CGG CTC CTC CTG TTG CTG CTG GTC TTC     622174  Gly Pro Arg Leu Pro Trp Thr Arg Leu Leu Leu Leu Leu Leu Val Phe     189623  GCT GTA GGC TTC CTG TGC CAT GAC CTC TGG TCA CAC AGC TCC TTC CAG     670190  Ala Val Gly Phe Leu Cys His Asp Leu Trp Ser His Ser Ser Phe Gln     205671  GCC TCC CTT ACT GGC CGG TTG CTT CGA TCA TCT GGC TTC TTA CCT GCT     718206  Ala Ser Leu Thr Gly Arg Leu Leu Arg Ser Ser Gly Phe Leu Pro Ala     221719  AGC CAA CAA GCG TGT GCC AAG CTC TAC TCC TAC AGT CTG CAA GGC TAC     766 222  Ser Gln Gln Ala Cys Ala Lys Leu Tyr Ser Tyr Ser Leu Gln Gly Tyr     237767  AGC TGG CTG GGG GAG ACA CTG CCG CTC TGG GGC TCC CAC CTG CTC ACC     814238  Ser Trp Leu Gly Glu Thr Leu Pro Leu Trp Gly Ser His Leu Leu Thr     253815  GTG GTG CGG CCC AGC TTG CAG CTG GCC TGG GCT CAC ACC AAT GCC ACA     862254  Val Val Arg Pro Ser Leu Gln Leu Ala Trp Ala His Thr Asn Ala Thr     269863  GTC AGC TTC CTT TCT GCC CAC TGT GCC TCT CAC CTT GCG TGG TTT GGT     910270  Val Ser Phe Leu Ser Ala His Cys Ala Ser His Leu Ala Trp Phe Gly     285911  GAC AGT CTC ACC AGT CTC TCT CAG AGG CTG CAG ATC CAG CTC CCC GAT     958286  Asp Ser Leu Thr Ser Leu Ser Gln Arg Leu Gln Ile Gln Leu Pro Asp     301959  TCC GTG AAT CAG CTA CTC CGC TAT CTG AGA GAG CTG CCC CTG CTT TTC    1006302  Ser Val Asn Gln Leu Leu Arg Tyr Leu Arg Glu Leu Pro Leu Leu Phe     3171007  CAC CAG AAT GTG CTG CTG CCA CTG TGG CAC CTC TTG CTT GAG GCC CTG    1054318  His Gln Asn Val Leu Leu Pro Leu Trp His Leu Leu Leu Glu Ala Leu     3331055  GCC TGG GCC CAG GAG CAC TGC CAT GAG GCA TGC AGA GGT GAG GTG ACC    1102334  Ala Trp Ala Gln Glu His Cys His Glu Ala Cys Arg Gly Glu Val Thr     3491103  TGG GAC TGC ATG AAG ACA CAG CTC AGT GAG GCT GTC CAC TGG ACC TGG    1150350  Trp Asp Cys Met Lys Thr Gln Leu Ser Glu Ala Val His Trp Thr Trp     3651151  CTT TGC CTA CAG GAC ATT ACA GTG GCT TTC TTG GAC TGG GCA CTT GCC    1198366  Leu Cys Leu Gln Asp Ile Thr Val Ala Phe Leu Asp Trp Ala Leu Ala     3811199  CTG ATA TCC CAG CAG TAG GCC CTG CCT TCC TGG CCA CTG ATT TCT GCA    1246382  Leu Ile Ser Gln Gln ***                                             3871247  TGG GTA GAC CAT CCA AGA CTG CAG CGG GTA GAA GGT GGC AGT TCT TCA    12941295  TGG GAG TCT TTT TAA CTT GGT GCC TGA GTT CTC TCC TAG GCA AGT GGC    13421343  CAG TTG CCT CCA CCT CAG TTC TTC CAT CTT TGG TGG GGA CAG GGC CCA    13901391  GCA GCA TCT CAG CCT CCT ACC CAC AAT TCC ACT GAA CAC TTT TCT GGC    14381439  CCT ACT GCA CAT GGC CCC CAG CCT CCA TCC TTG TGC TGG TAG CCT CTC    14861487  ACA ACT CCG CCC TTG CCC TCT GCC TTC CAC TTC CTT CCA TCT CAT TTC    15341535  TAA ACC CCA AAC AGC TCA TCT CTA AAA AGA TAG AAC TCC CAG CAG GTG    15821583  GCT TCT GTG TTC TTC TGA CAA ATG ATT CCT GCT TCT CCA GAC TTT AGC    16301631  AGC CTC CTG TTC CCA TTC TTG GTC ACA GCT CTA GCC ACA GCA GAA GGA    16781679  AAG GGG CTT CCA GAA GAA TAT AGC ACC GCA TTG GGA AAC AGC AGC CTC    17261727  ACC TCC ACC TGA AGC CTG GGT GTG GCT GTC AGT GGA CAT GGG GAG CTG    17741775  GAT GGA AAT GCC TCT CAC TTC AAA ATG CCC AGC CTG CCC CAA ATG CCT    18221823  CTA AGC CCC TCC CTG TCC CCT CCC TTG TAG TCC TAC TTC TTC CAA CTT    18701871  TCC ATT CCC CAT CAT GCT GGG GGT CTT GGT CAC AAG GCT CAG CTT CTC    19181919  TCC ACT GTC CAT CCC TCC TAT CAT CTG TAG AGC AGA GCA CAG GCA GTT    19661967  GTG TGC CTT GGG CCC AGG GAA CCC TCC ATC AAC CTG AGA CAG GAC TCA    20142015  GTA TAT GGT TCT TGG GTA TGC CCT ACC AGG TGG AAT AAA GGA CAC AGA    20622063  TTT GAA AAA AAA AAA AAA AAA AAA 20863. PP5715A：核苷酸序列(SEQ ID NO：7)长度：31781  GCCTGGCCCT CTTCTCCTTC GTCACAGCCC TCATGTTCAG CTCCATCGTC TGCAGCGTCC61  CGCACACCTG GCAGCAAAAG AGAGGCCCTG ATGAGGACGG GGAGGAGGAG GCCGCTCCAG121  GGCCGCGGCA GGCGCACGAC AGCCTCTACC GCGTCCACAT GCCCAGCCTG TACAGCTGTG181  GCAGCAGCTA CGGCAGTGAG ACCAGCATCC CGGCCGCGGC CCACACCGTC AGCAACGCCC241  CGGGCACTGA GTACATGAGC CAGAACGCTA ATTTCCAGAA CCCCCGCTGT GAGAACACCC301  CACTCATTGG GCGCGAGTCC CCGCCGCCTC ATACACCTCC AGCATGAGAG CCAAATACCT361  CGCCACGAGC CAGCCTCGCC CTGACTCCAG CGGCAGCCAC TAGACCGGCC CGGCAGCCAC421  CCACCCCACG TGCCAACTTC CCCTCCCCGT GCCAGCACTG CCGCTTCCAC CTGGGCCACC481  CACCGGACCC TCGCACGCCG TGCCAGGCCT GCCCCAGACG CGTCTGCAGG CCGCTTGCCC541  TCCTGTCCCC TCCCCGCAGG GGCACAGTGG AGACGCAGGG GCTCTGGGCC CGTACCGCCA601  ACTCGGGTCA CACCTGAACG CTGCTGCCAG CCGATGCCCC AGCCCTGCAC GCCACCCACT661  ATCCCGGCAC GCTCCCTCTG CAGATGGTCG CCTGCACCTA CAAGCCCTGG CCGCACCCAA 721  CCTGTGTTGT TGCCGCCCGG CCCTTCCCTC CACAGCTCTC CTTCCTCCCG CCCGGCACTT781  CTGTGGACCC CTTCTTAGTT CACAGGCACG GCTGGGGCCG CTCTGTGCTG GCGCCTGCTG841  GCCACTGAGG GACAGAGACA CGTGCCACCT GCTCATCTCT GCCCTGAGGT CACCCCGTGG901  TCCCTCCACG TGCCCATCTC TCTGCAGTGC CCTCCTCGCC TGTGCAGCCC GCCCACCCAC961  AGGCTCACCC CTCCTGCCGG CTGCCAGAGG CCCCCTCCAG CAGGGCCTCT CTCCGTTGCC1021  CCAGCTTCAC TCTCTCCCTC AGCACCTGCC CTGCTGGAGG CCCCAGCCCT CCGTGGACAG1081  CAGGGGCCAC GTGGAGCCCG GGCCGCTCAC CCGCCACCCA GTGCTGGCCG CCTTCTTGGT1141  GCCAAACCCC CTTCCCCCAC CCAGAGACTG GGCAGCTGTG TCTGGTTCGT TCTTTGCACT1201  AACCACATTT GTCATCTCTA GGACAGGCTG GGGCTGCGGG CTGAGGGGGA CCGCTGGCAC1261  CCCCCTTCCC TCCCTTCTTG GTTCCATTTC CATCCATGAC AGGTACAGCA TTCCAGGAGC1321  CCGGCCTGAG GGGCTGGACC CGAGCCGGCT GTGAACATCC CTCAGCCCCT GCTGTCCCCC1381  CTTGGGACTA ACCACTAACC TCACCCCCAA ACTCCACGGG TGCCCCTAGC TGGCCCAGAG1441  CCGGCAGTGT GAGCCCAAGT CCGGGCTGGA GCCGAGGCCG GAGCAGCTGT CTGGGAGTCA1501  AGGCTGCAGT AGCGTTTCTT CATGGGGTGC TCAGGGGGTG CCACAGACCG ACAGGCAGCC1561  CAAGGGCCTG GACACCCCTC CCCAGGCAGG TGCTGCCCCA GGAGGACTGT CCTCGGGAAT1621  GAACCTCCCG CGGGCTTTGG ACTGAGGTCC CTGTGGCCTC GGTCTCCTCC CCATGAAGTG1681  GGAGCGAGGC TCCCCAATGG TGCTTTTGGC TTTAGTGTAC GATGTTTGCT GTGCTTCCCG1741  CCGTGGAGGG CAGAGCCACC CCACATCAGG ATCGGACGTG CTACCCCTCC CGGTCCCGGC1801  CCTGGCCCAG CCAGCCCAGC CCTCGAGGCT CGATGCCTGT GCCAGGGCCA GGGGCAGCCA1861  GAGGGCAGCT GGATGGCCAC GTGCAGGGGT CAAGGCTGGG CCCCGCAGTG GGGCGGGCCG1921  CCAGCCCCAG CAGTTTACAG ACGCATGGCT CTTCCTCCCA GAGCAGCCGG CAGCTACCTG1981  GACCGGAAAT GTCCTCATCC CCTCCCTGGG GCCAGGCTCT GCCCTGGCCT TCCTCTGTGA2041  ACCCCTCCTT TCTTTGTGCT GGTGTCTGGG ACCAAAAAGG GGGAATATGG GAGGGCAGAG2101  TGGGGAGGGG AGTCCATGGG CCTGGGGCCC CAAGCCGGGG CGTCTGAGCT CCCCAGGCAT2161  GACCAAACCT CAGTGGAGGG GCCTCTGCTT CAGGCCCCGC CTGGCTGACA TTCTGAGCCC2221  CCCTCGGAGG CCCCGCCACA GCCAACCTGC CCAGTCTTTC CTCTGGGCTT GACCCGCCAG2281  GGGAGTTCTC CAGGCCTAGG GCCAGGAGAG AGGCCCTGGC ACCCTGGCGT GGGTGCCCGC2341  CAAACGCCCT GCGACCGCTC AGAAGCACAA ATGCTGTCCA TGGCCGTGAG GCTGCCTGCC2401  AGGTGAATGG ACATAGCGTG AGAGGCGGTG AGGCCAGGGC TTCCAGCCTC GTGCTGTCTC2461  GGGACTCCTG ACCGTGGTGT GCGTGTGTGC CCATCTGTGA CTTTCTACTC ACCAAGGTTG2521  AAGAAAGGAA ACGGGGAAAA TCAAAAGGGG TTCAAACCCC ACCTCAGTAG GTGGAGGGGA2581  GCGCCTGCCA TTGGTTGTAT TTTTGTTCTG AGTTTTCGGT GCCGTGTTCC TAACTACTCC2641  ATCCCATGAC CTCGCCACAC CTACTGGGGC ATCTGGCTGG CGCCTGCTGC CATGGCCAGC2701  CCCCACTCTC ACCCTGCACA GGGGGTCTTG CAGCCCCCAG GCCCACAGCC TCGTTGGGAG2761  GACAGGGTGG CCCTGGGGAC AAGAGGGAGG AGCCCAGGGG CTTACCTCAC TGAGAGTGCT2821  CCCCAGCAGG CATCCACTAC CCCAGGGCCC CCCACATGTC ATGGCAAGGT TGGTAGTGAA2881  TGGGCCTGGT TGGGAGCAGC CCCTGGCCCA TTGCCCACCC ACCCATCTCA CTATGCAATT2941  CGAGTTCCAA GCAACATTTG CTCCTCCCCT GGGGCCAGCT CTGCCCCAGC CCTGAGAGGG3001  GTGGTGAAGC AGCCCCCTGG ACCCCAGAAC CCCAGACAAG GGGGCAGGCG GGGGACCAGG3061  GCCTCTCCTG TGGGATCTTT GTTTTGTGTT TAACCATAAT GGTTGTGTAC TGAACCACTT3121  CATATTTGTT ATATATAATA TATATATATA TAATCTCAAA AAAAAAAAAA AAAAAAAAB：核苷酸序列(SEQ ID NO：8)长度：1991 MKWERGSPMV LLALVYDVCC ASRRGGQSHP TSGSDVLPLP VPALAQPAQP SRLDACARAR61  GSQRAAGMPR AGVKAGPRSG AGRQPQQFTD AWLFLPEQPA ATWTGNVLIP SLGPGSALAF121  LCEPLLSLCW CLGPKRGNMG GQSGEGSPWA WGPKPGRLSS PGMTKPQWRG LCFRPRLADI181  LSPPRRPRHS QPAQSFLWAC. Nucleotide and amino acid combination sequence (SEQ ID NO: 9) Clone number: PP5715 Start code: 1673 ATG Stop code: 2270 TGA Protein molecular weight: 21306. 371 G CCT GGC CCT CTT CTC CTT CGT CAC AGC CCT CAG CAG CTC CAG CAG Cat 4647 CGT CTG CGT CCC GCA CAC CTG GCA GCA GAG CCC GGA GGC GGC GGC G GGC G GGC G GGC G -G -G -G -G -G that CAG     142143    CCT CTA CCG CGT CCA CAT GCC CAG CCT GTA CAG CTG TGG CAG CAG CTA     190191    CGG CAG TGA GAC CAG CAT CCC GGC CGC GGC CCA CAC CGT CAG CAA CGC     238239    CCC GGG CAC TGA GTA CAT GAG CCA GAA CGC TAA TTT CCA GAA CCC CCG     286287    CTG TGA GAA CAC CCC ACT CAT TGG GCG CGA GTC CCC GCC GCC TCA TAC     334335    ACC TCC AGC ATG AGA GCC AAA TAC CTC GCC ACG AGC CAG CCT CGC CCT     382 383  GAC TCC AGC GGC AGC CAC TAG ACC GGC CCG GCA GCC ACC CAC CCC ACG     430431  TGC CAA CTT CCC CTC CCC GTG CCA GCA CTG CCG CTT CCA CCT GGG CCA     478479  CCC ACC GGA CCC TCG CAC GCC GTG CCA GGC CTG CCC CAG ACG CGT CTG     526527  CAG GCC GCT TGG CCT CCT GTC CCC TCC CCG CAG GGG CAC AGT GGA GAC     574575  GCA GGG GCT CTG GGC CCG TAC CGC CAA CTC GGG TCA CAC CTG AAC GCT     622623  GCT GCC AGC CGA TGC CCC AGC CCT GCA CGC CAC CCA CTA TCC CGG CAC     670671  GCT CCC TCT GCA GAT GGT CGC CTG CAC CTA CAA GCC CTG GCC GCA CCC     718719  AAC CTG TGT TGT TGC CGC CCG GCC CTT CCC TCC ACA GCT CTC CTT CCT     766767  CCC GCC CGG CAC TTC TGT GGA CCC CTT CTT AGT TCA CAG GCA CGG CTG     814815  GGG CCG CTC TGT GCT GGC GCC TGC TGG CCA CTG AGG GAC AGA GAC ACG     862863  TGC CAC CTG CTC ATC TCT GCC CTG AGG TCA CCC CGT GGT CCC TCC ACG     910911  TGC CCA TCT CTC TGC AGT GCC CTC CTC GCC TGT GCA GCC CGC CCA CCC     958959  ACA GGC TCA CCC CTC CTG CCG GCT GCC AGA GGC CCC CTC CAG CAG GGC    10061007  CTC TCT CCG TTG CCC CAG CTT CAC TCT CTC CCT CAG CAC CTG CCC TGC    10541055  TGG AGG CCC CAG CCC TCC GTG GAC AGC AGG GGC CAC GTG GAG CCC GGG    11021103  CCG CTC ACC CGC CAC CCA GTG CTG GCC GCC TTC TTG GTG CCA AAC CCC    11501151  CTT CCC CCA CCC AGA GAC TGG GCA GCT GTG TCT GGT TCG TTC TTT GCA    11981199  CTA ACC ACA TTT GTC ATC TCT AGG ACA GGC TGG GGC TGC GGG CTG AGG    12461247  GGG ACC GCT GGC ACC CCC CTT CCC TCC CTT CTT GGT TCC ATT TCC ATC    12941295  CAT GAC AGG TAC AGC ATT CCA GGA GCC CGG CCT GAG GGG CTG GAC CCG    13421343  AGG CGG CTG TGA ACA TCC CTC AGC CCC TGC TGT CCC CCC TTG GGA CTA    13901391  ACC ACT AAC CTC ACC CCC AAA CTC CAC GGG TGC CCC TAG CTG GCC CAG    14381439  AGC CGG CAG TGT GAG CCC AAG TCC GGG CTG GAG CCG AGG CCG GAG CAG    14861487  CTG TCT GGG AGT CAA GGC TGC AGT AGC GTT TCT TCA TGG GGT GCT CAG    15341535  GGG GTG CCA CAG ACC GAC AGG CAG CCC AAG GGC CTG GAC ACC CCT CCC    15821583  CAG GCA GGT GCT GCC CCA GGA GGA CTG TCC TCG GGA ATG AAC CTC CCG    16301631  CGG GCT TTG GAC TGA GGT CCC TGT GGC CTC GGT CTC CTC CCC ATG AAG    16781                                                          Met Lys       21679 TGG GAG CGA GGC TCC CCA ATG GTG CTT TTG GCT TTA GTG TAC GAT GTT    17263  Trp Glu Arg Gly Ser Pro Met Val Leu Leu Ala Leu Val Tyr Asp Val      181727  TGC TGT GCT TCC CGC CGT GGA CGG CAG AGC CAC CCC ACA TCA GGA TCG 177419  Cys Cys Ala Ser Arg Arg Gly Gly Gln Ser His Pro Thr Ser Gly Ser      341775  GAC GTG CTA CCC CTC CCG GTC CCG GCC CTG GCC CAG CCA GCC CAG CCC    182235  Asp Val Leu Pro Leu Pro Val Pro Ala Leu Ala Gln Pro Ala Gln Pro      501823  TCG AGG CTC GAT GCC TGT GCC AGG GCC AGG GGC AGC CAG AGG GCA GCT    187051  Ser Arg Leu Asp Ala Cys Ala Arg Ala Arg Gly Ser Gln Arg Ala Ala      661871  GGA TGG CCA CGT GCA GGG GTC AAG GCT GGG CCC CGC AGT GGG GCG GGC    191867  Gly Trp Pro Arg Ala Gly Val Lys Ala Gly Pro Arg Ser Gly Ala Gly      821919  CGC CAG CCC CAG CAG TTT ACA GAC GCA TGG CTC TTC CTC CCA GAG CAG    196683  Arg Gln Pro Gln Gln Phe Thr Asp Ala Trp Leu Phe Leu Pro Glu Gln      981967  CCG GCA GCT ACC TGG ACC GGA AAT GTC CTC ATC CCC TCC CTG GGG CCA    201499  Pro Ala Ala Thr Trp Thr Gly Asn Val Leu Ile Pro Ser Leu Gly Pro     1142015  GGC TCT GCC CTG GCC TTC CTC TGT GAA CCC CTC CTT TCT TTG TGC TGG    2062115  Gly Ser Ala Leu Ala Phe Leu Cys Glu Pro Leu Leu Ser Leu Cys Trp     1302063  TGT CTG GGA CCA AAA AGG GGG AAT ATG GGA GGG CAG AGT GGG GAG GGG    2110131  Cys Leu Gly Pro Lys Arg Gly Asn Met Gly Gly Gln Ser Gly Glu Gly     1462111  AGT CCA TGG GCC TGG GGC CCC AAG CCG GGG CGT CTG AGC TCC CCA GGC    2158147  Ser Pro Trp Ala Trp Gly Pro Lys Pro Gly Arg Leu Ser Ser Pro Gly     1622159  ATG ACC AAA CCT CAG TGG AGG GGC CTC TGC TTC AGG CCC CGC CTG GCT    2206163  Met Thr Lys Pro Gln Trp Arg Gly Leu Cys Phe Arg Pro Arg Leu Ala     1782207  GAC ATT CTG AGC CCC CCT CGG AGG CCC CGC CAC AGC CAA CCT GCC CAG    2254179  Asp Ile Leu Ser Pro Pro Arg Arg Pro Arg His Ser Gln Pro Ala Gln     1942255  TCT TTC CTC TGG GCT TGA CCC GCC AGG GGA GTT CTC CAG GCC TAG GGC    2302195  Ser Phe Leu Trp Ala ***                                             2002303  CAG GAG AGA GGC CCT GGC ACC CTG GCG TGG GTG CCC GCC AAA CGC CCT 23502351  GCG ACC GCT CAG AAG CAC AAA TGC TGT CCA TGG CCG TGA GGC TGC CTG    23982399  CCA GGT GAA TGG ACA TAG CGT GAG AGG CGG TGA GGC CAG GGC TTC CAG    24462447  CCT CGT GCT GTC TCG GGA CCC CTG ACC GTG GTG TGC GTG TGT GCC CAT    24942495  CTG TGA CTT TCT ACT CAC CAA GGT TGA AGA AAG GAA ACG GGG AAA ATC    25422543  AAA AGG GGT TCA AAC CCC ACC TCA GTA GGT GGA GGG GAG CGC CTG CCA    25902591  TTG GTT GTA TTT TTG TTC TGA GTT TTC GGT GCC GTG TTC CTA ACT ACT    26382639  CCA TCC CAT GAC CTC GCC ACA CCT ACT GGG GCA TCT GGC TGG CGC CTG    26862687  CTG CCA TGG CCA GCC CCC ACT CTC ACC CTG CAC AGG GGG TCT TGC AGC    27342735  CCC CAG GCC CAC AGC CTC GTT GGG AGG ACA GGG TGG CCC TGG GGA CAA    27822783  GAG GGA GGA GCC CAG GGG CTT ACC TCA CTG AGA GTG CTC CCC AGC AGG    28302831  CAT CCA CTA CCC CAG GGC CCC CCA CAT GTC ATG GCA AGG TTG GTA GTG    28782879  AAT GGG CCT GGT TGG GAG CAG CCC CTG GCC CAT TGC CCA CCC ACC CAT    29262927  CTC ACT ATG CAA TTC GAG TTC CAA GCA ACA TTT GCT CCT GCC CTG GGG    29742975  CCA GCT CTG CCC CAG CCC TGA GAG GGG TGG TGA AGC AGC CCC CTG GAC    30223023  CCC AGA ACC CCA GAC AAG GGG GCA GGC GGG GGA CCA GGG CCT CTC CTC CTC 30703071 TGG GAT CTT TGT GTG TTT AAC Cat AAT GGT GGT GTA CTG AAC CAC 31183119 TTC ATA TATA TAT AAA TATA AAAA AA. PP6977A：核苷酸序列(SEQ ID NO：10)长度：24691  GGGCCGCGGC CTGTCCTCCT GCCTCAGCCT GGGGAAGGCT GGGCCGGGCC GAAGAGGGAG61  GCCAAGTCCT TGGGACAGGA GGAGACCCAC ACCTGAGATT AGTGGAAACC CAGCCAGAAG121  CTGCCATGCA GGTGTGGCTC TGGGCATCAG GATCTGTCGT GAGAGCCCCC ATGAGTGCCC181  AGTGCAGAAT GGCTGGCAGC CCGCCCTGAC GGGGAGCAGA GGGGCTGGAC GCGGTGCCCT241  TCACGGGATG ACACCCAGCT GTTTGCCCTG TGTCCAGGGG GTTGCTTCTC TGACAGAGGC301  CCTATGGCTC GTGTCTGACT CCTGTCCAGG TTCTGCCAGC CTGACCATCC ATCGCTCTGG361  CACCAAGAGC CCACCCTTTT GTTCTTCCTG GCGTCCCAGG GAAAGCCCTG CCTGGGTGGG421  GCAGCTCCTG GCCCTTCAGA TGGAAGACGC AGTCCAGTCA GCACCATCAT AGGAAACAAG481  TTCAGAAATG TCTCACTTAC TATTCCGGGC AGGGAGGGCG CCATGAGTCA GGGGGTGCAT541  CCTCCCTCCT GGCGTCACCC GAGGCAGGAA TGAAGAGTCA GGCAGAGAGC GCGCGTGTGG601  CAGCTGGTGG TGTAGATATT AGGGACTAGT GTGAATTCTA GTTCACCGGC CAATGCCTGG661  ATGGTCCAGA GCTGGGTCGG CTGGGCGGAG AGCTGCCTCC AGGTTCCTGC CTCTGGCCCT721  GGCGTGGGGT CGACACTGGG TGTGGTGTGT GTCTCATGTC CAGGCAGTGG CCTTTGCTGT781  GCCGTCCTGT TACAGGAGCC AGGATGGTGG GGACGGGACC GGACCGGAGG GTTGGCGGGG841 CTGCCCCTGC AGCCGACAGC CCCATCCTGC AGCCACCAAT GGCATGACCC AGGGCCCCGG901  CACTGCCTGT GTGAGGGGCT GGCAGCTTTC CAACTGCAGC AAGTGGAGGC CCCTGCCAGC961  TTCGGGCCTG TGGGCAGGGG CTCAGTGGGG CAGGGGTGTG GCTGCCCCGC CCGGCACGCC1021  TGCACCTGTC TCCTCAGTGT GACCAGTACC GCAAGGGGAT CATCTCGGGC TCCGTCTGCC1081  AGGACCTGTG TGAGCTGCAT ATGGTGGAGT GGAGGACCTG CCTCTCGGTG GCCCCGGGCC1141  AGCAGGTGTA CAGCGGGCTC TGGCGGGACA AGGATGTAAC CATCAAGTGT GGCATTGAGG1201  AGACCCTCGA CTCCAAGGCC CGGTCGGATG CGGCCCCCCG GCGGGAGCTG GTACTGTTTG1261  ACAAGCCCAC CCGGGGCACC TCCATCAAGG AATTCCGGGA GATGACCCTC GGCTTCCTCA1321  AGGCGAACCT GGGAGACCTG CCTTCCCTGC CGGCGCTGGT TGGCCAGGTC CTGCTCATGG1381  CTGACTTCAA CAAGGACAAC CGGGTGTCCC TGGCGGAAGC CAAGTCCGTG TGGGCCCTGC1441  TGCAGCGTAA CGAGTTCCTG CTGCTGCTGT CCCTGCAGGA GAAGGAGCAC GCCTCCAGAC1501  TGCTGGGCTA CTGTGGGGAC CTCTACCTCA CCGAGGGCGT GCCGCATGGC GCCTGGCACG1561  CGGCCGCCCT TCCACCCCTG TTGCGCCCAC TGCTGCCGCC TGCCCTGCAG GGTGCTCTCC1621  AGCAGTGGCT GGGGCCTGCG TGGCCTTGGC GGGCCAAGAT CGCCATCGGC CTGCTGGAGT1681  TCGTGGAGGA GCTCTTCCAC GGCTCTTACG GGACTTTCTA CATGTGTGAG ACCACACTGG1741  CCAACGTGGG CTACACAGCC ACCTACGACT TCAAGATGGC CGACCTGCAG CAGGTGGCAC1801  CCGAGGCCAC CGTGCGCCGC TTCCTGCAGG GCCGCCGCTG CGAGCACAGC ACCGACTGCA1861  CTACGGGCGC GACTGCAGGG CCCCGTGTGA CAGGCTCATG AGGCAGTGCA AGGGCGACCT1921  CATCCAGCCC AACCTGGCCA AGGTGTGCGC ACTGCTACGG GGCTACCTGC TGCCTTGCGC1981  GCCCGCCGAC CTCCGCGAGG AGCTGGGCAC ACACTGCGCA CCTGTACCAC GCTGAGCGGG2041  CTGGCCAGCC AGGTGGAGGC CCATCACTCG CTGGTGCTCA GCCACCTCAA GACTCTGCTC2101  TGGAAGAAGA TCTCCAACAC CAAGTACTCT TGATGGGGCA GTGAGGGGCC TGGCCACCCT2161  TCCTGGAGCT GGCCAGGTGC CAGGGTCCAA CCCTCCCTCA AGGAATCCTG TCAGAAGATG2221  TGAAATGCAA CTGTGTTGCA AAATCACTCC CCTACCGTCA GGGCTCTGGA TTCCAGCACC2281  ACAGACATGA GACCCCAGCT CGGAGCAAAG GCGGACATGG ACATCCCGGC AGGAGAGTCC2341 TCCAAGGGGG TTTGTTACTC TGAAGAACGT AATGTCAATA AACAGCTTTT ATGTAAAAAA2401  AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA2461  AAAAAAAAAB：核苷酸序列(SEQ ID NO：11)长度：2661  MVEWRTCLSV APGQQVYSGL WRDKDVTIKC GIEETLDSKA RSDAAPRREL VLFDKPTRGT61  SIKEFREMTL GFLKANLGDL PSLPALVGQV LLMADFNKDN RVSLAEAKSV WALLQRNEFL121  LLLSLQEKEH ASRLLGYCGD LYLTEGVPHG AWHAAALPPL LRPLLPPALQ GALQQWLGPA181  WPWRAKIAIG LLEFVEELFH GSYGTFYMCE TTLANVGYTA TYDFKMADLQ QVAPEATVRR241 FLQGRRCEHS TDCTTGATAG PRVTGSC. Nucleotide and amino acid combination sequence (SEQ ID NO: 12) Clone number: PP6977 Start code: 1101 ATG Stop code: 1899 TGA Protein molecular weight: 29507. 341   GG GCC GCG GCC TGT CCT CCT GCC TCA GCC TGG GGA AGG CTG GGC CGG      4748  GCC GAA GAG GGA GGC CAA GTC CTT GGG ACA GGA GGA GAC CCA CAC CTG      9596  AGA TTA GTG GAA ACC CAG CCA GAA GCT GCC ATG CAG GTG TGG CTC TGG     143144  GCA TCA GGA TCT GTC GTG AGA GCC CCC ATG AGT GCC CAG TGC AGA ATG     191192  GCT GGC AGC CCG CCC TGA CGG GGA GCA GAG GGG CTG GAC GCG GTG CCC     239240  TTC ACG GGA TGA CAC CCA GCT GTT TGC CCT GTG TCC AGG GGG TTG CTT     287288  CTC TGA CAG AGG CCC TAT GGC TCG TGT CTG ACT CCT GTC CAG GTT CTG     335336  CCA GCC TGA CCA TCC ATC GCT CTG GCA CCA AGA GCC CAC CCT TTT GTT     383384  CTT CCT GGC GTC CCA GGG AAA GCC CTG CCT GGG TGG GGC AGC TCC TGG     431432  CCC TTC AGA TGG AAG ACG CAG TCC AGT CAG CAC CAT CAT AGG AAA CAA     479480  GTT CAG AAA TGT CTC ACT TAC TAT TCC GGG CAG GGA GGG CGC CAT GAG     527528  TCA GGG GGT GCA TCC TCC CTC CTG GCG TCA CCC GAG GCA GGA ATG AAG     575576  AGT CAG GCA GAG AGC GCG CGT GTG GCA GCT GGT GGT GTA GAT ATT AGG     623624  GAC TAG TGT GAA TTC TAG TTC ACC GGC CAA TGC CTG GAT GGT CCA GAG     671672  CTG GGT CGG CTG GGC GGA GAG CTG CCT CCA GGT TCC TGC CTC TGG CCC     719720  TGG CGT GGG GTC GAC ACT GGG TGT GGT GTG TGT CTC ATG TCC AGG CAG     767768  TGG CCT TTG CTG TGC CGT CCT GTT ACA GGA GCC AGG ATG GTG GGG ACG     815816  GGA CCG GAC CGG AGG GTT GGC GGG GCT GCC CCT GCA GCC GAC AGC CCC     863864  ATC CTG CAG CCA CCA ATG GCA TGA CCC AGG GCC CCG GCA CTG CCT GTG     911912  TGA GGG GCT GGC AGC TTT CCA ACT GCA GCA AGT GGA GGC CCC TGC CAG     959960  CTT CGG GCC TGT GGG CAG GGG CTC AGT GGG GCA GGG GTG TGG CTG CCC    10071008  CGC CCG GCA CGC CTG CAC CTG TCT CCT CAG TGT GAC CAG TAC CGC AAG    10551056  GGG ATC ATC TCG GGC TCC GTC TGC CAG GAC CTG TGT GAG CTG CAT ATG    11031                                                              Met       11104  GTG GAG TGG AGG ACC TGC CTC TCG GTG GCC CCG GGC CAG CAG GTG TAC    11512  Val Glu Trp Arg Thr Cys Leu Ser Val Ala Pro Gly Gln Gln Val Tyr      171152  AGC GGG CTC TGG CGG GAC AAG GAT GTA ACC ATC AAG TGT GGC ATT GAG    119918  Ser Gly Leu Trp Arg Asp Lys Asp Val Thr Ile Lys Cys Gly Ile Glu      331200  GAG ACC CTC GAC TCC AAG GCC CGG TCG GAT GCG GCC CCC CGG CGG GAG    124734  Glu Thr Leu Asp Ser Lys Ala Arg Ser Asp Ala Ala Pro Arg Arg Glu      491248  CTG GTA CTG TTT GAC AAG CCC ACC CGG GGC ACC TCC ATC AAG GAA TTC    129550  Leu Val Leu Phe Asp Lys Pro Thr Arg Gly Thr Ser Ile Lys Glu Phe      651296  CGG GAG ATG ACC CTC GGC TTC CTC AAG GCG AAC CTG GGA GAC CTG CCT    134366  Arg Glu Met Thr Leu Gly Phe Leu Lys Ala Asn Leu Gly Asp Leu Pro      811344  TCC CTG CCG GCG CTG GTT GGC CAG GTC CTG CTC ATG GCT GAC TTC AAC    139182  Ser Leu Pro Ala Leu Val Gly Gln Val Leu Leu Met Ala Asp Phe Asn      971392  AAG GAC AAC CGG GTG TCC CTG GCG GAA GCC AAG TCC GTG TGG GCC CTG    143998  Lys Asp Asn Arg Val Ser Leu Ala Glu Ala Lys Ser Val Trp Ala Leu     1131440  CTG CAG CGT AAC GAG TTC CTG CTG CTG CTG TCC CTG CAG GAG AAG GAG    1487114  Leu Gln Arg Asn Glu Phe Leu Leu Leu Leu Ser Leu Gln Glu Lys Glu     1291488  CAC GCC TCC AGA CTG CTG GGC TAC TGT GGG GAC CTC TAC CTC ACC GAG    1535130  His Ala Ser Arg Leu Leu Gly Tyr Cys Gly Asp Leu Tyr Leu Thr Glu     1451536 GGC GTG CCG CAT GGC GCC TGG CAC GCG GCC GCC CTT CCA CCC CTG TTG    1583146  Gly Val Pro His Gly Ala Trp His Ala Ala Ala Leu Pro Pro Leu Leu     1611584  CGC CCA CTG CTG CCG CCT GCC CTG CAG GGT GCT CTC CAG CAG TGG CTG 1631162  Arg Pro Leu Leu Pro Pro Ala Leu Gln Gly Ala Leu Gln Gln Trp Leu     1771632  GGG CCT GCG TGG CCT TCG CGG GCC AAG ATC GCC ATC GGC CTG CTG GAG    1679178  Gly Pro Ala Trp Pro Trp Arg Ala Lys Ile Ala Ile Gly Leu Leu Glu     1931680  TTC GTG GAG GAG CTC TTC CAC GGC TCT TAC GGG ACT TTC TAC ATG TGT    1727194  Phe Val Glu Glu Leu Phe His Gly Ser Tyr Gly Thr Phe Tyr Met Cys     2091728  GAG ACC ACA CTG GCC AAC GTG GGC TAC ACA GCC ACC TAC GAC TTC AAG    1775210  Glu Thr Thr Leu Ala Asn Val Gly Tyr Thr Ala Thr Tyr Asp Phe Lys     2251776  ATG GCC GAC CTG CAG CAG GTG GCA CCC GAG GCC ACC GTG CGC CGC TTC    1823226  Met Ala Asp Leu Gln Gln Val Ala Pro Glu Ala Thr Val Arg Arg Phe     2411824  CTG CAG GGC CGC CGC TGC GAG CAC AGC ACC GAC TGC ACT ACG GGC GCG    1871242  Leu Gln Gly Arg Arg Cys Glu His Ser Thr Asp Cys Thr Thr Gly Ala     2571872  ACT GCA GGG CCC CGT GTG ACA GGC TCA TGA GGC AGT GCA AGG GCG ACC    1919258  Thr Ala Gly Pro Arg Val Thr Gly Ser ***                             2671920  TCA TCC AGC CCA ACC TGG CCA AGG TGT GCG CAC TGC TAC GGG GCT ACC    19671968  TGC TGC CTT GCG CGC CCG CCG ACC TCC GCG AGG AGC TGG GCA CAC ACT    20152016  GCG CAC CTG TAC CAC GCT GAG CGG GCT GGC CAG CCA GGT GGA GGC CCA    20632064  TCA CTC GCT GGT GCT CAG CCA CCT CAA GAC TCT GCT CTG GAA GAA GAT    21112112  CTC CAA CAC CAA GTA CTC TTG ATG GGG CAG TGA GGG GCC TGG CCA CCC    21592160  TTC CTG GAG CTG GCC AGG TGC CAG GGT CCA ACC CTC CCT CAA GGA ATC    22072208  CTG TCA GAA GAT GTG AAA TGC AAC TGT GTT GCA AAA TCA CTC CCC TAC    22552256  CGT CAG GGC TCT GGA TTC CAG CAC CAC AGA CAT GAG ACC CCA GCT CGG    23032304  AGC AAA GGC GGA CAT GGA CAT CCC GGC AGG AGA GTC CTC CAA GGG GGT    23512352  TTG TTA CTC TGA AGA AGG TAA TGT CAA TAA ACA GCT TTT ATG TAA AAA    23992400  AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA 24472448 AAA AAA AAA AAA AAA AAA AAA A 24695. PP8482A：核苷酸序列(SEQ ID NO：13)长度：9391  GGGCTTCCTG GGGAGGGTGT GGCAGGGTGG TGGGCATCCC CTCCCTCACC AAAGCATGGG61  CTCTTTGTTT CCTCTTTGCC AGGCCTGGGT CCTTCCCAGT GACCCCTCAG CCTTCACTTC121  CTCCTCACTC CCGGGGAGCT GTGACAGGTG TTTGGGGGAG GGGAGGGGGG TATGATAAGC181  TGGGACAGCT GCACCCACGG GTGCTCTGGT GAGATGGGGG GCCCGGATGT TGGGGAGACA241  CATCTGCTGG GTTCCCAGCC CAAGGTCCCC AACCCTGGCT GTCTGGCCTT GTCTGTCACC301  CCCCGTGCCC ACTGGCAGGG ACAGGAAGCT CCCCCCCCAC CCCGCTTTGG GCAGTTTGCC361  TTGGCACGGG CCTGATCTGT TTTCCTCCCC AGAGCAGCTG CTGTTCTGTC TGCTGGGCAG421  AGGGCTGGGT TCCTCCGAGG TAGGCAGGGG CCTCAACCCA GAGCCCCTCT CACACCCTCT481  TTCAACTCAG GCTTATGTCT CTCCCTCCTC CCCCACCCCC ACCCCAGGAA GAGGAGATCC541  CAGAACTGGA GATTGACGTG GATGAGCTCC TGGACATGGA GAGTGACGAT GCCCGGGCTG601  CCAGGGTCAA GGAGCTGCTG GTTGACTGTT ACAAACCCAC AGAGGCCTTC ATTTCTGGCC661  TGCTGGACAA GATCCGGGGC ATGCAGAAGC TGAGCACACC CCAGAAGAAG TGAGGGTCCC721  CGACCCAGGA GAACGGTGGC TCCCACAGGA CAATCGCTGC CCCCCAACCT CGTAGCAACA781  GCAATACCGG GGGACCCTGC GGCCAGGCCT GGTGCCATGA GCAGGGCTCC TCGTGCCCCT841 GGCCCAGGGG TCTCTTCCCC TGCCCCCTCA GTTTTCCACT TTTGGGGTTT TTTATTGTTA901  TTAAACTGAT GGGACTTTAA AAAAAAAAAA AAAAAAAAAB：核苷酸序列(SEQ ID NO：14)长度：1091   MLGRHICWVP SPRSPTLAVW PCLSPPVPTG RDRKLPPHPA LGSLPWHGPD LFSSPEQLLF61   CLLGRGLGSS EVGRGLNPEP LSHPLSTQAY VSPSSPTPTP GRGDPRTGDC. Nucleotide and amino acid combination sequence (SEQ ID NO: 15) Clone number: PP8482 Start code: 227 ATG Stop code: 554 TGA Protein molecular weight: 11600. 601 GGC TTC CTG GGG GTG GTG TGG CAG GGT GGT GGT GGT GGT GGT GGT CCC CCC CCT 4647 CAA AGC AGC AGC TTG TTG TGC CAG GCC CCC CCC CCC TCCC TC -CCC TC -CCC TC -CTC -CTC's TGT     142143  GAC AGG TGT TTG GGG GAG GGG AGG GGG GTA TGA TAA GCT GGG ACA GCT     190191  GCA CCC ACC GGT GCT CTG GTG AGA TGG GGG GCC CGG ATG TTG GGG AGA     2381                                                  Met Leu Gly Arg       4239  CAC ATC TGC TGG GTT CCC AGC CCA AGG TCC CCA ACC CTG GCT GTC TGG     2865  His Ile Cys Trp Val Pro Ser Pro Arg Ser Pro Thr Leu Ala Val Trp      20287  CCT TGT CTG TCA CCC CCC GTG CCC ACT GGC AGG GAC AGG AAG CTC CCC     33421  Pro Cys Leu Ser Pro Pro Val Pro Thr Gly Arg Asp Arg Lys Leu Pro      36335  CCC CAC CCC GCT TTG GGC AGT TTG CCT TGG CAC GGG CCT GAT CTG TTT     38237  Pro His Pro Ala Leu Gly Ser Leu Pro Trp His Gly Pro Asp Leu Phe      52383  TCC TCC CCA GAG CAG CTG CTG TTC TGT CTG CTG GGC AGA GGG CTG GGT     43053  Ser Ser Pro Glu Gln Leu Leu Phe Cys Leu Leu Gly Arg Gly Leu Gly      68431  TCC TCC GAG GTA GGC AGG GGC CTC AAC CCA GAG CCC CTC TCA CAC CCT     47869  Ser Ser Glu Val Gly Arg Gly Leu asn Pro Glu Pro Leu Ser His Pro 84479 CTT TCA ACT CAG GCT GTC TCC TCC CCC CCC CCC CCC CCC CCC CCA 52685 Leu SERAGR VAGR PROHAGR PROGR PRR PRR PROR PRR PROR PRR PRR PRR PROR PRR PROR PROR PROR PROR PROR PRR PROR PRR PROR PRO 1005272727 AGA ACT GGA GAT TGA CGT GGA TGA GCT CCT GGA     574101  Gly Arg Gly Asp Pro Arg Thr Gly Asp ***                             110575  CAT GGA GAG TGA CGA TGC CCG GGC TGC CAG GGT CAA GGA GCT GCT GGT     622623  TGA CTG TTA CAA ACC CAC AGA GGC CTT CAT TTC TGG CCT GCT GGA CAA     670671  GAT CCG GGG CAT GCA GAA GCT GAG CAC ACC CCA GAA GAA GTG AGG GTC     718719  CCC GAC CCA GGA GAA CGG TGG CTC CCA CAG GAC AAT CGC TGC CCC CCA     766767  ACC TCG TAG CAA CAG CAA TAC CGG GGG ACC CTG CGG CCA GGC CTG GTG     814815  CCA TGA GCA GGG CTC CTC GTG CCC CTG GCC CAG GGG TCT CTT CCC CTG     862863  CCC CCT CAG TTT TCC ACT TTT GGG GTT TTT TAT TGT TAT TAA ACT GAT     910911  GGG ACT TTA AAA AAA AAA AAA AAA AAA AA 9396. PP8607A：核苷酸序列(SEQ ID NO：16)长度：23161  GCCGCTGCCC GCCGGAAGCC TGCCCCCGTA CCCTCCCTAC TTCGAAGGCG CCCCCTTCCC61  TCACCCGCTG TGGCTCCGGG ACACGTACAA GCTGTGGGTG CCCCAGCCGC CGCCCAGGAC121  CATCAAGCGC ACGCGGCGGC GTCTGTCCCG CAACCGCGAC CCGGGGCGCC TCATCCTCAG181  CACCATCCGC CTGCGGCCGC GCCAGGTCCT CTGTGAGAAG TGCAAGAGCA CGCTGAGCCC241  CCCGGAGGCC AGCCCCGGAC CCCCAGCCGC GCCCAGGGCC CGCAGGAGGC TGGGCAGCGG301  CCCGGACAGG GAGCTCCGCA AGCCGGAGGA GCCGGAGAAC GGCGAGCCCA CGGCTGCGGC361  CACCGCCAGG AGGAGCAAGA GGGAGAGGCG CGAGGAGGAC AGGGCCCCGG CAGAGCAGGT421  CCCGCGGAGC CCGGTCATCA AGATCTCCTA CAGCACGCCC CAGGGCAAGG GAGAGGTGGT481  CAAGATCCCC TCCCGCGTGC ACGGCTCTCT GGAGCCCTTC CGTCCCCAGC AGGCCCCGCA541  GGACGACGGC AGCCAGGACC CCGAGGTGCT GGACAGAGAG TCCCGGGACC GGCCGTCCTG601  CGCGCCCTCG GCCTCCATCC CCAAGTTGAA ACTGACACGG CCTGTGCCGG CCGGCGCGGA661  CCTGCCGCCC CCTAAGATCC GCCTGAAGCC CCACCGTCTG GGGGACAGCG AGCACGAGCC721  CGTGTACCGG GCCGAGCTGG TGGGGGAGCT GAACGGGTAC CTGCGGGACA GCTCGCCGGC781  GCCCTGTGCG GACGGCCCTG CCGGTGGGCT GGCGGACTTG TCTTCTGGAA GTTCGGGTGA841 GGACGATGAC TTCAAGAGCT GTCCCCAGGG TCCACAGGGA CGCGAGGGCT TGGCTTTTCT901  CGTCAGCTGC CCTGAGGGGA GAGCGGACTG TGCCAGTGAG TCGGCGTGCA GCAGCGACAG961  CCTGGACGAG GCCAGATCGT CCGGCTCGGA AGGGACGCCG GCAGACACGG GTGACCTCTC1021  GCCTGGCCAC GGCGCGTCAG CGCCCTCGGT GTCCAGAGAG GCTCGCCAAA CGGTGCCGCC1081  CCTGACGGTC AGGCTGCACA CACAGAGCGT GTCGGAGTGC ATCACGGAGG ACGGCAGGAC1141  TGTGGCCGTG GGGGACATCG TCTGGGGTAA GATCCATGGT TTTCCTTGGT GGCCGGCGCG1201  TGTTCTTGAC ATCAGTCTCG GCCAGAAGGA GGACGGAGAG CCGTCTTGGC GAGAAGCGAA1261  GGTCTCGTGG TTTGGTTCTC CGACTACGTC GTTCTTGTCT ATTTCAAAAC TCTCCCCTTT1321  CTCTGAATTT TTCAAACTGA GATTTAATCG TAAGAAGAAG GGGATGTATC GGAAAGCTAT1361  AACCGAGGCT GCAAATGCCG CAAGACACGT GGCCCCGGAA ATCAGGGAGC TCTTAACCCA1441  GTTTGAAACG TAACTGGTTC CCTGACCAGG TCACCGACGA TGAGGGCGCA CCTGCTGTCC1501  TGGAGCTTCC GATCTCTGTT CGGGGACCCT GTGAGCCTTC TGGCCGGCTG CGTGCAGAGC1561  CCACTGGGCA CGGTGGTCGG CCTGGTGTGA GGCCCCCCGG GGACCGGCAG TGTGTCCAGG1621  GAGGGGATGG CCCTGAGCCC AGCGGCTCCT CCCGCTGAGT GTATTTCTTC CCACCACTCA1681  GCGCATGGCT GCCCTGGCTC ACGAGGCAGT CGGGACTCGT GACTTGCTGG CTGCTGGCTG1741  CTGCTGCCTC GCGCGCTGGG GTTCCATGGA GGAACTGGGC CTGCCGCCCC GGCCTCACCT1801  GCTGCCCGCA TGCTGGGGTC CCATGGAGGA ACCAGGCCTG GCGCCCCGGC CTCGCCCAGC1861  GGCTGGTGTG GGCAGCTGTT CCCTGCCTCG CAGTGTCCTG GAGGCAGCTG TCTCGCAGAC1921  TCAGCTTGGT CTCCCGCAGG CTTCAGAAAA ACCCAATTGC ACGTGTGGGA TTCTTCCCCA1981  GCCCTTGGGT GCGGGGTCTC TGTGCACTTG AGAGCTGGGG GACCCACCCA CCGTCTCCCA2041  CTCCAAGTTC ATCCCAGAGC GTGGGGCCCG CTGGGCACCT GGCACCTGGC CTGCAGATGC2101  TGCTACGAGT GACCAGTGCT GTGTGGAGGA GGCCAAGGGC GGCCCCTGGG AAACCGGGCT2161  TCAACAAGTA CAAGGAAAAG AAACTTGCTC TGTTTTGTAA GAAGCGTGTT CCTTTTCCTC2221  TTTTTTGTCA CTTTAAAGAC CCAAAAGAAT AAAGAAAGAA AAGAAAAAAT TTTAAAAAAA2281  AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAB：核Nucleotide sequence (SEQ ID NO: 17) Length: 108l MAALAHEAVG TRDLLAAGCC CLARWGSMEE LGLPPRPHLL PACWGPMEEP GLAPRPRPAA61 GVGSCSLPRS VLEAAVSQTQ LGLPQASEKP NCTCGILPQP LGAGSLCTC. Nucleotide and amino acid combination sequence (SEQ ID NO: 18) Clone number: PP8607 Start code: 1685 ATG Stop code: 2009 TGA Protein molecular weight: 11038. 261      G CCG CTG CCC GCC GGA AGC CTG CCC CCG TAC CCT CCC TAC TTC GAA      4647    GGC GCC CCC TTC CCT CAC CCG CTG TGG CTC CGG GAC ACG TAC AAG CTG      9495    TGG GTG CCC CAG CCG CCG CCC AGG ACC ATC AAG CGC ACG CGG CGG CGT     142143    CTG TCC CGC AAC CGC GAC CCG GGG CGC CTC ATC CTC AGC ACC ATC CGC     190191    CTG CGG CCG CGC CAG GTC CTC TGT GAG AAG TGC AAG AGC ACG CTG AGC     238239    CCC CCG GAG GCC AGC CCC GGA CCC CCA GCC GCG CCC AGG GCC CGC AGG     286287    AGG CTG GGC AGC GGC CCG GAC AGG GAG CTC CGC AAG CCG GAG GAG CCG     334335    GAG AAC GGC GAG CCC ACG GCT GCG GCC ACC GCC AGG AGG AGC AAG AGG     382383    GAG AGG CGC GAG GAG GAC AGG GCC CCG GCA GAG CAG GTC CCG CGG AGC     430431    CCG GTC ATC AAG ATC TCC TAC AGC ACG CCC CAG GGC AAG GGA GAG GTG     478479    GTC AAG ATC CCC TCC CGC GTG CAC GGC TCT CTG GAG CCC TTC CGT CCC     526527    CAG CAG GCC CCG CAG GAC GAC GGC AGC CAG GAC CCC GAG GTG CTG GAC     574575    AGA GAG TCC CGG GAC CGG CCG TCC TGC GCG CCC TCG GCC TCC ATC CCC     622623    AAG TTG AAA CTG ACA CGG CCT GTG CCG GCC GGC GCG GAC CTG CCG CCC     670671    CCT AAG ATC CGC CTG AAG CCC CAC CGT CTG GGG GAC AGC GAG CAC GAG     718719    CCC GTG TAC CGG GCC GAG CTG GTG GGG GAG CTG AAC GGG TAC CTG CGG     766767    GAC AGC TCG CCG GCG CCC TGT GCG GAC GGC CCT GCC GGT GGG CTG GCG     814815    GAC TTG TCT TCT GGA AGT TCG GGT GAG GAC GAT GAC TTC AAG AGC TGT     862863    CCC CAG GGT CCA CAG GGA CGC GAG GGC TTG GCT TTT CTC GTC AGC TGC     910911    CCT GAG GGG AGA GCG GAC TGT GCC AGT GAG TCG GCG TGC AGC AGC GAC     958959    AGC CTG GAC GAG GCC AGA TCG TCC GGC TCG GAA GGG ACG CCG GCA GAC    10061007    ACG GGT GAC CTC TCG CCT GGC CAC GGC GCG TCA GCG CCC TCG GTG TCC    10541055    AGA GAG GCT CGC CAA ACG GTG CCG CCC CTG ACG GTC AGG CTG CAC ACA    11021103    CAG AGC GTG TCG GAG TGC ATC ACG GAG GAC GGC AGG ACT GTG GCC GTG    11501151    GGG GAC ATC GTC TGG GGT AAG ATC CAT GGT TTT CCT TGG TGG CCG GCG    11981199    CGT GTT CTT GAC ATC AGT CTC GGC CAG AAG GAG GAC GGA GAG CCG TCT    12461247    TGG CGA GAA GCG AAG GTC TCG TGG TTT GGT TCT CCG ACT ACG TCG TTC    12941295    TTG TCT ATT TCA AAA CTC TCC CCT TTC TCT GAA TTT TTC AAA CTG AGA    13421343    TTT AAT CGT AAG AAG AAG GGG ATG TAT CGG AAA GCT ATA ACC GAG GCT    13901391    GCA AAT GCC GCA AGA CAC GTG GCC CCG GAA ATC AGG GAG CTC TTA ACC    14381439    CAG TTT GAA ACG TAA CTG GTT CCC TGA CCA GGT CAC CGA CGA TGA GGG    14861487    CGC ACC TGC TGT CCT GGA GCT TCC GAT CTC TGT TCG GGG ACC CTG TGA    15341535    GCC TTC TGG CCG GCT GCG TGC AGA GCC CAC TGG GCA CGG TGG TCG GCC    15821583    TGG TGT GAG GCC CCC CGG GGA CCG GCA GTG TGT CCA GGG AGG GGA TGG    16301631  CCC TGA GCC CAG CGG CTC CTC CCG CTG AGT GTA TTT CTT CCC ACC ACT    16781679  CAG CGC ATG GCT GCC CTG GCT CAC GAG GCA GTC GGG ACT CGT GAC TTG    17261          Met Ala Ala Leu Ala His Glu Ala Val Gly Thr Arg Asp Leu      141727  CTG GCT GCT GGC TGC TGC TGC CTC GCG CGC TGG GGT TCC ATG GAG GAA    177415  Leu Ala Ala Gly Cys Cys Cys Leu Ala Arg Trp Gly Ser Met Glu Glu      301775  CTG GGC CTG CCG CCC CGG CCT CAC CTG CTG CCC GCA TGC TGG GGT CCC    182231  Leu Gly Leu Pro Pro Arg Pro His Leu Leu Pro Ala Cys Trp Gly Pro      461823  ATG GAG GAA CCA GGC CTG GCG CCC CGG CCT CGC CCA GCG GCT GGT GTG    187047  Met Glu Glu Pro Gly Leu Ala Pro Arg Pro Arg Pro Ala Ala Gly Val      621871  GGC AGC TGT TCC CTG CCT CGC AGT GTC CTG GAG GCA GCT GTC TCG CAG    191863  Gly Ser Cys Ser Leu Pro Arg Ser Val Leu Glu Ala Ala Val Ser Gln      781919  ACT CAG CTT GGT CTC CCG CAG GCT TCA GAA AAA CCC AAT TGC ACG TGT    196679  Thr Gln Leu Gly Leu Pro Gln Ala Ser Glu Lys Pro Asn Cys Thr Cys      941967  GGG ATT CTT CCC CAG CCC TTG GGT GCG GGG TCT CTG TGC ACT TGA GAG    201495  Gly Ile Leu Pro Gln Pro Leu Gly Ala Gly Ser Leu Cys Thr ***         1092015  CTG GGG GAC CCA CCC ACC GTC TCC CAC TCC AAG TTC ATC CCA GAG CGT    20622063 GGG GCC CGC TGG GCA CCT GGC ACC TGG CCT GCA GAT GCT GCT ACG AGT    21102111  GAC CAG TGC TGT GTG GAG GAG GCC AAG GGC GGC CCC TGG GAA ACC GGG    21582159  CTT CAA CAA GTA CAA GGA AAA GAA ACT TGC TCT GTT TTG TAA GAA GCG 22062207 TGT TCT TTT TCC TCT TTG TTG TCA CTT TAA AGA CCC AAA AGA AAG 22542255 AAA GAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAA AAAA AA. PP8857A：核苷酸序列(SEQ ID NO：19)长度：24231  GCAGCCGCGG AACTCCGGGC CCTGAGAGGG GGCGGGGGTG CAGGGGTCCC AGGGCCGGGC61  CGGGGTCTTT CCTGGCCCGG GGGAAACCGG CCCAGGCCTC CCGGGGGGGG CAATCGCCCA121  ACAAAGGATT CTTGGGGCGC CCGCCCTCGA GGACTTCCCT GCCCCTGGAT CCGGCCCCCC181  CAGCGCTCCG GGCCCGGCAT CCCGGGGCTC TCCATCGCGG GGTACCCCAG TTCGCGGTCT241  GCCATCGGGC AGCCCGGGCG CTACTCACCT CCGCCCGCGT CCGTGTTCCA GGTCCGGCCC301  GGAGCGGCCA TGTCCCACGG CCCCAAGCAG CCCGGCGCGG CCGCCGCGCC GGCGGGCGGC361  AAGGCTCCGG GCCAGCATGG GGGCTTCGTG GTGACTGTCA AGCAAGAGCG CGGCGAGGGT421  CCACGCGCGG GCGAGAAGGG GTCCCACGAG GAGGAGGTGA GAGTCCCTGC GCTGAGCTGG481  GGGAGGCCCC GGGCTCCCGC CCCAGCCTCG AAGCCCCGCC CCAGGCTGGA TTTGAATTGC541  TTGTGGCTCC GCCCACAGCC CATTTTCCTC TGGAAGCTGA GACCCCGCCC CGTGCCAGCT601  GCCACGCCCC TGACAGGTCC TCTGCCACTC TAAGTCCAGG CCCCGCCCAC CGCACAATGC661  CAGCTCTGCC CACTCTAAGG TCCCGCCCAC TTCCACTCCT TGGGGGCGGC ACCCTCCCCT721  TGGTCCTGTG GGCCCGTTCT CCAGCAGAAA ACCACGCCCA CCAAGCAGAG GCCACGCCCA781  CAACCGAAGT CAACGCCAAC CCTGTACTCA AACCTCGGCC CATAGTTCCT CAGATCCCCT841 CACCCCTGGC CAGGGATCCC TCTAACCCAC CGTGTCCCGA CTGCTGACCG GGCCCTACCT901  CCATCTTTTC CGGGTTCTTC CTCCCAGCTA GGCCCCGCCC CCATCCCCGC CCATACGCGT961  TAGGCCCCGC CCATGCCCCT CTGAGCCCTG CCCCAGTACG CCAGGCCCCC CTCCCAACGA1021  CGCAGCCCGG TTCTGCAGCC GGTGAAGAAA CGCGGCTGGC CCAAGGGCAA GAAGCGGAAG1081  AAGATTCTGC CGAATGGGCC CAAGGCACCG GTCACGGGCT ACGTGCGCTT CCTGAACGAG1141  CGGCGCGAGC AGATCCGCAC GCGCCACCCG GATCTGCCCT TTCCCGAGAT CACCAAGATG1201  CTGGGCCCCG AGTGGAGCAA GCTGCAGCCA ACGGAAAAGC AGCGGTACCT GGATGAGGCC1261  GAGAGAGAGA AGCAGCAGTA CATGAAGGAG CTGCGGGCGT ACCAGCAGTC TGAAGCCTAT1321  AAGATGTGCA CGGAGAAGAT CCAGGAGAAG AAGATCAAGA AAGAAGACTG AGCTCTGGGC1381  TCATGAACAC TCTCCTGAAT GGACACAAGG GTGGGGACTG CGATGGCTTC TCCACCTTCG1441  ATGTTCCCAT CTTCACTGAA GAGTTCTTGG ACCAAAACAA AGCGCGTGAG GCGGAGCTTC1501  GGCGCTTGCG GAAGATGAAT GTGGCCTTCG AGGAGCAGAA CGCGGTACTG CAGAGGCACA1561  CGCAGAGCAT GAGCAGCGCG CGCGAGCGTC TGGAGCAGGA GCTGGCGCTG GAGGAGCGGA1621  GGACGCTGGC GCTGCAGCAG CAGCTCCAGG CCGTGCGCCA GGCGCTCACC GCCAGCTTCG1681  CCTCACTGCC GGTGCCGGGC ACGGGCGAAA CGCCCACGCT GGGCACTCTG GACTTCTACA1741  TGGCCCGGCT TCACGGAGCC ATCGAGCGCG ACCCCGCCCA GCACGAGAAG CTCATCGTCC1801  GCATCAAGGA AATCCTGGCC CAGGTCGCCA GCGAGCACCT GTGAGGAGTG GGCGGGCCCA1861  CGATGCAGAG GAGAAGCTGT GGGCGCGGCC CTGCCACACC CCACCCCGTG GACGAGAGGC1921  TGGGGGTCCA CCCTTTGGGG CCTGGTCCCA TCCTGCACCT TGGGGGCTCC AGCCCCCCTA1981  AAATTAAATT TCTGCAGCAT CCCTTTAGCT TTCAATCTCC CCAGCCCCCT GAACCCGGAA2041  AAAGCACTCG CTGCGCGATA CACCCAGAAG AACCTCACAG CCGAGGGTGC CCCTCCTCGG2101  AGGACAGCCA CGCGCTACAC TGGCTCTCCG GGCCACCCCC AGGACACAGG GCAGACGAAA2161  CCCACCCCCA GCACACGGCA GGACCCCCCA AATTACTCAC TACGGGGGGC TGTGCCATAG2221  GCCACACAGG AAGCTGCCTT GTGGGGACTT ACCTGGGGTG TCCCCCGCAT GCCTGTACCC2281  CAGATGGGTG GGGGCCGGCT TTGCCCATCC TGCTCTCCTC CAGCCGAGGG ACCCTGGTGG2341 GGGTGGCTCC TTCTCACTGC TGGATCCGGA CTTTTTAAAT AAAAACAAGT AAAATTTGTG2401  TTTTAAAAAA AAAAAAAAAA AAAB：核苷酸序列  (SEQ ID NO：20)   长度：1711 MQRRSCGRGP ATPHPVDERL GVHPLGPGPI LHLGGSSPPK IKFLQHPFSF QSPQPPEPGK61 STRCAIHPEE PHSRGCPSSE DSHALHWLSG PPPGHRADET HPQHTAGPPK LLTTGGCAIG121 HTGSCLVGTY LGCPPHACTP DGWGPALPIL LSSSRGTLVG VAPSHCWIRT FC. Nucleotide and amino acid combination sequence (SEQ ID NO: 21) Clone number: PP8857 Start code: 1863 ATG Stop code: 2376 TAA Protein molecular weight: 17989. 501   GC AGC CGC GGA ACT CCG GGC CCT GAG AGG GGG CGG GGG TGC AGG GGT      4748  CCC AGG GCC GGG CCG GGG TCT TTC CTG GCC CGG GGG AAA CCG GCC CAG      9596  GCC TCC CGG GGG GGG CAA TCG CCC AAC AAA GGA TTC TTG GGG CGC CCG     143144  CCC TCG AGG ACT TCC CTG CCC CTG GAT CCG GCC CCC CCA GCG CTC CGG     191192  GCC CGG CAT CCC GGG GCT CTC CAT CGC GGG GTA CCC CAG TTC GCG GTC     239240  TGC CAT CGG GCA GCC CGG GCG CTA CTC ACC TCC GCC CGC GTC CGT GTT     287288  CCA GGT CCG GCC CGG AGC GGC CAT GTC CCA CGG CCC CAA GCA GCC CGG     335336  CGC GGC CGC CGC GCC GGC GGG CGG CAA GGC TCC GGG CCA GCA TGG GGG     383384  CTT CGT GGT GAC TGT CAA GCA AGA GCG CGG CGA GGG TCC ACG CGC GGG     431432  CGA GAA GGG GTC CCA CGA GGA GGA GGT GAG AGT CCC TGC GCT GAG CTG     479480  GGG GAG GCC CCG GGC TCC CGC CCC AGC CTC GAA GCC CCG CCC CAG GCT     527528  GGA TTT GAA TTG CTT GTG GCT CCG CCC ACA GCC CAT TTT CCT CTG GAA     575576  GCT GAG ACC CCG CCC CGT GCC AGC TGC CAC GCC CCT GAC AGG TCC TCT     623624  GCC ACT CTA AGT CCA GGC CCC GCC CAC CGC ACA ATG CCA GCT CTG CCC     671672  ACT CTA AGG TCC CGC CCA CTT CCA CTC CTT GGG GGC GGC ACC CTC CCC     719720  TTG GTC CTG TGG GCC CGT TCT CCA GCA GAA AAC CAC GCC CAC CAA GCA     767768  GAG GCC ACG CCC ACA ACC GAA GTC AAC GCC AAC CCT GTA CTC AAA CCT     815816  CGG CCC ATA GTT CCT CAG ATC CCC TCA CCC CTG GCC AGG GAT CCC TCT     863864  AAC CCA CCG TGT CCC GAC TGC TGA CCG GGC CCT ACC TCC ATC TTT TCC     911912  GGG TTC TTC CTC CCA GCT AGG CCC CGC CCC CAT CCC CGC CCA TAC GCG     959960  TTA GGC CCC GCC CAT GCC CCT CTG AGC CCT GCC CCA GTA CGC CAG GCC    10071008  CCC CTC CCA ACG ACG CAG CCC GGT TCT GCA GCC GGT GAA GAA ACG CGG    10551056  CTG GCC CAA GGG CAA GAA GCG GAA GAA GAT TCT GCC GAA TGG GCC CAA    11031104  GGC ACC GGT CAC GGG CTA CGT GCG CTT CCT GAA CGA GCG GCG CGA GCA    11511152  GAT CCG CAC GCG CCA CCC GGA TCT GCC CTT TCC CGA GAT CAC CAA GAT    11991200  GCT GGG CCC CGA GTG GAG CAA GCT GCA GCC AAC GGA AAA GCA GCG GTA    12471248  CCT GGA TGA GGC CGA GAG AGA GAA GCA GCA GTA CAT GAA GGA GCT GCG    12951296  GGC GTA CCA GCA GTC TGA AGC CTA TAA GAT GTG CAC GGA GAA GAT CCA    13431344  GGA GAA GAA GAT CAA GAA AGA AGA CTG AGC TCT GGG CTC ATG AAC ACT    13911392  CTC CTG AAT GGA CAC AAG GGT GGG GAC TGC GAT GGC TTC TCC ACC TTC    14391440  GAT GTT CCC ATC TTC ACT GAA GAG TTC TTG GAC CAA AAC AAA GCG CGT    14871488  GAG GCG GAG CTT CGG CGC TTG CGG AAG ATG AAT GTG GCC TTC GAG GAG    15351536  CAG AAC GCG GTA CTG CAG AGG CAC ACG CAG AGC ATG AGC AGC GCG CGC    15831584  GAG CGT CTG GAG CAG GAG CTG GCG CTG GAG GAG CGG AGG ACG CTG GCG    16311632  CTG CAG CAG CAG CTC CAG GCC GTG CGC CAG GCG CTC ACC GCC AGC TTC    16791680  GCC TCA CTG CCG GTG CCG GGC ACG GGC GAA ACG CCC ACG CTG GGC ACT    17271728  CTG GAC TTC TAC ATG GCC CGG CTT CAC GGA GCC ATC GAG CGC GAC CCC    17751776  GCC CAG CAC GAG AAG CTC ATC GTC CGC ATC AAG GAA ATC CTG GCC CAG    18231824  GTC GCC AGC GAG CAC CTG TGA GGA GTG GGC GGG CCC ACG ATG CAG AGG    18711                                                      Met Gln Arg       31872  AGA AGC TGT GGG CGC GGC CCT GCC ACA CCC CAC CCC GTG GAC GAG AGG    19194  Arg Ser Cys Gly Arg Gly Pro Ala Thr Pro His Pro Val Asp Glu Arg      191920  CTG GGG GTC CAC CCT TTG GGG CCT GGT CCC ATC CTG CAC CTT GGG GGC    196720  Leu Gly Val His Pro Leu Gly Pro Gly Pro Ile Leu His Leu Gly Gly      351968  TCC AGC CCC CCT AAA ATT AAA TTT CTG CAG CAT CCC TTT AGC TTT CAA    201536  Ser Ser Pro Pro Lys Ile Lys Phe Leu Gln His Pro Phe Ser Phe Gln      512016  TCT CCC CAG CCC CCT GAA CCC GGA AAA AGC ACT CGC TGC GCG ATA CAC    206352  Ser Pro Gln Pro Pro Glu Pro Gly Lys Ser Thr Arg Cys Ala Ile His      672064  CCA GAA GAA CCT CAC AGC CGA GGG TGC CCC TCC TCG GAG GAC AGC CAC    211168  Pro Glu Glu Pro His Ser Arg Gly Cys Pro Ser Ser Glu Asp Ser His      832112  GCG CTA CAC TGG CTC TCC GGG CCA CCC CCA GGA CAC AGG GCA GAC GAA    215984  Ala Leu His Trp Leu Ser Gly Pro Pro Pro Gly His Arg Ala Asp Glu      992160  ACC CAC CCC CAG CAC ACG GCA GGA CCC CCC AAA TTA CTC ACT ACG GGG    2207100  Thr His Pro Gln His Thr Ala Gly Pro Pro Lys Leu Leu Thr Thr Gly     1152208  GGC TGT GCC ATA GGC CAC ACA GGA AGC TGC CTT GTG GGG ACT TAC CTG    2255116  Gly Cys Ala Ile Gly His Thr Gly Ser Cys Leu Val Gly Thr Tyr Leu     1312256  GGG TGT CCC CCG CAT GCC TGT ACC CCA GAT GGG TGG GGG CCG GCT TTG    2303132  Gly Cys Pro Pro His Ala Cys Thr Pro Asp Gly Trp Gly Pro Ala Leu     1472304  CCC ATC CTG CTC TCC TCC AGC CGA GGG ACC CTG GTG GGG GTG GCT CCT    2351148  Pro Ile Leu Leu Ser Ser Ser Arg Gly THR Leu Val Gly Val Ala Pro 1632352 TCT CAC TGC TGG ATC CGG Act TAA AAA AAA AGT AAA AGT AAA ATT TGT 2399164 Serg THR PHE *** 1722400 GTT TAAA AAA AAA AAA AAA AAA AAAA AAAA AA. PP8875A：核苷酸序列(SEQ ID NO：22)长度：41091  GTTCCCGCAG GGGTGCTGGG CCCCTGCGGC TCCCACCACA TTGCGCTGGA CTCTTGTGGC61  CCGTGCTGAC CTGGTGTTCC AGATGCTGTC TCTGCAGAGC TCTGCGTGGT CTCTGGTGTT121  AGAGAGGTGG CCACCCACCG CCCTATCATT GTCCTCATCC CCACTGTGAG GAGAAGCTAT181  CAGATCTGCC TGTGGCCCCC AGGTGGCTCA GGAAGGGCCG TCCTGACCCC CATCCTGGCC241  CCTTTCGGAG CTGCAGAGAT TTCCTGTGCC TCCAGCTCTG GCTTCCTGGG TCTGTCCTTG301  GCGTGGAGCG GGCACAGGCT TCCCGTAGAC ACGGTTGCCC AGAGTGGGGT TCATAACTGG361  GCACTGTAAA GGGTGTGGTC TCCACGGCTT AGGATGGGCC CCCCCTTCCT GGTGGCCTGC421  TGTGCCCGGG GCTGGTGTGG AGGCCTGTGG GGGTGCAGAG GCCGCCCGGC CCTGGGCTTC481  CTCTGGGGTT ACATGTGTAC CCTTGCACCC ACCTGTTAGC ACCCACCGGG AGAGTCTCAC541  TCAGCCTAAA CCAGGGCCCC TCAGGAGGAA AAGGTCCCCA GCTTCATGAT GGGGCCCAGT601  GTGCCTTCCA TCCCCGCCCT GACTCAGTGC CCACTGTGCG AGGTGTGAGC ACTGTCCACA661  GCAGCCAGGG CGGCCGGTGG GGAGTGCATT GGAGGGGGTT GAGGTCTCTT GGGCACCTGG721  TGAGTTCTCA AGGGTGAGAG GAAGCCGAGG CCATCAGGCT TAGCTGACGC TGCATGGGGC781  AGGCTGCCAA GAGGGAGGCT GAATGGAGCA GCCTCAGGTG AGCCGACAAT CCTCACCTCC841 GCCTGGTCAG CCAGGACCCG GCTCCCCTCC AGTCCCGCCT GCTTTCCCCA AAGCAGATCC901  AGCCAGTCTC AATGGCTCGC CCGGGGGGTG CTGGTTAGGC TGTGAGCATC CTTCCTGGGT961  GCAGGCCCCC GACAGCCAGC AGTGCTGTGC TGTGTGTGTG TTGGGGACTC TGCTGAGCCC1021  TTTGTGGCCA GACTGGGGAG GCTCCTCCGG GCTGGCTCTG TCCCCTGTAC CTTGTGAGGG1081  AGGGGCTGAC CCCCTGACTG GGTTACATCG TGGTGAGCAG TTCAGAAACA AGCTGTGGAA1141  TGAAGTGGAC GTGGCGTTTT AAACACATGA GCCCCATCTG TTCTTAGGGG TTTTGTTTGT1201  TGTCCCAGTC CGTGACTCCA AGACTGGGAC CCCCAGAGTT CCCAGGATGG TCTGGAGCCT1261  TTATCCTCAG GTCAGCATTG TGGAGTTAAA GGGAGGGGAC CACGGCCCCT CATTCTCAGG1321  AGAGCCATGG TGACCTTGAT GGCGGAGGCT CAGGGGGACC TGGACCGTGG ACACCACACA1381  GCTGCCCTCC TCCCTCCCGA GGCCATTTCA GGGCTGGAAT CCCTGCCCCC CTCTCCTTTC1441  CTCCCGGGCT GGTTGTTGCC TTGAGAGTCC GTGCGCTCAT CTCCCCACTT TTACCCCAGG1501  GGGAGGCCCC TCACCTTCCC ACCATATCCC TTGTACTTCC TCCCACCCTG GACTTGGGGG1561  AGCTGGGGGG AGGGGGCCCT TCCTTCAGCA GCAAACCCTC CTGGTGTAGG GCTGTAGGCC1621  ATCCCACCGC AGCCTGTCCA GGAGCTGCTG AGCCTGTCAG CCCCAACTAG CACCTCCTGT1681  CCAGGCCCCG CCCAGCCCTG CCTCCAGAGC CTACAGACGG GCCTCGCCCA GGTCCTGCTG1741  CTCCAGAGCT TGTGGGTGCC CACGCTGCAG GCTGTTTGGG GTGGTGGAGT AGAGCACCCG1801  CTGGAGCTGG GGGCTGAGTG GCCATGGGGG GACCATGCTC CTCCTATGGC CCAAGGCCCA1861  GGGGTTCCAC CTCGTAATTT TTGTTTGTTT TTAAATAAGG AAAATGCAAA AAGCGAGGCG1921  ACGGCTTAAA GATGGAGAAC GACCCCCAGG AGGCGGAGTC TGAAATGGCC CTGGATGCTG1981  AGTTCCTGGA CGTGTACAAG AACTGCAACG GGGTGGTCAT GATGTTCGAC ATTACCAAGC2041  AGTGGACCTT CAATTACATT CTCCGGGAGC TTCCAAAAGT GCCCACCCAC GTGCCAGTGT2101  GCGTGCTGGG GAACTACCGG GACATGGGCG AGCACCGAGT CATCCTGCCG GACGACGTGC2161  GTGACTTCAT CGACAACCTG GACAGGTGGG TGCGGTGGCC CTGCTCCCGA GGGACCCTGC2221  CCGGTGCTCC GGTGTGCGGG GGAGGGTGCT GAGGCAGAGG CCCAGGGAGG GGTTAACGTT2281  AGCATGGGGC CCGGCGGATG TGGGTCTCGC CGCTGAGTGG GGCTCACTGA AGCCTGGGTC2341 TCCCCGATGG CAGGGCCGGG AACTGTGTGC TGGGGAACTG TGTGCCAGGG TGAAGTGCTG2401  GCACTGTGGG GTCACCTGCA GAAGGGCACT CGGCTTAGCT GCTTAGCAGG GCTCAGCAGG2461  GTCCTGTGGC CTCAGGAGCC TGCAGGAGGA GGGAGGGCAG TGCGGACCCA CAGCTGTGGG2521  CCCAGGGGTG ATCCTTGGCA CCAGGGCAAG GGTCTTTCTC TTGCATCTTT TTTCCTTTCT2581  GAAAGCAGAC CTCCAGGTTC CTCCTACTTC CGCTATGCTG AGTCTTCCAT GAAGAACAGC2641  TTCGGCCTAA AGTACCTTCA TAAGTTCTTC AATATCCCAT TTTTGCAGCT TCAGAGGGAG2701  ACGCTGTTGC GGCAGCTGGA GACGAACCAG CTGGACATGG ACGCCACGCT GGAGGAGCTG2761  TCGGTGCAGC AGGAGACGGA GGACCAGAAC TACGGCATGT ATGTGGCGGG ACCCGCCCGT2821  GCGGGCGGTG TGGGGGCTGC GGGCGTGGCC GTGGTGCAGG GCCATGGGCT GCACCAAGGA2881  GACAGCAGAG GGGAGTGTCC CCTGTTTGGG GTAAATTAGT CACCTTTGGG CACGGGTGGA2941  GGAGGACTCA GGTTTGCACT GCCCCCAGCA GCCCCCCCAC AGTCACCCCT GGCGTGGACT3001  CCTCATACAG GTCATGCTGT GCCTGCCACT CTGAGTACCG CTGACCGTGG CCAGGTGCTG3061  GTGCTCATGG AGTGCTGCTG GGGCTGCCTG CCCATCAGGG GCTTGGCCTC CCAGATTGAT3121  GCCAGCATGG GGTGTGCTTT CTGGGGAGCT GCTTGACTTT GGGAAGCTCC CTGTGTTGAA3181  GAGGCATACA GGCCAGGACA TGGAGGTCTC TGGTCCTCGA CAGCAGAGGG AGGCTCAGAG3241  CATCCTCCTG AGTGGGCCTG GGCAGTGCAT AGCCCCGGGG TTGCGGCCAG TGGGACAGCT3301  GGCCCGTTCT CTGCCTCAGG CTCCTGTACA GCTAGGGGCT TGGTGCCTCC CCTGGGACCC3361  AGGCAGGGAC CACGGAATCA GTGGCCCTCC TGAGGCCCCC CAGGAGGTCT CTGTTTCCAG3421  AAGGAGAGCC CTGTGGGTCA CCTTGGATCT GGCTGTTGGC TCAGACACAG CAAGAGACCG3481  AGAGGGAAGG CAGTTTGATG CCTGGAGAGG GACCCGTGGC TTCCAGCTGC CAGGCCAGCC3541  CCAGAATGGA GCCCCCCGCA TGGGCGCTTC TCTGTTGAAC CAATCCTGGC ATTTCCTGGG3601  CCTGAGAGTT GGGTCAAGCT GAATGCTGCG ATGGCCGCAC GTGCTCCACC AAGCCCCAGC3661  CCCCTCCTCT TCCCAGAAAC CCCCGCTCAC GGGAAGGTCC AGTTGCTTGC CATCTGGCCA3721  CCTCTGCATG GAGCCCCCAA CAGCTGTGCC TCAGAACAGA TCCGAAGTGA CTTTCAGGGG3781  AGCTGGACAC ATGTACGCTG GTGCCTGCTG TCCCCACCCT TTGGCACTGC TGCTCTTTCT3841 TTTTCTGAGA TGGAGTCTCG CTCTGTCGCC CAGGCTGGAG CGCAGTGGTG TGATCTCGGC3901  TCACCGCAAG CTCCGCCTCC CGGGTTCACG CCATTCTCCT GCCTCAGCCT CCCAGCTACT3961  GGGGAGGCTG AGGCAGGGGA ATTGCTTGAA CCCGGGAGGC AGAGGTTATC GTGAGCTGAC4021  ATTGCGCCAC TGCACTCCAG CGCGGAAGAC AGAGTGAGCA AAAAAAAAAA AAAAAAAAGA4081  AAAAGTGACC AAAAAAAAAA AAAAAAAAAB：核苷酸序列(SEQ ID NO：23)  长度：1901  MAGPGTVCWG TVCQGEVLAL WGHLQKGTRL SCLAGLSRVL WPQEPAGGGR AVRTHSCGPR61  GDPWHQGKGL SLASFFLSES RPPGSSYFRY AESSMKNSFG LKYLHKFFNI PFLQLQRETL121 LRQLETNQLD MDATLEELSV QQETEDQNYG MYVAGPARAG GVGAAGVAVV QGHGLHQGDS181 RGECPLFGVNC. Nucleotide and amino acid combination sequence (SEQ ID NO: 24) Clone number: PP8875 Start code: 2347 ATG Stop code: 2917 TAG Protein molecular weight: 20536. 181  GTT CCC GCA GGG GTG CTG GGC CCC TGC GGC TCC CAC CAC ATT GCG CTG      4849  GAC TCT TGT GGC CCG TGC TGA CCT GGT GTT CCA GAT GCT GTC TCT GCA      9697  GAG CTC TGC GTG GTC TCT GGT GTT AGA GAG GTG GCC ACC CAC CGC CCT     144145  ATC ATT GTC CTC ATC CCC ACT GTG AGG AGA AGC TAT CAG ATC TGC CTG     192193  TGG CCC CCA GGT GGC TCA GGA AGG GCC GTC CTG ACC CCC ATC CTG GCC     240241  CCT TTC GGA GCT GCA GAG ATT TCC TGT GCC TCC AGC TCT GGC TTC CTG     288289  GGT CTG TCC TTG GCG TGG AGC GGG CAC AGG CTT CCC GTA GAC ACG GTT     336337  GCC CAG AGT GGG GTT CAT AAC TGG GCA CTG TAA AGG GTG TGG TCT CCA     384 385  CGG CTT AGG ATG GGC CCC CCC TTC CTG GTG GCC TGC TGT GCC CGG GGC     432433  TGG TGT GGA GGC CTG TGG GGG TGC AGA GGC CGC CCG GCC CTG GGC TTC     480481  CTC TGG GGT TAC ATG TGT ACC CTT GCA CCC ACC TGT TAG CAC CCA CCG     528529  GGA GAG TCT CAC TCA GCC TAA ACC AGG GCC CCT CAG GAG GAA AAG GTC     576577  CCC AGC TTC ATG ATG GGG CCC AGT GTG CCT TCC ATC CCC GCC CTG ACT     624625  CAG TGC CCA CTG TGC GAG GTG TGA GCA CTG TCC ACA GCA GCC AGG GCG     672673  GCC GGT GGG GAG TGC ATT GGA GGG GGT TGA GGT CTC TTG GGC ACC TGG     720721  TGA GTT CTC AAG GGT GAG AGG AAG CCG AGG CCA TCA GGC TTA GCT GAC     768769  GCT GCA TGG GGC AGG CTG CCA AGA GGG AGG CTG AAT GGA GCA GCC TCA     816817  GGT GAG CCG ACA ATC CTC ACC TCC GCC TGG TCA GCC AGG ACC CGG CTC     864865  CCC TCC AGT CCC GCC TGC TTT CCC CAA AGC AGA TCC AGC CAG TCT CAA     912913  TGG CTC GCC CGG GGG GTG CTG GTT AGG CTG TGA GCA TCC TTC CTG GGT     960961  GCA GGC CCC CGA CAG CCA CCA GTG CTG TGC TGT GTG TGT GTT GGG GAC    10081009  TCT GCT GAG CCC TTT GTG GCC AGA CTG GGG AGG CTC CTC CGG GCT GGC    10561057  TCT GTC CCC TGT ACC TTG TGA GGG AGG GGC TGA CCC CCT GAC TGG GTT    11041105  ACA TCG TGG TGA GCA GTT CAG AAA CAA GCT GTG GAA TGA AGT GGA CGT    11521153  GGC GTT TTA AAC ACA TGA GCC CCA TCT GTT CTT AGG GGT TTT GTT TGT    12001201  TGT CCC AGT CCG TGA CTC CAA GAC TGG GAC CCC CAG AGT TCC CAG GAT    12481249  GGT CTG GAG CCT TTA TCC TCA GGT CAG CAT TGT GGA GTT AAA GGG AGG    12961297  GGA CCA CGG CCC CTC ATT CTC AGG AGA GCC ATG GTG ACC TTG ATG GCG    13441345  GAG GCT CAG GGG GAC CTG GAC CGT GGA CAC CAC ACA GCT GCC CTC CTC    13921393  CCT CCC GAG GCC ATT TCA GGG CTG GAA TCC CTG CCC CCC TCT CCT TTC    14401441  CTC CCG GGC TGG TTG TTG CCT TGA GAG TCC GTG CGC TCA TCT CCC CAC    14881489  TTT TAC CCC AGG GGG AGG CCC CTC ACC TTC CCA CCA TAT CCC TTG TAC    15361537  TTC CTC CCA CCC TGG ACT TGG GGG AGC TGG GGG GAG GGG GCC CTT CCT    15841585  TCA GCA GCA AAC CCT CCT GGT GTA GGG CTG TAG GCC ATC CCA CCG CAG    16321633  CCT GTC CAG GAG CTG CTG AGC CTG TCA GCC CCA ACT AGC ACC TCC TGT    16801681  CCA GGC CCG GCC CAG CCC TGC CTC CAG AGC CTA CAG AGG GGC CTC GCC    17281729  CAG GTC CTG CTG CTC CAG AGC TTG TGG GTG CCC ACG CTG CAG GCT GTT    17761777  TGG GGT GGT GGA GTA GAG CAC CCG CTG GAG CTG GGG GCT GAG TGG CCA    18241825  TGG GGG GAC CAT GCT CCT CCT ATG GCC CAA GGC CCA GGG GTT CCA CCT    18721873  CGT AAT TTT TGT TTG TTT TTA AAT AAG GAA AAT GCA AAA AGC GAG GCG    19201921  ACG GCT TAA AGA TGG AGA ACG ACC CCC AGG AGG CGG AGT CTG AAA TGG    19681969  CCC TGG ATG CTG AGT TCC TGG ACG TGT ACA AGA ACT GCA ACG GGG TGG    20162017  TCA TGA TGT TCG ACA TTA CCA AGC AGT GGA CCT TCA ATT ACA TTC TCC    20642065  GGG AGC TTC CAA AAG TGC CCA CCC ACG TGC CAG TGT GCG TGC TGG GGA    21122113 ACT ACC GGG ACA TGG GCG AGC ACC GAG TCA TCC TGC CGG ACG ACG TGC    21602161  GTG ACT TCA TCG ACA ACC TGG ACA GGT GGG TGC GGT GGC CCT GCT CCC    22082209  GAG GGA CCC TGC CCG GTG CTC CGG TGT GCG GGG GAG GGT GCT GAG GCA 22562257  GAG GCC CAG GGA GGG GTT AAC GTT AGC ATG GGG CCC GGC GGA TGT GGG    23042305  TCT CGC CGC TGA GTG GGG CTC ACT GAA GCC TGG GTC TCC CCG ATG GCA    23521                                                          Met Ala       22353  GGG CCG GGA ACT GTG TGC TGG GGA ACT GTG TGC CAG GGT GAA GTG CTG    24003  Gly Pro Gly Thr Val Cys Trp Gly Thr Val Cys Gln Gly Glu Val Leu      182401  GCA CTG TGG GGT CAC CTG CAG AAG GGC ACT CGG CTT AGC TGC TTA GCA    244819  Ala Leu Trp Gly His Leu Gln Lys Gly Thr Arg Leu Ser Cys Leu Ala      342449  GGG CTC AGC AGG GTC CTG TGG CCT CAG GAG CCT GCA GGA GGA GGG AGG    249635  Gly Leu Ser Arg Val Leu Trp Pro Gln Glu Pro Ala G1y Gly Gly Arg      502497  GCA GTG CGG ACC CAC AGC TGT GGG CCC AGG GGT GAT CCT TGG CAC CAG    254451  Ala Val Arg Thr His Ser Cys Gly Pro Arg Gly Asp Pro Trp His Gln      662545  GGC AAG GGT CTT TCT CTT GCA TCT TTT TTC CTT TCT GAA AGC AGA CCT    259267  Gly Lys Gly Leu Ser Leu Ala Ser Phe Phe Leu Ser Glu Ser Arg Pro      822593  CCA GGT TCC TCC TAC TTC CGC TAT GCT GAG TCT TCC ATG AAG AAC AGC    264083  Pro Gly Ser Ser Tyr Phe Arg Tyr Ala Glu Ser Ser Met Lys Asn Ser      982641  TTC GGC CTA AAG TAC CTT CAT AAG TTC TTC AAT ATC CCA TTT TTG CAG    268899  Phe Gly Leu Lys Tyr Leu His Lys Phe Phe Asn Ile Pro Phe Leu Gln     1142689  CTT CAG AGG GAG ACG CTG TTG CGG CAG CTG GAG ACG AAC CAG CTG GAC    2736115  Leu Gln Arg Glu Thr Leu Leu Arg Gln Leu Glu Thr Asn Gln Leu Asp     1302737  ATG GAC GCC ACG CTG GAG GAG CTG TCG GTG CAG CAG GAG ACG GAG GAC    2784131  Met Asp Ala Thr Leu Glu Glu Leu Ser Val Gln Gln Glu Thr Glu Asp     1462785  CAG AAC TAC GGC ATG TAT GTG GCG GGA CCC GCC CGT GCG GGC GGT GTG    2832147  Gln Asn Tyr Gly Met Tyr Val Ala Gly Pro Ala Arg Ala Gly Gly Val     1622833  GGG GCT GCG GGC GTG GCC GTG GTG CAG GGC CAT GGG CTG CAC CAA GGA    2880163  Gly Ala Ala Gly Val Ala Val Val Gln Gly His Gly Leu His Gln Gly     1782881  GAC AGC AGA GGG GAG TGT CCC CTG TTT GGG GTA AAT TAG TCA CCT TTG    2928179  Asp Ser Arg Gly Glu Cys Pro Leu Phe Gly Val Asn ***                 1912929  GGC ACG GGT GGA GGA GGA CTC AGG TTT GCA CTG CCC CCA GCA GCC CCC    29762977  CCA CAG TCA CCC CTG GCG TGG ACT CCT CAT ACA GGT CAT GCT GTG CCT    30243025  GCC ACT CTG AGT ACC GCT GAC CGT GGC CAG GTG CTG GTG CTC ATG GAG    30723073  TGC TGC TGG GGC TGC CTG CCC ATC AGG GGC TTG GCC TCC CAG ATT GAT    31203121  GCC AGC ATG GGG TGT GCT TTC TGG GGA GCT GCT TGA CTT TGG GAA GCT    31683169  CCC TGT GTT GAA GAG GCA TAC AGG CCA GGA CAT GGA GGT CrC TGG TCC    32163217  TCG ACA GCA GAG GGA GGC TCA GAG CAT CCT CCT GAG TGG GCC TGG GCA    32643265  GTG CAT AGC CCC GGG GTT GCG GCC AGT GGG ACA GCT GGC CCG TTC TCT    33123313  GCC TCA GGC TCC TGT ACA GCT AGG GGC TTG GTG CCT CCC CTG GGA CCC    33603361  AGG CAG GGA CCA CGG AAT CAG TGG CCC TCC TGA GGC CCC CCA GGA GGT    34083409  CTC TGT TTC CAG AAG GAG AGC CCT GTG GGT CAC CTT GGA TCT GGC TGT    34563457  TGG CTC AGA CAC AGC AAG AGA CCG AGA GGG AAG GCA GTT TGA TGC CTG    35043505  GAG AGG GAC CCG TGG CTT CCA GCT GCC AGG CCA GCC CCA GAA TGG AGC    35523553  CCC CCG CAT GGG CGC TTC TCT GTT GAA CCA ATC CTG GCA TTT CCT GGG    36003601  CCT GAG AGT TGG GTC AAG CTG AAT GCT GCG ATG GCC GCA CGT GCT CCA    36483649 CCA AGC CCC AGC CCC CTC CTC TTC CCA GAA ACC CCC GCT CAC GGG AAG    36963697  GTC CAG TTG CTT GCC ATC TGG CCA CCT CTG CAT GGA GCC CCC AAC AGC    37443745  TGT GCC TCA GAA CAG ATC CGA AGT GAC TTT CAG GGG AGC TGG ACA CAT 37923793  GTA CGC TGG TGC CTG CTG TCC CCA CCC TTT GGC ACT GCT GCT CTT TCT    38403841  TTT TCT GAG ATG GAG TCT CGC TCT GTC GCC CAG GCT GGA GCG CAG TGG    38883889  TGT GAT CTC GGC TCA CCG CAA GCT CCG CCT CCC GGG TTC ACG CCA TTC    39363937  TCC TGC CTC AGC CTC CCA GCT ACT GGG GAG GCT GAG GCA GGG GAA TTG    39843985  CTT GAA CCC GGG AGG CAG AGG TTA TCG TGA GCT GAC ATT GCG CCA CTG    40324033  CAC TCC AGC GCG GAA GAC AGA GTG AGC AAA AAA AAA AAA AAA AAA AGA 40804081 AAA AGT GAC CAA AAA AAA AAA AAA AAA AA 41099. PP8997A：核苷酸序列(SEQ ID NO：25) 长度：31911  GCGGACCCCT CGTCCCTCCG CAGTCTCCGG CTGGCAGCGA TGGAGGGCGC TGGGGAGAAC61  GCCCCGGAGT CCAGCTCCTC TGCCCCTGGG TCCGAAGAGT CTGCCAGGGA TCCACAGGTG121  CCGCCTCCGG AGGAAGAATC GGGGGACTGC GCCCGGTCCC TGGAGGCGGT CCCCAAGAAA181  CTCTGTGGGT ATTTAAGTAA GTTCGGCGGC AAAGGGCCCA TCCGGGGCTG GAAATCCCGC241  TGGTTCTTCT ACGACGAAAG GAAATGTCAG CTGTATTACT CGCGGACCGC TCAGGATGCC301  AATCCCTTGG ACAGCATCGA CCTCTCCAGT GCAGTGTTTG ACTGTAAGGC GGACGCTGAG361  GAGGGGATCT TCGAAATCAA GACTCCCAGC CGGGTTATTA CCCTGAAGGC CGCCACCAAG421  CAAGCGATGC TGTACTGGCT GCAGCAGCTG CAGATGAAGC GCTGGGAATT CCACAACAGC481  CCGCCGGCAC CTCCTGCCAC CCCTGATGCC GCCCTGGCTG GGAATGGGCC CGTCCTGCAC541  CTCGAGCTAG GGCAAGAAGA GGCAGAGCTG GAGGAGTTCC TGTGCCCTGT GAAAACACCC601  CCTGGGCTAG TGGGCGTGGC AGCTGCCTTG CAGCCCTTCC CTGCCCTTCA GAATATTTCC661  CTCAAGCACC TGGGGACTGA AATACAGAAC ACAATGCACA ACATCCGTGG CAACAAGCAG721  GCCCAGGGAA CAGGCCATGA ACCTCCAGGG GAAGATTCTC CACAGAGTGG GGAGCCTCAG781  AGGGAGGAGC AGCCCTTGGC CTCTGACGCC AGCACCCCAG GGAGAGAGCC AGAGGATTCT841 CCAAAGCCTG CACCCAAGCC TTCTCTGACC ATCAGTTTCG CTCAGAAAGC CAAGCGCCAG901  AACAACACCT TCCCATTCTT TTCTGAAGGA ATCACACGGA ACCGAACTGC CCAGGAGAAA961  GTGGCAGCCT TGGAGCAACA GGTTCTGATG CTCACCAAGG AGTTAAAGTC TCAGAAGGAG1021  CTAGTGAAGA TCCTGCACAA GGCACTGGAG GCCGCCCAGC AGGAGAAGCG GGCGTCCAGC1081  GCATACCTGG CGGCGGCTGA GGACAAGGAC CGGCTGGAGC TGGTGCGGCA CAAAGTGCGG1141  CAGATCGCGG AGCTGGGCCG GCGGGTGGAG GCCCTGGAGC AGGAGCGGGA GAGCCTGGCG1201  CACACAGCGA GCCTGCGGGA GCAGCAGGTG CAGGAGCTAC AGCAGCACGT GCAGCTGCTT1261  ATGGACAAGA ACCACGCCAA GCAGCAGGTC ATCTGCAAGC TCTCTGAGAA GGTCACCCAG1321  GACTTCACGC ACCCCCCTGA CCAGTCTCCT TTGCGCCCCG ACGCTGCCAA CAGGGACTTC1381  CTGAGCCAGC AGGGGAAGAT AGAGCACCTG AAGGATGACA TGGAAGCTTA CCGGACCCAG1441  AACTGCTTCC TCAACTCCGA GATCCACCAG GTCACAAAGA TCTGGAGAAA GGTGGCTGAG1501  AAGGAGAAGG CCCTTCTGAC GAAGTGCGCC TACCTCCAAG CCAGAAACTG CCAGGTGGAA1561  AGCAAGTACC TGGCCGGTCT GAGAAGGCTG CAGGAGGCCC TGGGGGACGA AGCCAGCGAG1621  TGCTCAGAGC TGCTGAGGCA GCTTGTCCAG GAGGCACTGC AGTGGGAAGC TGGGGAGGCC1681  TCATCTGACA GCATCGAGCT GAGCCCCATC AGTAAGTATG ATGAGTACGG CTTCCTGACG1741  GTGCCCGACT ATGAGGTGGA AGACCTGAAG CTGCTGGCCA AGATCCAGGC GTTGGAGTCA1801  CGATCCCACC ACCTGCTGGG CCTCGAGGCT GTGGATCGGC CGCTGAGGGA GCGCTGGGCT1861  GCCCTGGGCG ATCTTGTGCC CTCAGCCGAG CTCAAGCAGC TACTGCGGGC AGGAGTACCC1921  CGTGAACACC GGCCTCGTGT CTGGAGGTGG CTGGTCCACC TCCGTGTCCA GCACCTGCAC1981  ACTCCAGGCT GCTACCAGGA ACTGCTGAGC CGGGGCCAGG CCCGCGAGCA CCCTGCTGCC2041  CGCCAGATTG AGCTGGACCT GAACCGGACC TTCCCCAACA ACAAACACTT CACCTGCCCC2101  ACCTCCAGCT TCCCCGACAA GCTCCGCCGG GTGCTGCTGG CCTTCTCCTG GCAGAACCCC2161  ACCATCGGCT ACTGCCAGGG CCTGAACAGG CTGGCGGCCA TTGCCCTGCT GGTCCTAGAG2221  GAGGAGGAGA GCGCCTTCTG GTGCCTGGTG GCCATTGTGG AGACCATCAT GCCCGCTGAT2281  TACTACTGCA ACACGCTGAC GGCATCCCAG GTGGACCAGC GGGTGCTCCA GGACCTGCTC2341 TCGGAGAAGC TGCCCAGGCT GATGGCCCAT CTGGGGCAGC ACCACGTGGA TCTCTCCCTC2401  GTCACCTTCA ACTGGTTCCT CGTGGTCTTT GCGGACAGTC TCATTAGCAA CATCCTCCTT2461  CGGGTCTGGG ATGCCTTCCT GTACGAGGGG ACGAAGGTGG TGTTTCGCTA TGCCTTGGCC2521  ATTTTCAAGT ACAACGAGAA GGAGATCTTG AGGCTACACA ATGGCCTGGA AATCTACCAG2581  TACCTGCGCT TCTTCACCAA GACCATCTCC AACAGCCGCT GATGAACATC GCCTTCAATG2641  ACATGAACCC CTTCCGCATG AAACAGCTGC GGCAGCTGCG CATGGTCCAC CGGGAGCGGC2701  TGGAGGCTGA GCTGCGGGAG CTGGAGCAGC TTAAGGCAGA GTACCTGGAG AGGCGGGCAT2761  CCCGGCGCAG AGCTGTGTCC GAGGGCTGTG CCAGCGAGGA CGAGGTGGAG GGGGAAGCCT2821  GACTTGGCCA CCTCCCCTCC CCACAGCCTT CCTCACCCTT GGCTGGCAGA CCCACTGGAG2881  GTCAGGCACG GACCAGTGGC CCAGCCCTGG GTGTCCCATC ACCATGTGAC CTTGGACATG2941  TCCCTTCCCC TCTCTGGCCC TCAGTTTCCC CACTGGGACA TTGTGTGCTG CAAAGCCATT3001  GGTTGGGCTA CTTCTTCATA GGCACTTACT TACCCAGGGA TGCCACCCTT TCGTCACCTC3061  TTCCACAGAG CACTTTGGCA TGTAAACAAG CAAGAGCACT GCCTCTATAG GGTAACCTGG3121  AACATTCTCT AGGTTATATC AATATAAAAC AATGTAAATG GTGGAAATCA TTCAAAAAAA3181  AAAAAAAAAA AB：核苷酸序列(SEQ ID NO：26)  长度： 8601   MEGAGENAPE SSSSAPGSEE SARDPQVPPP EEESGDCARS LEAVPKKLCG YLSKFGGKGP61   IRGWKSRWFF YDERKCQLYY SRTAQDANPL DSIDLSSAVF DCKADAEEGI FEIKTPSRVI121   TLKAATKQAM LYWLQQLQMK RWEFHNSPPA PPATPDAALA GNGPVLHLEL GQEEAELEEF181   LCPVKTPPGL VGVAAALQPF PALQNISLKH LGTEIQNTMH NIRGNKQAQG TGHEPPGEDS241   PQSGEPQREE QPLASDASTP GREPEDSPKP APKPSLTISF AQKAKRQNNT FPFFSEGITR301   NRTAQEKVAA LEQQVLMLTK ELKSQKELVK ILHKALEAAQ QEKRASSAYL AAAEDKDRLE361   LVRHKVRQIA ELGRRVEALE QERESLAHTA SLREQQVQEL QQHVQLLMDK NHAKQQVICK421   LSEKVTQDFT HPPDQSPLRP DAANRDFLSQ QGKIEHLKDD MEAYRTQNCF LNSEIHQVTK481   IWRKVAEKEK ALLTKCAYLQ ARNCQVESKY LAGLRRLQEA LGDEASECSE LLRQLVQEAL541   QWEAGEASSD SIELSPISKY DEYGFLTVPD YEVEDLKLLA KIQALESRSH HLLGLEAVDR601   PLRERWAALG DLVPSAELKQ LLRAGVPREH RPRVWRWLVH LRVQHLHTPG CYQELLSRGQ661   AREHPAARQI ELDLNRTFPN NKHFTCPTSS FPDKLRRVLL AFSWQNPTIG YCQGLNRLAA721   IALLVLEEEE SAFWCLVAIV ETIMPADYYC NTLTASQVDQ RVLQDLLSEK LPRLMAHLGQ781   HHVDLSLVTF NWFLVVFADS LISNILLRVW DAFLYEGTKV VFRYALAIFK YNEKEILRLH841   NGLEIYQYLR FFTKTISNSRC. Nucleotide and amino acid combination sequence (SEQ ID NO: 27) Clone number: PP8997 Start code: 40 ATG Stop code: 2620 TGA Protein molecular weight: 97300. 381 GCG GAC CCC TCC CTC CTC CGC AGT CTC CTG CTG GCA GCG ATG GAG GGC 481 MET GLU GCT GGG GGG GCC CCC AGC TCC GCC GCC GAL GAA GLA GLY GLU GLU GLU Ser Ala Pro GLY Ser GAG TCT GCC AGG GAT CCA CAG CCG CCG GAG GAA GAA GAA TCG GGG 14420 GLU Serg ARG ASP PRO PRO PRO GLC GCC GCC GCC CGC CGC CGC CGC CGC CGC CGC CGC CGC GCC GCC GCC CCC AAG AAA CTC TGT GGG TAT     19236  Asp Cys Ala Arg Ser Leu Glu Ala Val Pro Lys Lys Leu Cys Gly Tyr      51193  TTA AGT AAG TTC GGC GGC AAA GGG CCC ATC CGG GGC TGG AAA TCC CGC     24052  Leu Ser Lys Phe Gly Gly Lys Gly Pro Ile Arg Gly Trp Lys Ser Arg      67241  TGG TTC TTC TAC GAC GAA AGG AAA TGT CAG CTG TAT TAC TCG CGG ACC     28868  Trp Phe Phe Tyr Asp Glu Arg Lys Cys Gln Leu Tyr Tyr Ser Arg Thr      83289  GCT CAG GAT GCC AAT CCC TTG GAC AGC ATC GAC CTC TCC AGT GCA GTG     33684  Ala Gln Asp Ala Asn Pro Leu Asp Ser Ile Asp Leu Ser Ser Ala Val      99337  TTT GAC TGT AAG GCG GAC GCT GAG GAG GGG ATC TTC GAA ATC AAG ACT     384100  Phe Asp Cys Lys Ala Asp Ala Glu Glu Gly Ile Phe Glu Ile Lys Thr     115385  CCC AGC CGG GTT ATT ACC CTG AAG GCC GCC ACC AAG CAA GCG ATG CTG     432116  Pro Ser Arg Val Ile Thr Leu Lys Ala Ala Thr Lys Gln Ala Met Leu     131433  TAC TGG CTG CAG CAG CTG CAG ATG AAG CGC TGG GAA TTC CAC AAC AGC     480132  Tyr Trp Leu Gln Gln Leu Gln Met Lys Arg Trp Glu Phe His Asn Ser     147481  CCG CCG GCA CCT CCT GCC ACC CCT GAT GCC GCC CTG GCT GGG AAT GGG     528148  Pro Pro Ala Pro Pro Ala Thr Pro Asp Ala Ala Leu Ala Gly Asn Gly     163529  CCC GTC CTG CAC CTC GAG CTA GGG CAA GAA GAG GCA GAG CTG GAG GAG     576164  Pro Val Leu His Leu Glu Leu Gly Gln Glu Glu Ala Glu Leu Glu Glu     179577  TTC CTG TGC CCT GTG AAA ACA CCC CCT GGG CTA GTG GGC GTG GCA GCT     624180  Phe Leu Cys Pro Val Lys Thr Pro Pro Gly Leu Val Gly Val Ala Ala     195625  GCC TTG CAG CCC TTC CCT GCC CTT CAG AAT ATT TCC CTC AAG CAC CTG     672196  Ala Leu Gln Pro Phe Pro Ala Leu Gln Asn Ile Ser Leu Lys His Leu     211673  GGG ACT GAA ATA CAG AAC ACA ATG CAC AAC ATC CGT GGC AAC AAG CAG     720212  Gly Thr Glu Ile Gln Asn Thr Met His Asn Ile Arg Gly Asn Lys Gln     227721  GCC CAG GGA ACA GGC CAT GAA CCT CCA GGG GAA GAT TCT CCA CAG AGT     768228  Ala Gln Gly Thr Gly His Glu Pro Pro Gly Glu Asp Ser Pro Gln Ser     243769  GGG GAG CCT CAG AGG GAG GAG CAG CCC TTG GCC TCT GAC GCC AGC ACC     816244 Gly Glu Pro Gln Arg Glu Glu Gln Pro Leu Ala Ser Asp Ala Ser Thr     259817  CCA GGG AGA GAG CCA GAG GAT TCT CCA AAG CCT GCA CCC AAG CCT TCT     864260  Pro Gly Arg Glu Pro Glu Asp Ser Pro Lys Pro Ala Pro Lys Pro Ser 275865  CTG ACC ATC AGT TTC GCT CAG AAA GCC AAG CGC CAG AAC AAC ACC TTC     912276  Leu Thr Ile Ser Phe Ala Gln Lys Ala Lys Arg Gln Asn Asn Thr Phe     291913  CCA TTC TTT TCT GAA GGA ATC ACA CGG AAC CGA ACT GCC CAG GAG AAA     960292  Pro Phe Phe Ser Glu Gly Ile Thr Arg Asn Arg Thr Ala Gln Glu Lys     307961  GTG GCA GCC TTG GAG CAA CAG GTT CTG ATG CTC ACC AAG GAG TTA AAG    1008308  Val Ala Ala Leu Glu Gln Gln Val Leu Met Leu Thr Lys Glu Leu Lys     3231009  TCT CAG AAG GAG CTA GTG AAG ATC CTG CAC AAG GCA CTG GAG GCC GCC    1056324  Ser Gln Lys Glu Leu Val Lys Ile Leu His Lys Ala Leu Glu Ala Ala     3391057  CAG CAG GAG AAG CGG GCG TCC AGC GCA TAC CTG GCG GCG GCT GAG GAC    1104340  Gln Gln Glu Lys Arg Ala Ser Ser Ala Tyr Leu Ala Ala Ala Glu Asp     3551105  AAG GAC CGG CTG GAG CTG GTG CGG CAC AAA GTG CGG CAG ATC GCG GAG    1152356  Lys Asp Arg Leu Glu Leu Val Arg His Lys Val Arg Gln Ile Ala Glu     3711153  CTG GGC CGG CGG GTG GAG GCC CTG GAG CAG GAG CGG GAG AGC CTG GCG    1200372  Leu Gly Arg Arg Val Glu Ala Leu Glu Gln Glu Arg Glu Ser Leu Ala     3871201  CAC ACA GCG AGC CTG CGG GAG CAG CAG GTG CAG GAG CTA CAG CAG CAC    1248388  His Thr Ala Ser Leu Arg Glu Gln Gln Val Gln Glu Leu Gln Gln His     4031249  GTG CAG CTG CTT ATG GAC AAG AAC CAC GCC AAG CAG CAG GTC ATC TGC    1296404  Val Gln Leu Leu Met Asp Lys Asn His Ala Lys Gln Gln Val Ile Cys     4191297  AAG CTC TCT GAG AAG GTC ACC CAG GAC TTC ACG CAC CCC CCT GAC CAG    1344420  Lys Leu Ser Glu Lys Val Thr Gln Asp Phe Thr His Pro Pro Asp Gln     4351345  TCT CCT TTG CGC CCC GAC GCT GCC AAC AGG GAC TTC CTG AGC CAG CAG    1392436  Ser Pro Leu Arg Pro Asp Ala Ala Asn Arg Asp Phe Leu Ser Gln Gln     4511393  GGG AAG ATA GAG CAC CTG AAG GAT GAC ATG GAA GCT TAC CGG ACC CAG    1440452  Gly Lys Ile Glu His Leu Lys Asp Asp Met Glu Ala Tyr Arg Thr Gln     4671441  AAC TGC TTC CTC AAC TCC GAG ATC CAC CAG GTC ACA AAG ATC TGG AGA    1488468  Asn Cys Phe Leu Asn Ser Glu Ile His Gln Val Thr Lys Ile Trp Arg     4831489  AAG GTG GCT GAG AAG GAG AAG GCC CTT CTG ACG AAG TGC GCC TAC CTC    1536484  Lys Val Ala Glu Lys Glu Lys Ala Leu Leu Thr Lys Cys Ala Tyr Leu     4991537  CAA GCC AGA AAC TGC CAG GTG GAA AGC AAG TAC CTG GCC GGT CTG AGA    1584500  Gln Ala Arg Asn Cys Gln Val Glu Ser Lys Tyr Leu Ala Gly Leu Arg     5151585  AGG CTG CAG GAG GCC CTG GGG GAC GAA GCC AGC GAG TGC TCA GAG CTG    1632516  Arg Leu Gln Glu Ala Leu Gly Asp Glu Ala Ser Glu Cys Ser Glu Leu     5311633  CTG AGG CAG CTT GTC CAG GAG GCA CTG CAG TGG GAA GCT GGG GAG GCC    1680532  Leu Arg Gln Leu Val Gln Glu Ala Leu Gln Trp Glu Ala Gly Glu Ala     5471681  TCA TCT GAC AGC ATC GAG CTG AGC CCC ATC AGT AAG TAT GAT GAG TAC    1728548  Ser Ser Asp Ser Ile Glu Leu Ser Pro Ile Ser Lys Tyr Asp Glu Tyr     5631729  GGC TTC CTG ACG GTG CCC GAC TAT GAG GTG GAA GAC CTG AAG CTG CTG    1776564  Gly Phe Leu Thr Val Pro Asp Tyr Glu Val Glu Asp Leu Lys Leu Leu     5791777  GCC AAG ATC CAG GCG TTG GAG TCA CGA TCC CAC CAC CTG CTG GGC CTC    1824580  Ala Lys Ile Gln Ala Leu Glu Ser Arg Ser His His Leu Leu Gly Leu     5951825  GAG GCT GTG GAT CGG CCG CTG AGG GAG CGC TGG GCT GCC CTG GGC GAT    1872596  Glu Ala Val Asp Arg Pro Leu Arg Glu Arg Trp Ala Ala Leu Gly Asp     6111873  CTT GTG CCC TCA GCC GAG CTC AAG CAG CTA CTG CGG GCA GGA GTA CCC    1920612  Leu Val Pro Ser Ala Glu Leu Lys Gln Leu Leu Arg Ala Gly Val Pro     6271921  CGT GAA CAC CGG CCT CGT GTC TGG AGG TGG CTG GTC CAC CTC CGT GTC    1968628  Arg Glu His Arg Pro Arg Val Trp Arg Trp Leu Val His Leu Arg Val     6431969  CAG CAC CTG CAC ACT CCA GGC TGC TAC CAG GAA CTG CTG AGC CGG GGC    2016644 Gln His Leu His Thr Pro Gly Cys Tyr Gln Glu Leu Leu Ser Arg Gly     6592017  CAG GCC CGC GAG CAC CCT GCT GCC CGC CAG ATT GAG CTG GAC CTG AAC    2064660  Gln Ala Arg Glu His Pro Ala Ala Arg Gln Ile Glu Leu Asp Leu Asn 6752065  CGG ACC TTC CCC AAC AAC AAA CAC TTC ACC TGC CCC ACC TCC AGC TTC    2112676  Arg Thr Phe Pro Asn Asn Lys His Phe Thr Cys Pro Thr Ser Ser Phe     6912113  CCC GAC AAG CTC CGC CGG GTG CTG CTG GCC TTC TCC TGG CAG AAC CCC    2160692  Pro Asp Lys Leu Arg Arg Val Leu Leu Ala Phe Ser Trp Gln Asn Pro     7072161  ACC ATC GGC TAC TGC CAG GGC CTG AAC AGG CTG GCG GCC ATT GCC CTG    2208708  Thr Ile Gly Tyr Cys Gln Gly Leu Asn Arg Leu Ala Ala Ile Ala Leu     7232209  CTG GTC CTA GAG GAG GAG GAG AGC GCC TTC TGG TGC CTG GTG GCC ATT    2256724  Leu Val Leu Glu Glu Glu Glu Ser Ala Phe Trp Cys Leu Val Ala Ile     7392257  GTG GAG ACC ATC ATG CCC GCT GAT TAC TAC TGC AAC ACG CTG ACG GCA    2304740  Val Glu Thr Ile Met Pro Ala Asp Tyr Tyr Cys Asn Thr Leu Thr Ala     7552305  TCC CAG GTG GAC CAG CGG GTG CTC CAG GAC CTG CTC TCG GAG AAG CTG    2352756  Ser Gln Val Asp Gln Arg Val Leu Gln Asp Leu Leu Ser Glu Lys Leu     7712353  CCC AGG CTG ATG GCC CAT CTG GGG CAG CAC CAC GTG GAT CTC TCC CTC    2400772  Pro Arg Leu Met Ala His Leu Gly Gln His His Val Asp Leu Ser Leu     7872401  GTC ACC TTC AAC TGG TTC CTC GTG GTC TTT GCG GAC AGT CTC ATT AGC    2448 788  Val Thr Phe Asn Trp Phe Leu Val Val Phe Ala Asp Ser Leu Ile Ser     8032449  AAC ATC CTC CTT CGG GTC TGG GAT GCC TTC CTG TAC GAG GGG ACG AAG    2496804  Asn Ile Leu Leu Arg Val Trp Asp Ala Phe Leu Tyr Glu Gly Thr Lys     8192497  GTG GTG TTT CGC TAT GCC TTG GCC ATT TTC AAG TAC AAC GAG AAG GAG    2544820  Val Val Phe Arg Tyr Ala Leu Ala Ile Phe Lys Tyr Asn Glu Lys Glu     8352545  ATC TTG AGG CTA CAC AAT GGC CTG GAA ATC TAC CAG TAC CTG CGC TTC    2592836  Ile Leu Arg Leu His Asn Gly Leu Glu Ile Tyr Gln Tyr Leu Arg Phe     8512593  TTC ACC AAG ACC ATC TCC AAC AGC CGC TGA TGA ACA TCG CCT TCA ATG    2640852  Phe Thr Lys Thr Ile Ser Asn Ser Arg ***                             8612641  ACA TGA ACC CCT TCC GCA TGA AAC AGC TGC GGC AGC TGC GCA TGG TCC    26882689  ACC GGG AGC GGC TGG AGG CTG AGC TGC GGG AGC TGG AGC AGC TTA AGG    27362737  CAG AGT ACC TGG AGA GGC GGG CAT CCC GGC GCA GAG CTG TGT CCG AGG    27842785  GCT GTG CCA GCG AGG ACG AGG TGG AGG GGG AAG CCT GAC TTG GCC ACC    28322833  TCC CCT CCC CAC AGC CTT CCT CAC CCT TGG CTG GCA GAC CCA CTG GAG    28802881  GTC AGG CAC GGA CCA GTG GCC CAG CCC TGG GTG TCC CAT CAC CAT GTG    29282929  ACC TTG GAC ATG TCC CTT CCC CTC TCT GGC CCT CAG TTT CCC CAC TGG    29762977  GAC ATT GTG TGC TGC AAA GCC ATT GGT TGG GCT ACT TCT TCA TAG GCA    30243025  CTT ACT TAC CCA GGG ATG CCA CCC TTT CGT CAC CTC TTC CAC AGA GCA    30723073  CTT TGG CAT GTA AAC AAG CAA GAG CAC TGG CTC TAT AGG GTA ACC TGG    31203121  AAC ATT CTC TAG GTT ATA TCA ATA TAA AAC AAT GTA AAT GGT GGA AAT    31683169  CAT TCA AAA AAA AAA AAA AAA AA 319110. PP9012A：核苷酸序列(SEQ ID NO：28)长度：5241  GGTGAGGGTG TGAGGGTCGC GTTCCTGCTG TCTGGACTTT TTCTGTCCCA CTGAGACGCA61  GCTGTGTGAA ATATGATTTG GCGAGGAAGA TCAACATATA GGCATAGGCC GAGGAGAAGT121  GTACCACCTC CTGAGCTGAT TGGGCCTATG CTGGAGCCCG GTGATGAGGA GCCTCAGCAA181  GAGGAACCAC CAACTGAAAG TCGGGATCCT GCACCTGGTC AGGAGAGAGA AGAAGATCAG241  GGTGCAGCTG AGACTCAAGT GCCTGACCTG GAAGCTGATC TCCAGGAGCT GTCTCAGTCA301  AAGACTGGGG GTGAATGTGG AAATGGTCCT GATGACCAGG GGAAGATTCT GCCAAAATCA361  GAACAATTTA AAATGCCAGA AGGAGGTGAC AGGCAACCAC AGGTTTAAAT GAAGACAAGC421  TGAAACAACA CAAAACTGTT TTTATCTAAG ATATTTGACT TAAAAATATC AAAATAAACT481  TTTGCAGCTT TCTCCAAAAA AAAAAAAAAA AAAAAAAAAA AAAAB：核苷酸序列(SEQ ID NO：29)长度：111l MIWRGRSTYR HRPRRSVPPP ELIGPMLEPG DEEPQQEEPP TESRDPAPGQ EREEDQGAAE61 TQVPDLEADL QELSQSKTGG ECGNGPDDQG KILPKSEQFK MPEGGDRQPQ VC. Nucleotide and amino acid combination sequence (SEQ ID NO: 30) Clone number: PP9012 Start code: 73 ATG Stop code: 406 TAA Protein molecular weight: 12341. 841 GGT GGT GGT GGG GTC GCG TTC CTG CTG TCT GGA CTT CTT CTG TCC 4849 CAC GCA GCA GCA GCA GCA GCA GCA GCA GCA GCA GCA GCA ATG CGG CGA AGA TCA 961 MET Ile TRG GLY GLY ARG GLY 897 TAGR 897 TAGR 897 THR 89 TAGR ARGG's AGA AGT GTA CCA CCT CCT GAG CTG ATT GGG     1449  Tyr Arg His Arg Pro Arg Arg Ser Val Pro Pro Pro Glu Leu Ile Gly      24145  CCT ATG CTG GAG CCC GGT GAT GAG GAG CCT CAG CAA GAG GAA CCA CCA     19225  Pro Met Leu Glu Pro Gly Asp Glu Glu Pro Gln Gln Glu Glu Pro Pro      40193  ACT GAA AGT CGG GAT CCT GCA CCT GGT CAG GAG AGA GAA GAA GAT CAG     24041  Thr Glu Ser Arg Asp Pro Ala Pro Gly Gln Glu Arg Glu Glu Asp Gln      56241  GGT GCA GCT GAG ACT CAA GTG CCT GAC CTG GAA GCT GAT CTC CAG GAG     28857  Gly Ala Ala Glu Thr Gln Val Pro Asp Leu Glu Ala Asp Leu Gln Glu      72289  CTG TCT CAG TCA AAG ACT GGG GGT GAA TGT GGA AAT GGT CCT GAT GAC     33673  Leu Ser Gln Ser Lys Thr Gly Gly Glu Cys Gly Asn Gly Pro Asp Asp      88337  CAG GGG AAG ATT CTG CCA AAA TCA GAA CAA TTT AAA ATG CCA GAA GGA     38489  Gln Gly Lys Ile Leu Pro Lys Ser Glu Gln Phe Lys Met Pro Glu Gly     104385  GGT GAC AGG CAA CCA CAG GTT TAA ATG AAG ACA AGC TGA AAC AAC ACA     432105  Gly Asp Arg Gln Pro Gln Val ***                                     112433  AAA CTG TTT TTA TCT AAG ATA TTT GAC TTA AAA ATA TCA AAA TAA ACT     480481  TTT GCA GCT TTC TCC AAA AAA AAA AAA AAA AAA AAA AAA AAA AA 52411. PP9286A：核苷酸序列(SEQ ID NO：31)长度：29431  GCTGAAGGCT GCAAATCTAA GATCAGGGCA ACATAATGAG ACCTTGTCTC TACCAAAAAA61  AAACTTAAAA ATTAGCCAGG CATGGTGACT GGTGTCTATA GCCCCACCTG CTCAGGAGGC121  TGAGGTGGGA GGACCACTTG AGCCCAGGAG TGTGAGGATG CAGTGAATGC CATGATCACA181  CCATACACTC CAGCCTGGGT GACAGAGTAA GGCCCTGTTA AAAAAAAAAA AAAAGCAGAG241  ACTCTAGTCT TAGACTGCTT GGGCTCAAAT CCCTGTCCCC TACTTACTAA CTTGTGATCT301  CGGGCAAGTT ACTTAATTCT CAGTGCCTCA GTTTGCTTAT CTGTGAAAGA CATAATGATA361  CTAGGTACCC ACTTTAAGGT GTTTGGAGAA TTAAGTGTGT TAATTTATGT AGCTTGCTCT421  GAATGTGCCT GGCACATGGT GAGCTCTCAG TACATATTCA CTGTTATTAT CCTTGGCCTT481  TGACAATCAA GATTACCACC AGCCCCCTTG GCTGGTGAAG TGAAACCAGT TGACAGTCAC541  CCCCCACCCC ACCTTTGTCA TACAAGCCTC AAAAGGCTGG AGTCTTGGCT CACTGCAGCT601  TCAGCCTCTG GAGCTCAAGT GATCCTCCTG CCTCACCCCG CAAGCAGCTG GGAGTACACA661  CATGTGCCAC CACGCCTGGC TATTTTTATT TTTTGTAGAG ATGGGGTTTC ACCATGCTGC721  CCAGGCTGGT CTCGAACTCC TCACCTTAGG CAACCCACCC ATCTTGGCCT CCCAAAGTGC781  TGGGATTACA GGCATGGGCC ACTGCACCCA GCTAACATGT TTGTAACATC TGATTTAAAG841 TCTTTATCCA GTAAGGTCAG TGTCAGCTTC CTCGGGCGCA GTTTGCATTG ATTGCTTTTT901  TTCCTCCCGT GTCTGGGCCA TGCTTCTTTG CATGTTTCAG AATTTTGTTA AAAGCTGGAC961  ATTTTAAGTA ACATAATGTG GCAACTGTGG AAATCATATT CTCCTCCCTC CCCATGGTGG1021  TTCCTTTTTC TTGTTTAATG TCTTTTCTGA ACTAATTATG TAAAGTTGTG TTCTTTGTCA1081  TGTGTGGCCA CTATAGTCTC TGCTTGATTA GCTTAGTGGT CCTCTAACCA TTAGATCTCC1141  TTAATTGCCT GGAACCCGTA AGTCACTCAG CCAAGAGTTT ATAACTGCCT TAGACTTTAC1201  TTCCTCATTC TGCAGAGGCT CAAGGTAGCC AGTGGTGAGA GCTTAGGGCT TTCTAGATCT1261  TACCTGAGCA TGCACACAGC ACTGGGCATA AGCACATCCC TATGCATATG AATGGCCTTC1321  TAGACTCCCA GGAGTACGTC ACAGCCTTTC AAAGCCCCCT GTAGCCATCT CATAGTAACA1381  GAAAGCAGAT CAGTGGATGC CTGGGTCCAG TAGTAGCGGG ACGGTTGCAC AGGAAGTGAT1441  GAAAATGTTC TGCAACTTCA CTGCGAGGGA GGTTACACAG GTACATACAT TTGTCACCTC1501  ACGTTGAACT TTATACTTTA AACACAGTTT ATATATAAAT TATACCTCAA CAAAGCTGAT1561  GTTTTTAAAG ATGTAGTTTA AAAACGAAAC AAAAAACGTG GTTTGCAGGA GACACCTTGC1621  TCGTGATCCT CTAAAACACA GGTCTCCACT CAGATACCTG CAGGATGAGG ACAGGGTGGG1681  CGAGGGAAAG GAGCCAGAGC CCTCCAGGGG TGTGAAGCAG CTTTTCCTGG GTGGGGCTTG1741  GCGTGCTGCG CTCACTCTCC CTGGAGGAGG AAGTGCCTAA TCCAGTCCTC TGGGTCTGGG1801  CCCAGGAGAT GGGGCCTTAA AGCCTCTCTT GGTAAAGACT AGCCCTGTGG GAACAAACAG1861  GACACCCTCT CCTCTGATTC TGTATCTTCT AGGGGCTCCT ACTGTACTTC AGGGATACCT1921  GACCTGAGTT GCAGTCACAT TAGCTCCTGG AAAGCCAGGA CAGCCCATGT TGAACCCCAC1981  TTACTACTGC TGAGGACTGT GCGCCCTAAG GGGTTTGGGG CCTCTGCTCT TGCCACTGGC2041  CTTGGAACAT GTGTGGCAGT TCTTCTGCCT CACCCTCACT CTGGGGCATG GCCCACTCTG2101  CCAGGGCATC TGACATGTTC TTTGTCCCTG GCTCAGTTTG GGGGCAGCCC AGTGTCCTGC2161  GCTGTGGGGC TGGCCGTCCT GAATGTCTTG GAGAAGGAGC AGCTCCAGGA TCATGCCACC2221  AGTGTAGGCA GCTTCCTGAT GCAGCTCCTC GGGCAGCAAA AAATCAAACA TCCCATCGTC2281  GGGGATGTCA GGGGTGTTGG GCTCTTCATT GGTGTGGATC TGATCAAAGA TGAGGCCACA2341 AGGACACCAG CAACTGAAGA GGCTGCCTAC TTGGTATCAA GGCTGAAGGA GAACTACGTT2401  TTGCTGAGCA CTGATGGCCC TGGGAGGAAC ATCCTGAAGT TTAAGCCCCC AATGTGCTTC2461  AGCCTGGACA ATGCACGGCA GGTGGTGGCA AAGCTGGATG CCATTCTGAC TGACATGGAA2521  GAGAAGGTGA GAAGTTGTGA AACGCTGAGG CTCCAGCCCT AAGCCAGCCC TGCTCTGCCT2581  AAGTGTACTC CAGAAGAAAC TCATCTCATC CAAATACACG CTATTGAGAA GGCGAGCCTG2641  ACCTCCCTCT TACAGATAAA GTCAGCTTTC AGAGGCTCAG GGTGGGGGGG CCTGCCCGAG2701  GCCATAATGC TACCCACCCC CTCCTCCTAA CCACTGGTCT GTTGGAATAA CCCAGATGTC2761  TGCATCCCCT CAAGTCAGTC AATTTCCTTT CTGTCCACTG GGGGTGGAAT GGGGTAGGGT2821  GGGATACTTT AAAGTGCTCC TGCTTAAATA AATTAGACCA GACCAGTGTA TTTCTAAAGA2881  AAATCCTGAC ATGCACACCC ATTAAAAATA GTACATTTTA CAGTGAAAAA AAAAAAAAAA2941  AAAB：核苷酸序列(SEQ ID NO：32)  长度：1071 MQLLGQQKIK HPIVGDVRGV GLFIGVDLIK DEATRTPATE EAAYLVSRLK ENYVLLSTDG61 PGRNILKFKP PMCFSLDNAR QVVAKLDAIL TDMEEKVRSC ETLRLQPC. Nucleotide and amino acid combination sequence (SEQ ID NO: 33) Clone number: PP9286 Start code: 2239 ATG Stop code: 2560 TAA Protein molecular weight: 11923. 311  GCT GAA GGC TGC AAA TCT AAG ATC AGG GCA ACA TAA TGA GAC CTT GTC      4849  TCT ACC AAA AAA AAA CTT AAA AAT TAG CCA GGC ATG GTG ACT GGT GTC      9697  TAT AGC CCC ACC TGC TCA GGA GGC TGA GGT GGG AGG ACC ACT TGA GCC     144145  CAG GAG TGT GAG GAT GCA GTG AAT GCC ATG ATC ACA CCA TAC ACT CCA     192193  GCC TGG GTG ACA GAG TAA GGC CCT GTT AAA AAA AAA AAA AAA GCA GAG     240241  ACT CTA GTC TTA GAC TGC TTG GGC TCA AAT CCC TGT CCC CTA CTT ACT     288289  AAC TTG TGA TCT CGG GCA AGT TAC TTA ATT CTC AGT GCC TCA GTT TGC     336337  TTA TCT GTG AAA GAC ATA ATG ATA CTA GGT ACC CAC TTT AAG GTG TTT     384385  GGA GAA TTA AGT GTG TTA ATT TAT GTA GCT TGC TCT GAA TGT GCC TGG     432433  CAC ATG GTG AGC TCT CAG TAC ATA TTC ACT GTT ATT ATC CTT GGC CTT     480481  TGA CAA TCA AGA TTA CCA CCA GCC CCC TTG GCT GGT GAA GTG AAA CCA     528529  GTT GAC AGT CAC CCC CCA CCC CAC CTT TGT CAT ACA AGC CTC AAA AGG     576577  CTG GAG TCT TGG CTC ACT GCA GCT TCA GCC TCT GGA GCT CAA GTG ATC     624625  CTC CTG CCT CAC CCC GCA AGC AGC TGG GAG TAC ACA CAT GTG CCA CCA     672673  CGC CTG GCT ATT TTT ATT TTT TGT AGA GAT GGG GTT TCA CCA TGC TGC     720721  CCA GGC TGG TCT CGA ACT CCT CAC CTT AGG CAA CCC ACC CAT CTT GGC     768769  CTC CCA AAG TGC TGG GAT TAC AGG CAT GGG CCA CTG CAC CCA GCT AAC     816817  ATG TTT GTA ACA TCT GAT TTA AAG TCT TTA TCC AGT AAG GTC AGT GTC     864865  AGC TTC CTC GGG CGC AGT TTG CAT TGA TTG CTT TTT TTC CTC CCG TGT     912913  CTG GGC CAT GCT TCT TTG CAT GTT TCA GAA TTT TGT TAA AAG CTG GAC     960961  ATT TTA AGT AAC ATA ATG TGG CAA CTG TGG AAA TCA TAT TCT CCT CCC    10081009  TCC CCA TGG TGG TTC CTT TTT CTT GTT TAA TGT CTT TTC TGA ACT AAT    10561057  TAT GTA AAG TTG TGT TCT TTG TCA TGT GTG GCC ACT ATA GTC TCT GCT    11041105  TGA TTA GCT TAG TGG TCC TCT AAC CAT TAG ATC TCC TTA ATT GCC TGG    11521153  AAC CCG TAA GTC ACT CAG CCA AGA GTT TAT AAC TGC CTT AGA CTT TAC    12001201  TTC CTC ATT CTG CAG AGG CTC AAG GTA GCC AGT GGT GAG AGC TTA GGG    12481249  CTT TCT AGA TCT TAC CTG AGC ATG CAC ACA GCA CTG GGC ATA AGC ACA    12961297  TCC CTA TGC ATA TGA ATG GCC TTC TAG ACT CCC AGG AGT ACG TCA CAG    13441345  CCT TTC AAA GCC CCC TGT AGC CAT CTC ATA GTA ACA GAA AGC AGA TCA    13921393  GTG GAT GCC TGG GTC CAG TAG TAG CGG GAC GGT TGC ACA GGA AGT GAT    14401441  GAA AAT GTT CTG CAA CTT CAC TGC GAG GGA GGT TAC ACA GGT ACA TAC    14881489  ATT TGT CAC CTC ACG TTG AAC TTT ATA CTT TAA ACA CAG TTT ATA TAT    15361537  AAA TTA TAC CTC AAC AAA GCT GAT GTT TTT AAA GAT GTA GTT TAA AAA    15841585  CGA AAC AAA AAA CGT GGT TTG CAG GAG ACA CCT TGC TCG TGA TCC TCT    16321633  AAA ACA CAG GTC TCC ACT CAG ATA CCT GCA GGA TGA GGA CAG GGT GGG    16801681  CGA GGG AAA GGA GCC AGA GCC CTC CAG GGG TGT GAA GCA GCT TTT CCT    17281729  GGG TGG GGC TTG GCG TGC TGC GCT CAC TCT CCC TGG AGG AGG AAG TGC    17761777  CTA ATC CAG TCC TCT GGG TCT GGG CCC AGG AGA TGG GGC CTT AAA GCC    18241825  TCT CTT GGT AAA GAC TAG CCC TGT GGG AAC AAA CAG GAC ACC CTC TCC    18721873  TCT GAT TCT GTA TCT TCT AGG GGC TCC TAC TGT ACT TCA GGG ATA CCT    19201921  GAC CTG AGT TGC AGT CAC ATT AGC TCC TGG AAA GCC AGG ACA GCC CAT    19681969  GTT GAA CCC CAC TTA CTA CTG CTG AGG ACT GTG CGC CCT AAG GGG TTT    20162017  GGG GCC TCT GCT CTT GCC ACT GGC CTT GGA ACA TGT GTG GCA GTT CTT    20642065  CTG CCT CAC CCT CAC TCT GGG GCA TGG CCC ACT CTG CCA GGG CAT CTG    21122113  ACA TGT TCT TTG TCC CTG GCT CAG TTT GGG GGC AGC CCA GTG TCC TGC    21602161  GCT GTG GGG CTG GCC GTC CTG AAT GTC TTG GAG AAG GAG CAG CTC CAG    22082209  GAT CAT GCC ACC AGT GTA GGC AGC TTC CTG ATG CAG CTC CTC GGG CAG    22561 MET GLN Leu Leu Leu Gln 62257 CAA AAA ATC AAA Cat CCC ATC GGG GGG GTC GGG GGT GGG CTC GAT GAG GCC ACA AGG ACA CCA GCA    235223  Phe Ile Gly Val Asp Leu Ile Lys Asp Glu Ala Thr Arg Thr Pro Ala      382353  ACT GAA GAG GCT GCC TAC TTG GTA TCA AGG CTG AAG GAG AAC TAC GTT    240039  Thr Glu Glu Ala Ala Tyr Leu Val Ser Arg Leu Lys Glu Asn Tyr Val      542401  TTG CTG AGC ACT GAT GGC CCT GGG AGG AAC ATC CTG AAG TTT AAG CCC    244855  Leu Leu Ser Thr Asp Gly Pro Gly Arg Asn Ile Leu Lys Phe Lys Pro      702449  CCA ATG TGC TTC AGC CTG GAC AAT GCA CGG CAG GTG GTG GCA AAG CTG    249671  Pro Met Cys Phe Ser Leu Asp Asn Ala Arg Gln Val Val Ala Lys Leu      862497  GAT GCC ATT CTG ACT GAC ATG GAA GAG AAG GTG AGA AGT TGT GAA ACG    254487  Asp Ala Ile Leu Thr Asp Met Glu Glu Lys Val Arg Ser Cys Glu Thr     1022545  CTG AGG CTC CAG CCC TAA GCC AGC CCT GCT CTG CCT AAG TGT ACT CCA    2592103  Leu Arg Leu Gln Pro ***                                             1082593  GAA GAA ACT CAT CTC ATC CAA ATA CAC GCT ATT GAG AAG GCG AGC CTG    26402641  ACC TCC CTC TTA CAG ATA AAG TCA GCT TTC AGA GGC TCA GGG TGG GGG    26882689  GGC CTG CCC GAG GCC ATA ATG CTA CCC ACC CCC TCC TCC TAA CCA CTG    27362737  GTC TGT TGG AAT AAC CCA GAT GTC TGC ATC CCC TCA AGT CAG TCA ATT    27842785  TCC TTT CTG TCC ACT GGG GGT GGA ATG GGG TAG GGT GGG ATA CTT TAA    28322833  AGT GCT CCT GCT TAA ATA AAT TAG ACC AGA CCA GTG TAT TTC TAA AGA    28802881  AAA TCC TGA CAT GCA CAC CCA TTA AAA ATA GTA CAT TTT ACA GTG AAA 29282929 AAA AAA AAA AAA AAA 294312. PP9363A：核苷酸序列(SEQ ID NO：34) 长度：35031  GGCCGGGAGC TCGGGAGTCG GCCGCCGCGC CGAGGTTCGC CCCGTTTTGC AGAGAGAGCC61  GAGTCGGGAC CTGGAAAGAC GTCCCCGCGG GGCTCCGGCC GCCGCGCCTC CCCGCCGGCG121  CCTGCCCTGC CCTGCCCGTC CCAGCCCCGC GGTTCGGGGC GTGCGGCCGG GACGCGCGGA181  GCCCCGGCCC TGACCCGCTG CGCCGGGACG GGACGCTCCT AACGCCGCCG TACCGGTCCG241  TGGTTGCAGG GTCGCTCCGC GCCTTTCCGT CAGTGAGGGT CGGAACCCCA GCTCCAGGGC301  TAGCGCAGTG TGGCCCCAGG CCCTCGCCTC CGGTGCACGG GACCCCGGAC CCCCCCAAGC361  CTCTGGCTTC ACGAGACCCC AACCTTCAGT TGGAACAGCT TGGAACAGCG CGAGCGCCCG421  GGAAGCCCTG GCCGGGTCGT GCGCTCCGTG AGGGGTCCTA GGCGGGCAGG ACAGTCGGAC481  CGAACCGCCG GGCTGGTGCC GCGAGCCCAG GCTGTCACCT TCGTCCCGCC TCAGGCGAGG541  GGTTCAGCGC CTGCCCCGAA GATAACACAG GGGTCCCCTT CTGTCCCGGC GGCCCGCGAG601  AGCCAAGGCT GCAGCTCTCC CAGTGAAGTG ATATCACTGC CTCTGTGGAC AAGACACCTC661  CAGGAGCCCA GCTCACAGCC ACCGGTACCT TCTTCCAGGA CAAGCTGGGG GCCTCCATGG721  GCGCCTGAGG GCCAGGCGCC AGGGCCGTGG GCACGAGTAT GGTGAGACAC CAGCCCCTGC781  AGTACTACGA GCCACAGCTG TGCCTCTCCT GCCTCACGGG CATCTACGGC TGCCGTTGGA841 AGCGCTACCA GCGCTCCCAT GATGATACCA CACCGTGGGA GCGCCTCTGG TTCCTGCTCC901  TCACCTTCAC CTTTGGCCTC ACGCTCACCT GGCTTTACTT CTGGTGGGAA GTCCACAATG961  ACTATGATGA ATTCAACTGG TACCTCTACA ACCGCATGGG CTACTGGAGC GACTGGCCCG1021  TACCCATCCT TGTGACCACA GCTGCTGCCT TCGCATACAT CGCTGGCCTC CTGGTCCTGG1081  CACTATGTCA CATTGCCGTG GGGCAGCAGA TGAACCTGCA CTGGCTGCAC AAGATCGGGC1141  TGGTGGTCAT CCTGGCTTCC ACGGTGGTGG CCATGTCGGC CGTGGCCCAG CTGTGGGAGG1201  ACGAGTGGGA GGTGCTGCTG ATCTCCCTGC AGGGCACAGC GCCATTCCTG CATGTGGGGG1261  CTGTGGCAGC AGTCACCATG CTCTCCTGGA TCGTGGCAGG ACAGTTCGCC CGTGCAGAGC1321  GGACCTCCTC CCAGGTGACC ATTCTCTGTA CCTTCTTCAC CGTGGTGTTT GCCCTCTACC1381  TGGCCCCTCT CACCATCTCC TCTCCCTGCA TCATGGAGAA GAAAGACCTC GGCCCCAAGC1441  CTGCTCTCAT TGGCCACCGC GGGGCCCCCA TGCTGGCTCC AGAGCACACG CTCATGTCCT1501  TCCGGAAGGC CCTCGAGCAG AAGCTGTACG GGCTCCAGGC TGACATTACC ATCAGCCTGG1561  ACGGCGTGCC CTTCCTCATG CATGACACCA CCCTGCGGCG CACCACCAAC GTGGAGGAGG1621  AGTTCCCGGA GCTGGCCCGC AGGCCTGCCT CCATGCTTAA CTGGACCACC CTGCAGAGAC1681  TCAACGCTGG CCAGTGGTTC CTGAAGACTG ACCCCTTCTG GACAGCCAGC TCCCTGTCAC1741  CCTCCGACCA CAGAGAGGCC CAGAACCAGT CCATCTGCAG CCTGGCAGAG CTCCTGGAGC1801  TGGCCAAGGG CAATGCCACA CTGCTGCTCA ACCTGCGTGA CCCGCCCCGG GAGCACCCCT1861  ACCGCAGCAG TTTTATCAAC GTGACTCTGG AGGCCGTGCT GCACTCCGGC TTCCCCCAGC1921  ACCAGGTCAT GTGGCTGCCT AGCAGGCAGA GGCCCCTGGT GCGGAAGGTG GCTCCCGGCT1981  TCCAACAGAC ATCAGGCTCC AAGGAGGCAG TCGCCAGCCT GCGGAGAGGC CACATCCAGC2041  GGCTGAACCT GCGCTACACT CAGGTGTCCC GCCAGGAGCT CAGGGACTAC GCGTCCTGGA2101  ACCTGAGTGT GAACCTCTAC ACAGTGAAGG CACCGTGGCT CTTCTCCCTG CTGTGGTGTG2161  CGGGGGTCCC ATCCGTCACC TCTGACAACT CCCACACCCT GTCCCAGGTG CCTTCCCCCC2221  TCTGGATCAT GCCCCCGGAC GAGTACTGTC TCATGTGGGT CACTGCCGAC CTGGTCTCCT2281  TCACCCTCAT CGTGGGCATC TTCGTGCTCC AGAAGTGGCG CCTGGGTGGC ATACGGAGCT2341 ACAACCCTGA GCAGATCATG CTGAGTGCTG CGGTGCGCCG GACCAGCCGG GACGTCAGCA2401  TCATGAAGGA GAAGCTTATT TTCTCAGAGA TCAGCGATGG TGTAGAGGTC TCCGATGTGC2461  TCTCCGTATG TTCAGACAAC AGTTATGACA CATATGCCAA CAGCACCGCC ACCCCTGTGG2521  GCCCCCGAGG GGGTGGCAGC CACACCAAGA CCCTCATAGA GCGGAGTGGG CGTTAGCTGA2581  AGACATGTCT GTCCCACCTG TACCTGACAC AGAAGCTGGG GAGCCTAGGA GAGCTGGTGG2641  AAGTGTGTCT GAACTCGGAG TGCTCTGGGA GCGGGCTCCA CAGCCTCCTT GTGGGCTCCA2701  GCCCCTTGTC AGCCGCAGCC TCTCTTGAGG GGGACTCCCT GTCTCCTGAG GCCCAGCTGG2761  GCCAGGACTC CATCCTTTCA GATGCCCCTG CAGGCCTGGG GCTCCTTCTG GGAAGTATGG2821  GGCCTAGGGC TTGGTCCCCC TCTTCTGAGG CCCTCTCCTG TATCCCGACC TGGAAGCTTT2881  GATGGGTCAT GGGCCATGCC ATACCCCCTG TGGCAATGGA GTGTGTGGAT GCTCACCTGT2941  GCCATCTGTC CTCCTGTCTG TGCCAGGAGG CACCTGAGTT CTCTGCTGTT ATCCTGCCCC3001  AAGGGCCTGG GCCGAGCCTC TACCTGAAGC AACTCTGCTC TTCCTGTCAG TCTCAAAGCA3061  CAAGGAGGTT CAGCCCAGGA GGAAGCCAGC TGCAATGTGG AGACACGTCC TCCTCCCCAA3121  CCCACCTCAT GCCACCGCCA ACCCCCTGCC CCAGGAGCGG GCCTGAGCCA CGTCCCCTAG3181  GAGCAGCTGG AGATGGCCAA AAGAGTGAGC TCAGGACTAC TGGATCCCAT GCCCAGGTGT3241  CCAGCAGACC TCAAGGCAGA AGGGTCACCT AACCCAGGAG TCCACAGACT GATGTGACCT3301  CAGGTTCCCA CATCAGTGGC CACAGGGCAG GGCCCACCTG GTAGAAGTGT TCTGGATATG3361  GCCAGGGTGG GTGTGTGGCT AAGTGGGCCT GAACAGAGGG AACCTAGGGC CCTTGGCAAT3421  GTGATTTAAA GCTGCCATCT TGCGGAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA3481  AAAAAAAAAA AAAAAAAAAA AAAB：核苷酸序列(SEQ ID NO：35)  长度：6051  MVRHQPLQYY EPQLCLSCLT GIYGCRWKRY QRSHDDTTPW ERLWFLLLTF TFGLTLTWLY61  FWWEVHNDYD EFNWYLYNPM GYWSDWPVPI LVTTAAAFAY IAGLLVLALC HIAVGQQMNL121  HWLHKIGLVV ILASTVVAMS AVAQLWEDEW EVLLISLQGT APFLHVGAVA AVTMLSWIVA181 GQFARAERTS SQVTILCTFF TVVFALYLAP LTISSPCIME KKDLGPKPAL IGHRGAPMLA241  PEHTLMSFRK ALEQKLYGLQ ADITISLDGV PFLMHDTTLR RTTNVEEEFP ELARRPASML301  NWTTLQRLNA GQWFLKTDPF WTASSLSPSD HREAQNQSIC SLAELLELAK GNATLLLNLR361  DPPREHPYRS SFINVTLEAV LHSGFPQHQV MWLPSRQRPL VRKVAPGFQQ TSGSKEAVAS421  LRRGHIQRLN LRYTQVSRQE LRDYASWNLS VNLYTVNAPW LFSLLWCAGV PSVTSDNSHT481  LSQVPSPLWI MPPDEYCLMW VTADLVSFTL IVGIFVLQKW RLGGIRSYNP EQIMLSAAVR541  RTSRDVSIMK EKLIFSEISD GVEVSDVLSV CSDNSYDTYA NSTATPVGPR GGGSHTKTLI601  ERSGRC. Nucleotide and amino acid combination sequence (SEQ ID NO: 36) Clone number: PP9363 Start code: 759 ATG Stop code: 2574 TAG Protein molecular weight: 68612. 341   GG CCG GGA GCT CGG GAG TCG GCC GCC GCG CCG AGG TTC GCC CCG TTT      4748  TGC AGA GAG AGC CGA GTC GGG ACC TGG AAA GAC GTC CCC GCG GGG CTC      9596  CGG CCG CCG CGC CTC CCC GCC GGC GCC TGC CCT GCC CTG CCC GTC CCA     143144  GCC CCG CGG TTC GGG GCG TGC GGC CGG GAC GCG CGG AGC CCC GGC CCT     191192  GAC CCG CTG CGC CGG GAC GGG ACG CTC CTA ACG CCG CCG TAC CGG TCC     239240  GTG GTT GCA GGG TCG CTC CGC GCC TTT CCG TCA GTG AGG GTC GGA ACC     287288  CCA GCT CCA GGG CTA GCG CAG TGT GGC CCC AGG CCC TCG CCT CCG GTG     335336  CAC GGG ACC CCG GAC CCC CCC AAG CCT CTG GCT TCA CGA GAC CCC AAC     383384  CTT CAG TTG GAA CAG CTT GGA ACA GCG CGA GCG CCC GGG AAG CCC TGG     431432  CCG GGT CGT GCG CTC CGT GAG GGG TCC TAG GCG GGC AGG ACA GTC GGA     479480  CCG AAC GGC CGG GCT GGT GCC GCG AGC CCA GGC TGT CAC CTT CGT CCC     527528  GCC TCA GGC GAG GGG TTC AGC GCC TGC CCC GAA GAT AAC ACA GGG GTC     575576  CCC TTC TGT CCC GGC GGC CCG CGA GAG CCA AGG CTG CAG CTC TCC CAG     623624  TGA AGT GAT ATC ACT GCC TCT GTG GAC AAG ACA CCT CCA GGA GCC CAG     671672  CTC ACA GCC ACC GGT ACC TTC TTC CAG GAC AAG CTG GGG GCC TCC ATG     719 720  GGC GCC TGA GGG CCA GGC GCC AGG GCC GTG GGC ACG AGT ATG GTG AGA     7671                                                      Met Val Arg       3768  CAC CAG CCC CTG CAG TAC TAC GAG CCA CAG CTG TGC CTC TCC TGC CTC     8154  His Gln Pro Leu Gln Tyr Tyr Glu Pro Gln Leu Cys Leu Ser Cys Leu      19816  ACG GGC ATC TAC GGC TGC CGT TGG AAG CGC TAC CAG CGC TCC CAT GAT     86320  Thr Gly Ile Tyr Gly Cys Arg Trp Lys Arg Tyr Gln Arg Ser His Asp      35864  GAT ACC ACA CCG TGG GAG CGC CTC TGG TTC CTG CTC CTC ACC TTC ACC     91136  Asp Thr Thr Pro Trp Glu Arg Leu Trp Phe Leu Leu Leu Thr Phe Thr      51912  TTT GGC CTC ACG CTC ACC TGG CTT TAC TTC TGG TGG GAA GTC CAC AAT     95952  Phe Gly Leu Thr Leu Thr Trp Leu Tyr Phe Trp Trp Glu Val His Asn      67960  GAC TAT GAT GAA TTC AAC TGG TAC CTC TAC AAC CGC ATG GGC TAC TGG    100768  Asp Tyr Asp Glu Phe Asn Trp Tyr Leu Tyr Asn Arg Met Gly Tyr Trp      831008  AGC GAC TGG CCC GTA CCC ATC CTT GTG ACC ACA GCT GCT GCC TTC GCA    105584  Ser Asp Trp Pro Val Pro Ile Leu Val Thr Thr Ala Ala Ala Phe Ala      991056  TAC ATC GCT GGC CTC CTG GTC CTG GCA CTA TGT CAC ATT GCC GTG GGG    1103100  Tyr Ile Ala Gly Leu Leu Val Leu Ala Leu Cys His Ile Ala Val Gly     1151104  CAG CAG ATG AAC CTG CAC TGG CTG CAC AAG ATC GGG CTG GTG GTC ATC    1151116  Gln Gln Met Asn Leu His Trp Leu His Lys Ile Gly Leu Val Val Ile     1311152 CTG GCT TCC ACG GTG GTG GCC ATG TCG GCC GTG GCC CAG CTG TGG GAG    1199132  Leu Ala Ser Thr Val Val Ala Met Ser Ala Val Ala Gln Leu Trp Glu     1471200  GAC GAG TGG GAG GTG CTG CTG ATC TCC CTG CAG GGC ACA GCG CCA TTC 1247148  Asp Glu Trp Glu Val Leu Leu Ile Ser Leu Gln Gly Thr Ala Pro Phe     1631248  CTG CAT GTG GGG GCT GTG GCA GCA GTC ACC ATG CTC TCC TGG ATC GTG    1295164  Leu His Val Gly Ala Val Ala Ala Val Thr Met Leu Ser Trp Ile Val     1791296  GCA GGA CAG TTC GCC CGT GCA GAG CGG ACC TCC TCC CAG GTG ACC ATT    1343180  Ala Gly Gln Phe Ala Arg Ala Glu Arg Thr Ser Ser Gln Val Thr Ile     1951344  CTC TGT ACC TTC TTC ACC GTG GTG TTT GCC CTC TAC CTG GCC CCT CTC    1391196  Leu Cys Thr Phe Phe Thr Val Val Phe Ala Leu Tyr Leu Ala Pro Leu     2111392  ACC ATC TCC TCT CCC TGC ATC ATG GAG AAG AAA GAC CTC GGC CCC AAG    1439212  Thr Ile Ser Ser Pro Cys Ile Met Glu Lys Lys Asp Leu Gly Pro Lys     2271440  CCT GCT CTC ATT GGC CAC CGC GGG GCC CCC ATG CTG GCT CCA GAG CAC    1487228  Pro Ala Leu Ile Gly His Arg Gly Ala Pro Met Leu Ala Pro Glu His     2431488  ACG CTC ATG TCC TTC CGG AAG GCC CTC GAG CAG AAG CTG TAC GGG CTC    1535244  Thr Leu Met Ser Phe Arg Lys Ala Leu Glu Gln Lys Leu Tyr Gly Leu     2591536  CAG GCT GAC ATT ACC ATC AGC CTG GAC GGC GTG CCC TTC CTC ATG CAT    1583260  Gln Ala Asp Ile Thr Ile Ser Leu Asp Gly Val Pro Phe Leu Met His     2751584  GAC ACC ACC CTG CGG CGC ACC ACC AAC GTG GAG GAG GAG TTC CCG GAG    1631276  Asp Thr Thr Leu Arg Arg Thr Thr Asn Val Glu Glu Glu Phe Pro Glu     2911632  CTG GCC CGC AGG CCT GCC TCC ATG CTT AAC TGG ACC ACC CTG CAG AGA    1679292  Leu Ala Arg Arg Pro Ala Ser Met Leu Asn Trp Thr Thr Leu Gln Arg     3071680  CTC AAC GCT GGC CAG TGG TTC CTG AAG ACT GAC CCC TTC TGG ACA GCC    1727308  Leu Asn Ala Gly Gln Trp Phe Leu Lys Thr Asp Pro Phe Trp Thr Ala     3231728  AGC TCC CTG TCA CCC TCC GAC CAC AGA GAG GCC CAG AAC CAG TCC ATC    1775324  Ser Ser Leu Ser Pro Ser Asp His Arg Glu Ala Gln Asn Gln Ser Ile     3391776  TGC AGC CTG GCA GAG CTC CTG GAG CTG GCC AAG GGC AAT GCC ACA CTG    1823340  Cys Ser Leu Ala Glu Leu Leu Glu Leu Ala Lys Gly Asn Ala Thr Leu     3551824  CTG CTC AAC CTG CGT GAC CCG CCC CGG GAG CAC CCC TAC CGC AGC AGT    1871356  Leu Leu Asn Leu Arg Asp Pro Pro Arg Glu His Pro Tyr Arg Ser Ser     3711872  TTT ATC AAC GTG ACT CTG GAG GCC GTG CTG CAC TCC GGC TTC CCC CAG    1919 372  Phe Ile Asn Val Thr Leu Glu Ala Val Leu His Ser Gly Phe Pro Gln     387920  CAC CAG GTC ATG TGG CTG CCT AGC AGG CAG AGG CCC CTG GTG CGG AAG    1967388  His Gln Val Met Trp Leu Pro Ser Arg Gln Arg Pro Leu Val Arg Lys     403968  GTG GCT CCC GGC TTC CAA CAG ACA TCA GGC TCC AAG GAG GCA GTC GCC    2015404  Val Ala Pro Gly Phe Gln Gln Thr Ser Gly Ser Lys Glu Ala Val Ala     4192016  AGC CTG CGG AGA GGC CAC ATC CAG CGG CTG AAC CTG CGC TAC ACT CAG    2063420  Ser Leu Arg Arg Gly His Ile Gln Arg Leu Asn Leu Arg Tyr Thr Gln     4352064  GTG TCC CGC CAG GAG CTC AGG GAC TAC GCG TCC TGG AAC CTG AGT GTG    2111436  Val Ser Arg Gln Glu Leu Arg Asp Tyr Ala Ser Trp Asn Leu Ser Val     4512112  AAC CTC TAC ACA GTC AAC GCA CCG TGG CTC TTC TCC CTG CTG TGG TGT    2159452  Asn Leu Tyr Thr Val Asn Ala Pro Trp Leu Phe Ser Leu Leu Trp Cys     4672160  GCG GGG GTC CCA TCC GTC ACC TCT GAC AAC TCC CAC ACC CTG TCC CAG    2207468  Ala Gly Val Pro Ser Val Thr Ser Asp Asn Ser His Thr Leu Ser Gln     4832208  GTG CCT TCC CCC CTC TGG ATC ATG CCC CCG GAC GAG TAC TGT CTC ATG    2255484  Val Pro Ser Pro Leu Trp Ile Met Pro Pro Asp Glu Tyr Cys Leu Met     4992256  TGG GTC ACT GCC GAC CTG GTC TCC TTC ACC CTC ATC GTG GGC ATC TTC    2303500 Trp Val Thr Ala Asp Leu Val Ser Phe Thr Leu Ile Val Gly Ile Phe     5152304  GTG CTC CAG AAG TGG CGC CTG GGT GGC ATA CGG AGC TAC AAC CCT GAG    2351516  Val Leu Gln Lys Trp Arg Leu Gly Gly Ile Arg Ser Tyr Asn Pro Glu 5312352  CAG ATC ATG CTG AGT GCT GCG GTG CGC CGG ACC AGC CGG GAC GTC AGC    2399532  Gln Ile Met Leu Ser Ala Ala Val Arg Arg Thr Ser Arg Asp Val Ser     5472400  ATC ATG AAG GAG AAG CTT ATT TTC TCA GAG ATC AGC GAT GGT GTA GAG    2447548  Ile Met Lys Glu Lys Leu Ile Phe Ser Glu Ile Ser Asp Gly Val Glu     5632448  GTC TCC GAT GTG CTC TCC GTA TGT TCA GAC AAC AGT TAT GAC ACA TAT    2495564  Val Ser Asp Val Leu Ser Val Cys Ser Asp Asn Ser Tyr Asp Thr Tyr     5792496  GCC AAC AGC ACC GCC ACC CCT GTG GGC CCC CGA GGG GGT GGC AGC CAC    2543580  Ala Asn Ser Thr Ala Thr Pro Val Gly Pro Arg Gly Gly Gly Ser His     5952544  ACC AAG ACC CTC ATA GAG CGG AGT GGG CGT TAG CTG AAG ACA TGT CTG    2591596  Thr Lys Thr Leu Ile Glu Arg Ser Gly Arg ***                         6062592  TCC CAC CTG TAC CTG ACA CAG AAG CTG GGG AGC CTA GGA GAG CTG GTG    26392640  GAA GTG TGT CTG AAC TCG GAG TGC TCT GGG AGC GGG CTC CAC AGC CTC    26872688  CTT GTG GGC TCC AGC CCC TTG TCA GCC GCA GCC TCT CTT GAG GGG GAC    27352736  TCC CTG TCT CCT GAG GCC CAG CTG GGC CAG GAC TCC ATC CTT TCA GAT    27832784  GCC CCT GCA GGC CTG GGG CTC CTT CTG GGA AGT ATG GGG CCT AGG GCT    28312832  TGG TCC CCC TCT TCT GAG GCC CTC TCC TGT ATC CCG ACC TGG AAG CTT    28792880  TGA TGG GTC ATG GGC CAT GCC ATA CCC CCT GTG GCA ATG GAG TGT GTG    29272928  GAT GCT CAC CTG TGC CAT CTG TCC TCC TGT CTG TGC CAG GAG GCA CCT    29752976  GAG TTC TCT GCT GTT ATC CTG CCC CAA GGG CCT GGG CCG AGC CTC TAC    30233024  CTG AAG CAA CTC TGC TCT TCC TGT CAG TCT CAA AGC ACA AGG AGG TTC    30713072  AGC CCA GGA GGA AGC CAG CTG CAA TGT GGA GAC ACG TCC TCC TCC CCA    31193120  ACC CAC CTC ATG CCA CCG CCA ACC CCC TGC CCC AGG AGC GGG CCT GAG    31673168  CCA CGT CCC CTA GGA GCA GCT GGA GAT GGC CAA AAG AGT GAG CTC AGG    32153216  ACT ACT GGA TCC CAT GCC CAG GTG TCC AGC AGA CCT CAA GGC AGA AGG    32633264  GTC ACC TAA CCC AGG AGT CCA CAG ACT GAT GTG ACC TCA GGT TCC CAC    33113312  ATC AGT GGC CAC AGG GCA GGG CCC ACC TGG TAG AAG TGT TCT GGA TAT    33593360  GGC CAG GGT GGG TGT GTG GCT AAG TGG GCC TGA ACA GAG GGA ACC TAG 34073408 GGC CCT TGG CAA TGT GAT TTA AAG CTG CCA TCT TGC GGA AAA AAA AAA AAA 34553456 AAA AAA AAA AAA AAA AAA AAA 3 AAA 0 AAA 3 AAA AAA AA AA

Claims (10)

1. An isolated human protein with tumor suppressor function, characterized in that it comprises a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23 , 26, 29, 32, 35; Or its conservative variant polypeptide, or its active fragment, or its active derivative. 2. The polypeptide according to claim 1, wherein the polypeptide is a polypeptide having an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26 , 29, 32, 35. 3. An isolated polynucleotide, characterized in that it comprises a nucleotide sequence having at least 85% identity to a nucleotide sequence selected from the group consisting of: (a) polynucleotide encoding the polypeptide as claimed in claims 1 and 2; (b) A polynucleotide complementary to polynucleotide (a). 4. The polynucleotide according to claim 3, wherein the polypeptide encoded by the polynucleotide has an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, 5, 8, 11, 14, 17, 20 , 23, 26, 29, 32, 35. 5. The polynucleotide of claim 3, wherein the sequence of the polynucleotide is selected from the group consisting of: SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 coding region sequence or full-length sequence. 6. A vector comprising the polynucleotide according to claim 3. 7. A genetically engineered host cell, characterized in that it is a host cell selected from the group consisting of: (a) host cells transformed or transduced with the vector according to claim 6; (b) A host cell transformed or transduced with the polynucleotide of claim 3. 8. A method for preparing a polypeptide with human protein activity having a tumor suppressor function, characterized in that the method comprises: (a) cultivating the host cell according to claim 7 under conditions suitable for expressing a human protein with tumor suppressor function; (b) Isolating a human protein active polypeptide having a tumor suppressor function from the culture. 9. An antibody capable of specifically binding to the human protein with tumor suppressor function according to claim 1. 10. A pharmaceutical composition, characterized in that it contains a safe and effective amount of the polypeptide according to claim 1 and a pharmaceutically acceptable carrier.